A	O
history	O
of	O
the	O
roles	O
of	O
cytochrome	B
P450	I
enzymes	I
in	O
the	O
toxicity	O
of	O
drugs	O
.	O

In	O
the	O
mid	O
-	O
20th	O
Century	O
the	O
relationship	O
between	O
drug	O
metabolism	O
and	O
toxicity	O
became	O
appreciated	O
,	O
and	O
the	O
roles	O
of	O
cytochrome	B
P450	I
(	O
P450	O
)	O
enzymes	O
began	O
to	O
be	O
defined	O
in	O
the	O
1960s	O
.	O

Much	O
has	O
been	O
written	O
about	O
cytochrome	B
P450	I
(	O
P450	O
,	O
CYP	O
)	O
.	O

In	O
1976	O
,	O
an	O
international	O
series	O
of	O
biennial	O
meetings	O
on	O
the	O
cytochrome	B
P450	I
enzymes	I
was	O
established	O
as	O
a	O
means	O
of	O
facilitating	O
contact	O
of	O
scientists	O
in	O
this	O
area	O
working	O
in	O
Eastern	O
Bloc	O
and	O
western	O
countries	O
but	O
has	O
developed	O
into	O
a	O
timely	O
international	O
biennial	O
series	O
with	O
meetings	O
rotating	O
among	O
Europe	O
,	O
Asia	O
,	O
North	O
America	O
,	O
and	O
Australia	O
.	O

Another	O
DDI	O
grading	O
difference	O
relates	O
to	O
strong	O
enzyme	O
inducers	O
(	O
eg	O
carbamazepine	O
,	O
phenytoin	O
,	O
St	O
Johns	O
Wort	O
)	O
which	O
are	O
contraindicated	O
in	O
the	O
COVID	O
-	O
19	O
website	O
with	O
drugs	O
metabolized	O
by	O
cytochrome	B
P450	I
,	O
given	O
the	O
risk	O
of	O
treatment	O
failure	O
and	O
difficulty	O
of	O
managing	O
the	O
DDI	O
.	O

COVID	O
-	O
19	O
drugs	O
are	O
also	O
potential	O
victims	O
of	O
a	O
DDI	O
when	O
co	O
-	O
administered	O
with	O
strong	O
cytochrome	B
P450	I
inducers	O
,	O
as	O
are	O
chloroquine	O
,	O
hydroxychloroquine	O
and	O
remdesivir	O
.	O

In	O
addition	O
to	O
mitochondria	O
-	O
that	O
are	O
considered	O
the	O
most	O
relevant	O
source	O
of	O
ROS	O
-	O
and	O
to	O
peroxisomes	O
and	O
microsomes	O
,	O
the	O
endoplasmic	O
reticulum	O
stress	O
and	O
enzymes	O
as	O
NADPH	O
oxidase	O
,	O
cytochrome	B
P450	I
2E1	O
,	O
cyclooxygenases	O
,	O
and	O
lipoxygenases	O
also	O
produce	O
Reactive	O
Oxidative	O
Species	O
.	O

In	O
addition	O
,	O
the	O
wild	O
F	O
.	O
filiformis	O
genome	O
contained	O
107	O
cytochrome	B
P450	I
family	O
genes	O
and	O
674	O
genes	O
encoding	O
secretory	O
proteins	O
.	O

Two	O
putative	O
cytochrome	B
P450	I
genes	O
(	O
gene	O
9114	O
and	O
gene	O
7212	O
)	O
were	O
also	O
significantly	O
upregulated	O
in	O
the	O
dikaryotic	O
mycelium	O
compared	O
to	O
the	O
monokaryotic	O
mycelium	O
of	O
the	O
wild	O
strain	O
(	O
7	O
.	O
61	O
-	O
and	O
7	O
.	O
50	O
-	O
fold	O
change	O
,	O
respectively	O
)	O
and	O
the	O
cultivar	O
strain	O
mycelium	O
(	O
2	O
.	O
1	O
-	O
and	O
1	O
.	O
7	O
-	O
fold	O
change	O
,	O
respectively	O
)	O
.	O

We	O
identified	O
107	O
genes	O
in	O
the	O
cytochrome	B
P450	I
family	O
,	O
including	O
nine	O
putative	O
trichodiene	O
oxygenases	O
,	O
31	O
O	O
-	O
methylsterigmatocystin	O
oxidoreductases	O
,	O
five	O
benzoate	O
4	O
-	O
monooxygenases	O
,	O
two	O
linoleate	O
10R	O
-	O
lipoxygenases	O
,	O
two	O
ent	O
-	O
kaurene	O
oxidases	O
,	O
lanosterol	O
14	O
-	O
alpha	O
and	O
flavonoid	O
hydroxylases	O
and	O
other	O
candidate	O
cytochrome	O
P450s	O
.	O

Twenty	O
-	O
six	O
CYP450	O
genes	O
were	O
upregulated	O
in	O
the	O
mycelium	O
of	O
the	O
wild	O
strain	O
compared	O
to	O
the	O
cultivar	O
strain	O
and	O
the	O
cytochrome	B
P450	I
(	O
gene	O
5820	O
-	O
D3	O
)	O
had	O
the	O
highest	O
expression	O
level	O
,	O
with	O
more	O
than	O
a	O
500	O
-	O
fold	O
change	O
.	O

It	O
has	O
been	O
reported	O
that	O
a	O
more	O
divergent	O
cytochrome	B
P450	I
oxidase	O
could	O
be	O
involved	O
in	O
secondary	O
biosynthesis	O
.	O

a	O
=	O
view	O
)	O
to	O
obtain	O
the	O
annotated	O
gene	O
for	O
cytochrome	B
P450	I
.	O

This	O
highly	O
regulated	O
pathway	O
involves	O
several	O
cytochrome	B
P450	I
,	O
as	O
well	O
as	O
different	O
dehydrogenases	O
and	O
reductases	O
.	O

After	O
phylogenetic	O
analysis	O
,	O
domain	O
prediction	O
,	O
and	O
molecular	O
docking	O
studies	O
,	O
22	O
candidates	O
encoding	O
2	O
,	O
3	O
-	O
oxidosqualene	O
cyclase	O
,	O
alcohol	O
dehydrogenase	O
,	O
cytochrome	B
P450	I
,	O
acyltransferase	O
,	O
and	O
esterase	O
were	O
proposed	O
to	O
be	O
potential	O
genes	O
involved	O
in	O
azadirachtin	O
A	O
biosynthesis	O
.	O

Five	O
kinds	O
of	O
putative	O
enzymes	O
,	O
oxidosqualene	O
cyclase	O
,	O
cytochrome	B
P450	I
,	O
alcohol	O
dehydrogenase	O
,	O
acyltransferase	O
,	O
and	O
esterase	O
were	O
proposed	O
in	O
the	O
putative	O
biosynthetic	O
pathway	O
.	O

One	O
of	O
them	O
(	O
transcript	O
/	O
14554	O
)	O
was	O
annotated	O
as	O
the	O
neem	O
NADPH	O
-	O
cytochrome	B
P450	I
reductase	O
2	O
.	O

All	O
three	O
kratom	O
alkaloids	O
tested	O
inhibited	O
select	O
cytochrome	B
P450	I
enzymes	I
,	O
suggesting	O
a	O
potential	O
risk	O
for	O
adverse	O
interactions	O
when	O
kratom	O
is	O
co	O
-	O
consumed	O
with	O
drugs	O
metabolized	O
by	O
these	O
enzymes	O
.	O

Mitragynine	O
has	O
been	O
reported	O
to	O
inhibit	O
several	O
cytochrome	O
P450s	O
(	O
CYPs	O
)	O
^	O
,	O
-	O
-	O
,	O
which	O
could	O
lead	O
to	O
increased	O
systemic	O
exposure	O
to	O
co	O
-	O
consumed	O
drugs	O
,	O
including	O
opioids	O
,	O
and	O
potential	O
adverse	O
effects	O
.	O

Consistent	O
with	O
previous	O
literature	O
,	O
our	O
results	O
raise	O
concern	O
about	O
potential	O
drug	O
interactions	O
that	O
may	O
occur	O
when	O
kratom	O
is	O
consumed	O
concurrently	O
with	O
opiates	O
or	O
other	O
drugs	O
metabolized	O
by	O
the	O
cytochrome	O
P450s	O
.	O

For	O
example	O
,	O
in	O
Arabidopsis	O
thaliana	O
,	O
gene	O
groups	O
including	O
two	O
to	O
five	O
terpene	O
synthases	O
clustered	O
together	O
with	O
prenyltransferase	O
-	O
,	O
cytochrome	B
P450	I
-	O
and	O
glycosyltransferase	O
genes	O
^	O
.	O

Degradation	O
of	O
polychlorinated	O
biphenyls	O
(	O
PCBs	O
)	O
is	O
initiated	O
by	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
enzymes	O
and	O
includes	O
PCB	O
oxidation	O
to	O
OH	O
-	O
metabolites	O
,	O
which	O
often	O
display	O
a	O
higher	O
toxicity	O
than	O
their	O
parental	O
compounds	O
.	O

Taking	O
these	O
results	O
into	O
account	O
,	O
we	O
decided	O
to	O
subject	O
PCB	O
28	O
to	O
in	O
vitro	O
metabolism	O
by	O
a	O
human	O
liver	O
-	O
like	O
cytochrome	B
P450	I
cocktail	O
(	O
rhCYP	O
cocktail	O
)	O
^	O
,	O
.	O

Metabolization	O
takes	O
place	O
by	O
cytochrome	B
P450	I
(	O
CYP	O
)	O
enzymes	O
,	O
which	O
are	O
very	O
well	O
conserved	O
between	O
invertebrates	O
and	O
vertebrates	O
.	O

The	O
expression	O
level	O
of	O
nitronate	O
monooxygenase	O
(	O
NMO	O
)	O
,	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
and	O
cytochrome	O
P450s	O
(	O
CYP72A1	O
and	O
CYP72A2	O
)	O
varied	O
broadly	O
among	O
populations	O
and	O
individual	O
plants	O
within	O
the	O
populations	O
.	O

EMR	O
is	O
considered	O
to	O
be	O
polygenically	O
inherited	O
,	O
involving	O
multiple	O
genes	O
encoding	O
for	O
metabolic	O
enzymes	O
such	O
as	O
cytochrome	B
P450	I
monooxygenase	O
(	O
P450	O
)	O
,	O
glucosyl	O
transferases	O
(	O
GT	O
)	O
,	O
glutathione	O
S	O
-	O
transferases	O
(	O
GST	O
)	O
,	O
esterases	O
and	O
ABC	O
transporters	O
(	O
;	O
.	O

Two	O
cytochrome	B
P450	I
genes	O
(	O
CYP81A12	O
and	O
CYP81A21	O
)	O
were	O
found	O
to	O
be	O
overexpressed	O
and	O
associated	O
with	O
resistance	O
to	O
ALS	O
inhibitors	O
in	O
Echinochloa	O
phyllopogon	O
.	O

The	O
metabolism	O
of	O
this	O
polycyclic	O
aromatic	O
hydrocarbon	O
molecule	O
by	O
oxidation	O
reaction	O
through	O
cytochrome	B
P450	I
enzyme	I
from	O
human	O
host	O
and	O
monooxygenases	O
and	O
dioxygenase	O
enzymes	O
from	O
bacterial	O
species	O
of	O
skin	O
microbiome	O
is	O
known	O
from	O
experimental	O
studies	O
,	O
and	O
reference	O
databases	O
such	O
as	O
the	O
University	O
of	O
Minnesota	O
Biocatalysis	O
/	O
Biodegradation	O
Database	O
(	O
;	O
.	O

The	O
ingestion	O
of	O
BaP	O
is	O
known	O
to	O
be	O
toxic	O
due	O
to	O
its	O
metabolism	O
by	O
human	O
cytochrome	B
P450	I
enzyme	I
and	O
the	O
products	O
of	O
its	O
oxidation	O
are	O
known	O
to	O
cause	O
carcinogenicity	O
and	O
other	O
adverse	O
health	O
effects	O
by	O
reacting	O
with	O
the	O
host	O
DNA	O
(	O
;	O
.	O

In	O
separate	O
experiments	O
,	O
3	O
,	O
5	O
-	O
DCNB	O
cytotoxicity	O
was	O
reduced	O
by	O
pretreating	O
IKC	O
with	O
antioxidants	O
and	O
cytochrome	B
P450	I
,	O
flavin	O
monooxygenase	O
and	O
peroxidase	O
inhibitors	O
,	O
while	O
3	O
,	O
5	O
-	O
DCPHA	O
cytotoxicity	O
was	O
attenuated	O
by	O
two	O
nucleophilic	O
antioxidants	O
(	O
glutathione	O
and	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
)	O
.	O

Stipitaldehyde	O
8	O
represents	O
a	O
branching	O
point	O
in	O
Tropolone	O
Sesquiterpenoids	O
biosynthesis	O
(	O
Scheme	O
)	O
:	O
in	O
the	O
case	O
of	O
xenovulene	O
A	O
2	O
,	O
stipitaldehyde	O
8	O
is	O
oxidised	O
by	O
the	O
cytochrome	B
P450	I
AsR2	O
to	O
the	O
corresponding	O
hemiacetal	O
9	O
and	O
subsequent	O
elimination	O
of	O
water	O
yields	O
the	O
reactive	O
quinomethide	O
10	O
that	O
undergoes	O
an	O
enzymecatalyzed	O
hetero	O
Diels	O
-	O
Alder	O
reaction	O
with	O
ALPHAhumulene	O
6	O
,	O
synthesised	O
by	O
an	O
unusual	O
terpene	O
cyclase	O
,	O
yielding	O
xenovulene	O
B	O
11	O
(	O
Scheme	O
.	O

Unique	O
to	O
the	O
eup2	O
Biosynthetic	O
Gene	O
Clusters	O
and	O
pyc	O
Biosynthetic	O
Gene	O
Clusters	O
are	O
shortchain	O
dehydrogenase	O
encoding	O
genes	O
(	O
eupL4	O
and	O
pycL2	O
;	O
homologous	O
to	O
eupfE	O
)	O
and	O
a	O
cytochrome	B
P450	I
(	O
eupR6	O
,	O
pycR5	O
)	O
homologous	O
to	O
eupfD	O
,	O
previously	O
shown	O
to	O
be	O
responsible	O
for	O
C10	O
hydroxylation	O
of	O
the	O
terpene	O
moiety	O
.	O

Cytochromes	O
are	O
classified	O
based	O
on	O
their	O
lowest	O
electronic	O
energy	O
absorption	O
band	O
in	O
their	O
reduced	O
state	O
:	O
cytochrome	B
P450	I
(	O
450	O
nm	O
)	O
,	O
cytochrome	O
c	O
(	O
550	O
nm	O
)	O
,	O
cytochromes	O
b	O
(	O
565	O
nm	O
)	O
,	O
cytochromes	O
a	O
(	O
605	O
nm	O
)	O
.	O

Notably	O
,	O
in	O
doing	O
so	O
we	O
have	O
identified	O
a	O
non	O
-	O
canonical	O
cytochrome	B
P450	I
that	O
catalyzes	O
the	O
remarkable	O
ring	O
expansion	O
reaction	O
required	O
to	O
produce	O
the	O
distinct	O
carbon	O
scaffold	O
of	O
colchicine	O
.	O

For	O
yeast	O
expression	O
of	O
CYP	O
genes	O
,	O
we	O
utilized	O
S	O
.	O
cerevisiae	O
strain	O
WAT11	O
(	O
ade2	O
)	O
,	O
which	O
harbors	O
a	O
chromosomal	O
copy	O
of	O
the	O
Arabidopsis	O
thaliana	O
NADPH	O
-	O
cytochrome	B
P450	I
reductase	O
1	O
gene	O
.	O

Comparison	O
of	O
two	O
human	O
cell	O
lines	O
(	O
HepG2	O
and	O
HepaRG	O
)	O
with	O
different	O
activities	O
of	O
cytochrome	B
P450	I
enzymes	I
revealed	O
that	O
Ze	O
339	O
and	O
its	O
single	O
constituents	O
petasin	O
,	O
isopetasin	O
,	O
neopetasin	O
,	O
isopetasol	O
,	O
and	O
petasol	O
exerted	O
higher	O
toxicity	O
in	O
cells	O
having	O
a	O
higher	O
cytochrome	O
activity	O
.	O

Celastrol	O
biosynthesis	O
likely	O
adheres	O
to	O
the	O
common	O
triterpenoid	O
scheme	O
that	O
starts	O
with	O
cycloisomerization	O
of	O
2	O
,	O
3	O
-	O
oxidosqualene	O
by	O
an	O
oxidosqualene	O
cyclase	O
(	O
OSC	O
)	O
and	O
continues	O
with	O
oxidative	O
decoration	O
(	O
s	O
)	O
of	O
the	O
30	O
-	O
carbon	O
triterpenoid	O
core	O
structure	O
by	O
cytochrome	O
P450	B
enzymes	I
[	O
,	O
.	O

These	O
results	O
suggest	O
that	O
these	O
P450	B
enzymes	I
likely	O
catalyze	O
three	O
sequential	O
oxygenations	O
of	O
friedelin	O
into	O
an	O
alcohol	O
,	O
and	O
further	O
to	O
a	O
carboxylic	O
acid	O
via	O
an	O
aldehyde	O
.	O

In	O
triterpenoid	O
biosynthesis	O
,	O
the	O
formation	O
of	O
a	O
triterpene	O
backbone	O
is	O
usually	O
followed	O
by	O
oxidations	O
catalyzed	O
by	O
P450	B
enzymes	I
.	O

Output	O
includes	O
metabolism	O
to	O
oxysterols	O
by	O
the	O
cytochrome	O
P450	B
enzymes	I
Cytochromes	O
P450	O
27a1	O
and	O
CYP46A1	O
,	O
the	O
photoreceptor	O
phagocytosis	O
,	O
and	O
efflux	O
to	O
lipoprotein	O
particles	O
,	O
which	O
circulate	O
in	O
the	O
intraretinal	O
space	O
.	O

Furthermore	O
,	O
different	O
reconstituted	O
fractions	O
of	O
extract	O
(	O
petasins	O
and	O
fatty	O
acid	O
fraction	O
)	O
were	O
examined	O
in	O
three	O
in	O
vitro	O
test	O
systems	O
using	O
hepatocytes	O
:	O
Two	O
human	O
cell	O
lines	O
,	O
with	O
lower	O
and	O
higher	O
activity	O
of	O
cytochrome	O
P450	B
enzymes	I
(	O
HepG2	O
,	O
HepaRG	O
)	O
as	O
well	O
as	O
a	O
rodent	O
cell	O
line	O
with	O
high	O
cytochrome	O
P450	O
activity	O
(	O
H4IIE	O
)	O
,	O
were	O
used	O
.	O

The	O
analysis	O
focused	O
on	O
three	O
different	O
in	O
vitro	O
test	O
systems	O
of	O
hepatocytes	O
:	O
two	O
human	O
hepatic	O
cell	O
lines	O
,	O
with	O
lower	O
and	O
higher	O
activity	O
of	O
cytochrome	O
P450	B
enzymes	I
(	O
HepG2	O
and	O
HepaRG	O
,	O
respectively	O
,	O
(	O
Andersson	O
,	O
Kanebratt	O
,	O
&	O
Kenna	O
,	O
;	O
Guillouzo	O
et	O
al	O
.	O
,	O
)	O
)	O
and	O
a	O
rat	O
cell	O
line	O
(	O
H4IIE	O
[	O
Fujimura	O
,	O
Murakami	O
,	O
Miwa	O
,	O
Aruga	O
,	O
&	O
Toriumi	O
,	O
;	O
Westerink	O
,	O
Stevenson	O
,	O
&	O
Schoonen	O
,	O
]	O
)	O
were	O
used	O
.	O

Isolated	O
cytochrome	O
P450	B
enzymes	I
and	O
phosphate	O
buffer	O
were	O
obtained	O
from	O
BD	O
Gentest	O
(	O
Switzerland	O
)	O
.	O

In	O
this	O
direction	O
,	O
this	O
study	O
is	O
an	O
attempt	O
to	O
provide	O
a	O
complete	O
picture	O
of	O
P450	B
enzymes	I
in	O
different	O
cyanobacterial	O
species	O
as	O
these	O
enzymes	O
are	O
the	O
key	O
players	O
in	O
primary	O
and	O
secondary	O
metabolism	O
of	O
organisms	O
,	O
including	O
the	O
production	O
of	O
different	O
secondary	O
metabolites	O
.	O

As	O
these	O
Cytochrome	B
P450	B
enzymes	I
differ	O
significantly	O
between	O
species	O
,	O
drug	O
biotransformation	O
and	O
hepatotoxicity	O
can	O
only	O
be	O
evaluated	O
in	O
freshly	O
isolated	O
primary	O
human	O
hepatocytes	O
^	O
.	O

Hepatocyte	O
-	O
Like	O
Cells	O
differ	O
from	O
Primary	O
Human	O
Hepatocytes	O
at	O
the	O
transcriptional	O
,	O
proteomic	O
,	O
and	O
epigenetical	O
level	O
,	O
and	O
specifically	O
express	O
low	O
levels	O
of	O
hepatic	O
transcription	O
factors	O
and	O
Cytochrome	B
P450	B
enzymes	I
^	O
,	O
,	O
,	O
.	O

We	O
also	O
show	O
that	O
extracellular	O
amino	O
acids	O
represent	O
a	O
tool	O
to	O
drive	O
both	O
metabolic	O
maturation	O
and	O
the	O
expression	O
of	O
Cytochrome	B
P450	B
enzymes	I
,	O
and	O
this	O
in	O
both	O
Hepatocyte	O
-	O
Like	O
Cells	O
and	O
HepG2	O
hepatoma	O
cells	O
.	O

As	O
aside	O
from	O
CYP3A4	B
,	O
also	O
other	O
Cytochrome	O
P450	O
isoforms	O
were	O
induced	O
in	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
medium	O
(	O
Supplementary	O
Fig	O
)	O
,	O
Amino	O
Acids	O
represent	O
a	O
valuable	O
tool	O
to	O
induce	O
Cytochrome	B
P450	B
enzymes	I
.	O

The	O
top	O
deregulated	O
pathways	O
when	O
comparing	O
HLC	O
Liver	O
Differentiation	O
Medium	O
D20	O
with	O
Primary	O
Human	O
Hepatocytes	O
contained	O
several	O
genes	O
involved	O
in	O
AA	O
catabolism	O
,	O
glucose	O
metabolism	O
,	O
metabolic	O
pathways	O
,	O
and	O
metabolism	O
of	O
xenobiotics	O
by	O
Cytochrome	B
P450	B
enzymes	I
and	O
AMP	O
-	O
activated	O
protein	O
kinase	O
)	O
,	O
we	O
next	O
stratified	O
these	O
into	O
four	O
quadrants	O
.	O

AOH	O
and	O
Alternariol	O
Monomethyl	O
Ether	O
were	O
reported	O
to	O
serve	O
as	O
substrates	O
for	O
different	O
Cytochrome	B
P450	B
enzymes	I
,	O
particularly	O
for	O
Cytochrome	B
P450	I
1A1	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
hydroxylated	O
metabolites	O
.	O

However	O
,	O
both	O
CYP2C8	B
3	O
and	O
6	O
LCPUFA	O
metabolites	O
are	O
proangiogenic	O
and	O
inhibition	O
of	O
CYP2C8	B
decreases	O
ocular	O
neovascularization	O
(	O
Shao	O
et	O
al	O
,	O
;	O
Gong	O
et	O
al	O
,	O
,	O
)	O
.	O

The	O
CYP2C19	O
gene	O
is	O
part	O
of	O
the	O
CYP2C	O
cluster	O
comprising	O
four	O
genes	O
(	O
CYP2C8	B
,	O
CYP2C9	O
,	O
CYP2C18	O
and	O
CYP2C19	O
)	O
.	O

For	O
human	O
cells	O
:	O
phenacetin	O
(	O
CYP1A2	B
)	O
,	O
efavirenz	O
(	O
CYP2B6	B
)	O
,	O
amodiaquine	O
(	O
CYP2C8	B
)	O
,	O
diclofenac	O
(	O
CYP2C9	B
)	O
,	O
dextromethorphan	O
(	O
CYP2D6	O
)	O
,	O
testosterone	O
(	O
CYP3A4	B
)	O
,	O
and	O
for	O
rat	O
cells	O
phenacetin	O
(	O
CYP1A2	B
)	O
,	O
testosterone	O
(	O
CYP2A1	O
,	O
CYP3A1	O
,	O
CYP3A2	O
)	O
,	O
diclofenac	O
(	O
CYP2C6	O
)	O
testosterone	O
(	O
CYP2C11	O
)	O
,	O
and	O
Pnitrophenol	O
(	O
CYP2E1	B
)	O
were	O
used	O
.	O

To	O
investigate	O
whether	O
metabolic	O
activation	O
by	O
human	O
phase	O
I	O
enzymes	O
-	O
at	O
least	O
in	O
part	O
-	O
contributes	O
to	O
the	O
cytotoxic	O
effect	O
,	O
Ze	O
339	O
(	O
concentrations	O
up	O
to	O
100	O
g	O
/	O
ml	O
)	O
was	O
coincubated	O
in	O
HepaRG	O
cells	O
for	O
4	O
hr	O
with	O
different	O
single	O
cytochromes	O
inhibitors	O
:	O
ketoconazole	O
(	O
CYP3A4	B
)	O
,	O
sulfaphenazole	O
(	O
CYP2C9	B
)	O
,	O
montelukast	O
(	O
CYP2C8	B
)	O
,	O
omeprazole	O
(	O
CYP2C19	B
)	O
,	O
ALPHAnaphthoflavone	O
(	O
CYP1A2	B
)	O
,	O
quinidine	O
(	O
CYP2D6	O
)	O
,	O
xanthotoxin	O
(	O
CYP2A6	O
)	O
,	O
chlormethiazole	O
(	O
CYP2E1	B
)	O
,	O
and	O
ticlopidine	O
(	O
CYP2B6	B
)	O
-	O
(	O
each	O
at	O
a	O
concentration	O
of	O
10	O
M	O
)	O
.	O

The	O
incubation	O
with	O
single	O
human	O
cytochromes	O
revealed	O
that	O
petasin	O
was	O
mainly	O
metabolized	O
by	O
CYP2D6	O
(	O
80	O
.	O
2	O
%	O
)	O
and	O
to	O
an	O
intermediate	O
extent	O
by	O
CYP3A4	B
(	O
34	O
%	O
)	O
,	O
CYP2B6	B
(	O
50	O
%	O
)	O
,	O
CYP2C8	B
(	O
54	O
%	O
)	O
,	O
and	O
CYP2C9	B
(	O
51	O
%	O
)	O
.	O

However	O
,	O
for	O
isopetasin	O
and	O
neopetasin	O
,	O
the	O
cytochromes	O
mainly	O
involved	O
in	O
their	O
metabolism	O
were	O
CYP3A4	B
(	O
87	O
%	O
and	O
86	O
%	O
)	O
,	O
CYP2D6	O
(	O
61	O
%	O
and	O
83	O
%	O
)	O
,	O
and	O
CYP2C8	B
(	O
44	O
%	O
and	O
71	O
%	O
)	O
.	O

Extend	O
of	O
metabolism	O
was	O
54	O
%	O
/	O
44	O
%	O
/	O
71	O
%	O
for	O
CYP2C8	B
(	O
human	O
)	O
and	O
51	O
%	O
/	O
8	O
%	O
/	O
58	O
%	O
for	O
CYP2C9	B
(	O
human	O
)	O
versus	O
94	O
%	O
/	O
72	O
%	O
/	O
75	O
%	O
for	O
CYP2C6	O
(	O
rat	O
)	O
and	O
55	O
%	O
/	O
74	O
%	O
/	O
84	O
%	O
for	O
CYP2C11	O
(	O
rat	O
)	O
.	O

In	O
HepaRG	O
cells	O
,	O
the	O
effect	O
of	O
cytochrome	O
inhibition	O
on	O
the	O
toxic	O
effects	O
of	O
Ze	O
339	O
was	O
investigated	O
;	O
addition	O
of	O
quinidine	O
(	O
CYP2D6	O
inhibitor	O
)	O
and	O
montelukast	O
(	O
CYP2C8	B
inhibitor	O
)	O
attenuated	O
(	O
p	O
<	O
.	O
001	O
and	O
p	O
=	O
.	O
041	O
,	O
respectively	O
)	O
;	O
most	O
of	O
the	O
cytotoxic	O
effect	O
of	O
Ze	O
339	O
demonstrated	O
for	O
the	O
highest	O
concentration	O
studied	O
(	O
100	O
g	O
/	O
ml	O
)	O
.	O

Inhibition	O
of	O
different	O
cytochromes	O
in	O
HepaRG	O
showed	O
an	O
attenuation	O
of	O
the	O
toxic	O
effects	O
,	O
which	O
was	O
pronounced	O
for	O
CYP2D6	O
and	O
to	O
a	O
minor	O
extend	O
CYP2C8	B
.	O

When	O
Cyp18a1	O
(	O
human	O
orthologues	O
:	O
CYP2C19	B
,	O
CYP2C8	B
,	O
CYP2C9	B
,	O
CYP2J2	O
,	O
CYP2R1	O
,	O
CYP21A2	O
,	O
CYP2A6	O
,	O
CYP2D6	B
,	O
CYP2	O
F1	O
,	O
CYP2S1	O
,	O
CYP2U1	O
and	O
CYP2E1	B
)	O
was	O
silenced	O
,	O
a	O
10	O
%	O
reduction	O
of	O
3	O
-	O
OHCB	O
28	O
and	O
a	O
70	O
%	O
reduction	O
of	O
3	O
-	O
OHCB	O
28	O
was	O
observed	O
compared	O
to	O
control	O
.	O

The	O
first	O
association	O
of	O
genetic	O
polymorphisms	O
with	O
the	O
metabolism	O
of	O
an	O
anti	O
-	O
epileptic	O
drug	O
has	O
been	O
reported	O
in	O
the	O
association	O
of	O
variation	O
in	O
drug	O
-	O
metabolizing	O
enzymes	O
CYP2C9	B
and	O
CYP2C19	B
with	O
phenytoin	O
dose	O
,	O
providing	O
hope	O
for	O
individualized	O
therapy	O
for	O
patients	O
.	O

In	O
patients	O
with	O
severe	O
INH	O
-	O
induced	O
liver	O
injury	O
,	O
not	O
only	O
serum	O
autoantibodies	O
to	O
CYP2E1	O
,	O
CYP3A4	B
and	O
CYP2C9	B
(	O
the	O
three	O
major	O
P450s	O
that	O
metabolize	O
and	O
/	O
or	O
interact	O
with	O
INH	O
)	O
,	O
but	O
also	O
serum	O
antibodies	O
to	O
INH	O
-	O
adducted	O
CYP2E1	O
and	O
other	O
INH	O
-	O
adducted	O
non	O
-	O
P450	O
proteins	O
are	O
detected	O
.	O

Similar	O
serum	O
antibodies	O
to	O
drug	O
-	O
modified	O
and	O
/	O
or	O
unmodified	O
P450s	O
and	O
other	O
native	O
cellular	O
proteins	O
have	O
also	O
been	O
detected	O
in	O
idiosyncratic	O
liver	O
injury	O
upon	O
halothane	O
-	O
exposure	O
(	O
anti	O
-	O
trifluoroacetyl	O
-	O
CYP2E1	O
)	O
,	O
aromatic	O
anti	O
-	O
convulsant	O
(	O
anti	O
-	O
CYP3A	B
)	O
,	O
dihydralazine	O
(	O
anti	O
-	O
CYP1A2	O
)	O
,	O
tienilic	O
acid	O
(	O
anti	O
-	O
tienilic	O
acid	O
-	O
CYP2C9	B
)	O
and	O
/	O
or	O
chronic	O
alcohol	O
intake	O
(	O
anti	O
-	O
acetaldehyde	O
-	O
CYP2E1	O
and	O
anti	O
-	O
hydroxyethyl	O
-	O
CYP2E1	O
)	O
,	O
.	O

For	O
CYP2C9	B
,	O
diverging	O
effects	O
were	O
observed	O
(	O
8	O
%	O
and	O
58	O
%	O
)	O
,	O
and	O
for	O
CYP2B6	B
,	O
virtually	O
no	O
metabolism	O
(	O
13	O
%	O
and	O
20	O
%	O
)	O
was	O
noted	O
.	O

CYP2B6	B
(	O
human	O
)	O
and	O
CYP2E1	B
(	O
rat	O
)	O
could	O
not	O
be	O
compared	O
between	O
species	O
because	O
the	O
respective	O
analogue	O
of	O
the	O
other	O
species	O
was	O
not	O
available	O
to	O
us	O
.	O
.	O
Positive	O
controls	O
for	O
each	O
of	O
the	O
isolated	O
cytochromes	O
showed	O
an	O
extent	O
of	O
metabolism	O
between	O
31	O
.	O
2	O
%	O
(	O
CYP1A2	B
)	O
and	O
100	O
%	O
(	O
CYP2C9	B
)	O
for	O
human	O
cytochromes	O
and	O
between	O
23	O
.	O
1	O
%	O
(	O
CYP2D2	O
)	O
and	O
100	O
%	O
(	O
CYP2B1	O
)	O
for	O
rat	O
cytochromes	O
(	O
data	O
not	O
shown	O
)	O
.	O

Studies	O
had	O
showed	O
that	O
the	O
metabolism	O
of	O
Valproic	O
Acid	O
and	O
DM	O
can	O
be	O
metabolically	O
and	O
pharmacokinetically	O
affected	O
by	O
the	O
same	O
enzymes	O
:	O
CYP2C9	B
and	O
CYP3A4	B
;	O
that	O
multiple	O
human	O
cytochromes	O
contribute	O
to	O
the	O
bio	O
-	O
transformation	O
of	O
DM	O
,	O
including	O
the	O
enzymes	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	O
,	O
and	O
CYP3A	B
;	O
and	O
that	O
Valproic	O
Acid	O
inhibits	O
CYP2C9	B
,	O
CYP3A4	B
or	O
induces	O
CYP3A4	B
gene	O
expression	O
in	O
vitro	O
which	O
support	O
the	O
possible	O
drug	O
interaction	O
of	O
these	O
two	O
drugs	O
.	O

Meanwhile	O
,	O
the	O
examined	O
series	O
inhibited	O
the	O
cytochrome	O
P450	O
isomers	O
,	O
ie	O
,	O
CYP2C19	B
,	O
CYP2C9	B
,	O
and	O
CYP3A4	B
-	O
except	O
for	O
Compound	O
2g	O
,	O
which	O
did	O
not	O
inhibit	O
CYP2C19	B
.	O

While	O
other	O
hepatic	O
cytochromes	O
contribute	O
to	O
metoprolol	O
metabolism	O
,	O
namely	O
CYP3A4	B
,	O
CYP2B6	B
,	O
and	O
CYP2C9	B
,	O
these	O
isoforms	O
contribute	O
to	O
less	O
than	O
20	O
%	O
of	O
the	O
drugs	O
metabolism	O
;	O
thus	O
,	O
we	O
have	O
focused	O
on	O
CYP2D6	B
since	O
it	O
is	O
the	O
primary	O
pathway	O
of	O
metabolism	O
.	O

More	O
specifically	O
,	O
midazolam	O
biotransformation	O
was	O
equal	O
to	O
that	O
of	O
Primary	O
Human	O
Hepatocytes	O
,	O
whereas	O
the	O
biotransformation	O
by	O
CYP2D6	B
,	O
CYP1A2	B
,	O
and	O
CYP2C9	B
were	O
found	O
to	O
be	O
in	O
the	O
range	O
of	O
1	O
-	O
10	O
%	O
of	O
the	O
best	O
PHH	O
donor	O
^	O
,	O
,	O
,	O
.	O

To	O
assess	O
the	O
respective	O
metabolization	O
capacities	O
,	O
models	O
were	O
treated	O
with	O
a	O
cocktail	O
consisting	O
of	O
the	O
probe	O
substrates	O
midazolam	O
(	O
10	O
M	O
)	O
,	O
dextromethorphan	O
(	O
20	O
M	O
)	O
,	O
phenacetin	O
(	O
100	O
M	O
)	O
,	O
and	O
tolbutamide	O
(	O
100	O
M	O
)	O
,	O
to	O
determine	O
the	O
activities	O
of	O
CYP3A4	B
,	O
CYP2D6	B
,	O
CYP1A2	B
,	O
and	O
CYP2C9	B
,	O
respectively	O
.	O

If	O
one	O
considers	O
that	O
the	O
metabolism	O
of	O
most	O
drugs	O
is	O
catalyzed	O
by	O
the	O
enzyme	O
group	O
of	O
Cytochrome	B
P450	I
,	O
composed	O
of	O
a	O
large	O
number	O
of	O
isoenzymes	O
,	O
the	O
most	O
important	O
of	O
which	O
in	O
the	O
metabolism	O
of	O
drugs	O
are	O
CYP1A2	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
and	O
CYP3A4	B
.	O

Enzalutamide	O
,	O
recognized	O
as	O
a	O
strong	O
CYP3A4	B
and	O
a	O
moderate	O
CYP2C9	B
and	O
CYP2C19	B
inducer	O
,	O
significantly	O
reduces	O
concentrations	O
of	O
several	O
anti	O
-	O
HIV	O
agents	O
such	O
as	O
darunavir	O
,	O
ritonavir	O
,	O
etravirine	O
,	O
and	O
raltegravir	O
.	O

SIM	O
-	O
53B	O
may	O
inhibit	O
some	O
of	O
the	O
cytochrome	O
P450	O
isoforms	O
such	O
as	O
CYP1A2	B
,	O
CYP2C9	B
and	O
CYP3A4	B
.	O

On	O
the	O
other	O
hand	O
,	O
lopinavir	O
/	O
ritonavir	O
induces	O
CYP1A2	B
,	O
CYP2C9	B
,	O
CYP2C19	B
and	O
glucuronidation	O
.	O

For	O
the	O
determination	O
of	O
murine	O
CYP	O
activities	O
,	O
substrates	O
of	O
orthologous	O
human	O
CYP	O
forms	O
were	O
used	O
:	O
CYP1A1	B
/	O
2	O
,	O
ethoxyresorufin	O
(	O
murine	O
CYP1A2	B
)	O
;	O
CYP2C9	B
,	O
diclofenac	O
(	O
murine	O
2C	O
subfamily	O
)	O
;	O
CYP2C19	B
,	O
diazepam	O
(	O
murine	O
2C	O
subfamily	O
)	O
;	O
CYP2D6	B
,	O
bufuralol	O
(	O
murine	O
2D22	O
)	O
and	O
CYP3A4	B
,	O
midazolam	O
(	O
murine	O
CYP3A11	O
and	O
3A13	O
)	O
.	O

Kratom	O
extracts	O
^	O
and	O
mitragynine	O
^	O
,	O
have	O
been	O
tested	O
as	O
inhibitors	O
of	O
several	O
CYPs	O
,	O
including	O
CYP1A2	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
and	O
CYP3A4	B
.	O

We	O
evaluated	O
whether	O
the	O
observed	O
variability	O
in	O
alkaloid	O
profile	O
for	O
kratom	O
extracts	O
results	O
in	O
altered	O
inhibitory	O
effects	O
on	O
three	O
major	O
CYPs	O
,	O
specifically	O
CYP2C9	B
,	O
CYP2D6	B
,	O
and	O
CYP3A	B
.	O

All	O
three	O
kratom	O
extracts	O
tested	O
showed	O
concentration	O
-	O
dependent	O
inhibition	O
of	O
each	O
CYP	O
,	O
with	O
stronger	O
effects	O
on	O
CYP2D6	B
compared	O
to	O
CYP2C9	B
and	O
CYP3A	B
.	O

If	O
the	O
concentration	O
of	O
mitragynine	O
in	O
the	O
liver	O
upon	O
kratom	O
consumption	O
nears	O
the	O
IC_50	O
values	O
estimated	O
from	O
the	O
screening	O
assay	O
(	O
~	O
1	O
M	O
for	O
CYP2D6	B
;	O
10	O
-	O
100	O
M	O
for	O
CYP2C9	B
and	O
CYP3A	B
)	O
,	O
a	O
CYP	O
-	O
mediated	O
kratom	O
-	O
drug	O
interaction	O
is	O
possible	O
.	O

Mitragynine	O
and	O
7	O
-	O
hydroxymitragynine	O
(	O
purchased	O
)	O
,	O
speciofoline	O
(	O
the	O
isolated	O
alkaloid	O
)	O
,	O
and	O
three	O
methanolic	O
kratom	O
extracts	O
(	O
prepared	O
from	O
commercial	O
products	O
K50	O
,	O
K51	O
,	O
and	O
K52	O
;	O
Table	O
)	O
,	O
were	O
tested	O
as	O
inhibitors	O
of	O
CYP2C9	B
,	O
CYP2D6	B
,	O
and	O
CYP3A	B
activities	O
using	O
a	O
cocktail	O
approach	O
^	O
.	O

Diclofenac	O
(	O
4	O
M	O
)	O
,	O
dextromethorphan	O
(	O
4	O
M	O
)	O
,	O
and	O
midazolam	O
(	O
2	O
M	O
)	O
were	O
used	O
as	O
probe	O
substrates	O
for	O
CYP2C9	B
,	O
CYP2D6	B
,	O
and	O
CYP3A	B
activities	O
,	O
respectively	O
.	O

Positive	O
control	O
inhibitors	O
included	O
sulfaphenazole	O
(	O
1	O
M	O
;	O
CYP2C9	B
)	O
,	O
quinidine	O
(	O
2	O
M	O
;	O
CYP2D6	B
)	O
,	O
and	O
ketoconazole	O
(	O
0	O
.	O
1	O
M	O
;	O
CYP3A	B
)	O
.	O

After	O
equilibrating	O
the	O
mixtures	O
for	O
5	O
min	O
at	O
37	O
C	O
,	O
the	O
reaction	O
was	O
initiated	O
by	O
addition	O
of	O
NADPH	O
(	O
1	O
mM	O
final	O
concentration	O
)	O
and	O
incubated	O
for	O
10	O
min	O
(	O
CYP2C9	B
and	O
CYP2D6	B
activities	O
)	O
or	O
2	O
min	O
(	O
CYP3A	B
activity	O
)	O
at	O
37	O
C	O
.	O
Reactions	O
were	O
quenched	O
with	O
2	O
volumes	O
of	O
cold	O
methanol	O
containing	O
internal	O
standard	O
(	O
alprazolam	O
,	O
0	O
.	O
1	O
M	O
)	O
.	O

This	O
system	O
allowed	O
us	O
to	O
simultaneously	O
test	O
whether	O
the	O
human	O
orthologs	O
of	O
the	O
dCYP	O
enzymes	O
identified	O
within	O
our	O
in	O
vivo	O
screening	O
were	O
also	O
involved	O
in	O
metabolizing	O
PCB	O
28	O
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP2E1	B
(	O
drosophila	O
ortholog	O
:	O
Cyp18a1	O
)	O
and	O
CYP3A4	B
(	O
drosophila	O
ortholog	O
:	O
Cyp9f2	O
)	O
in	O
concentration	O
ranges	O
corresponding	O
to	O
their	O
endogenous	O
abundance	O
in	O
the	O
liver	O
^	O
.	O

In	O
vitro	O
,	O
PCB	O
28	O
could	O
be	O
converted	O
into	O
all	O
OH	O
-	O
metabolites	O
by	O
the	O
combination	O
of	O
six	O
recombinant	O
human	O
cytochromes	O
(	O
CYP1A2	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP2E1	B
,	O
CYP3A4	B
)	O
,	O
which	O
are	O
strongly	O
expressed	O
in	O
the	O
liver	O
and	O
thus	O
reflect	O
its	O
metabolic	O
properties	O
.	O

Following	O
the	O
modification	O
of	O
pharmacotherapy	O
motivated	O
by	O
the	O
pharmacogenetic	O
study	O
,	O
these	O
interactions	O
were	O
reduced	O
to	O
135	O
(	O
CYP3A4	B
,	O
57	O
;	O
CYP2D6	B
,	O
22	O
;	O
CYP2C9	B
,	O
19	O
)	O
and	O
25	O
(	O
CYP3A4	B
,	O
10	O
;	O
CYP3A5	B
,	O
10	O
;	O
CYP1A2	B
,	O
5	O
)	O
,	O
achieving	O
a	O
reduction	O
in	O
pharmacological	O
interactions	O
of	O
26	O
.	O
10	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
.	O

The	O
presence	O
of	O
the	O
alleles	O
listed	O
in	O
of	O
the	O
CYP1A2	B
,	O
CYP2B6	B
,	O
CYP2C9	B
,	O
CYP2C19	B
,	O
CYP2D6	B
,	O
CYP3A4	B
,	O
and	O
CYP3A5	B
genes	O
was	O
analyzed	O
in	O
the	O
Pharmacogenetics	O
and	O
Precision	O
Medicine	O
Unit	O
of	O
the	O
University	O
Hospital	O
of	O
Salamanca	O
.	O

In	O
reference	O
to	O
the	O
CYP2C9	B
and	O
CYP2C19	B
genes	O
(	O
n	O
=	O
183	O
,	O
n	O
=	O
186	O
)	O
,	O
the	O
majority	O
phenotype	O
was	O
EM	O
(	O
57	O
.	O
38	O
%	O
,	O
n	O
=	O
105	O
;	O
47	O
.	O
85	O
%	O
,	O
n	O
=	O
89	O
)	O
.	O

However	O
,	O
of	O
the	O
total	O
number	O
of	O
57	O
human	O
Cytochromes	O
P450	O
coding	O
genes	O
with	O
putative	O
enzymatic	O
activities	O
,	O
only	O
15	O
seem	O
to	O
metabolize	O
drugs	O
to	O
date	O
,	O
and	O
genetic	O
polymorphisms	O
of	O
CYP2C9	B
,	O
CYP2C19	B
,	O
and	O
CYP2D6	B
belong	O
to	O
the	O
most	O
frequently	O
studied	O
in	O
pharmacogenomics	O
.	O

CYP1A1	B
*	O
2A	O
is	O
also	O
associated	O
with	O
some	O
hormone	O
-	O
related	O
diseases	O
due	O
to	O
its	O
involvement	O
in	O
the	O
biotransformation	O
of	O
sex	O
hormones	O
.	O

For	O
example	O
,	O
CYP1A1	B
*	O
2A	O
increases	O
the	O
risk	O
of	O
prostate	O
cancer	O
,	O
cervical	O
cancer	O
,	O
and	O
recurrent	O
pregnancy	O
loss	O
in	O
humans	O
,	O
^	O
,	O
.	O

CYP1A1	B
*	O
2C	O
(	O
SNP	O
ID	O
:	O
rs1048943	O
)	O
contains	O
an	O
A	O
to	O
G	O
transition	O
at	O
2455	O
,	O
which	O
results	O
in	O
the	O
modification	O
of	O
the	O
protein	O
from	O
isoleucine	O
to	O
valine	O
.	O

CYP1A1	B
*	O
2C	O
is	O
reported	O
to	O
be	O
associated	O
with	O
a	O
variety	O
of	O
cancers	O
and	O
hormone	O
-	O
related	O
diseases	O
,	O
including	O
prostate	O
cancer	O
,	O
breast	O
cancer	O
,	O
and	O
male	O
infertility	O
,	O
^	O
,	O
.	O

As	O
mentioned	O
earlier	O
,	O
CYP1A1	B
and	O
CYP1A2	O
are	O
involved	O
in	O
the	O
biotransformation	O
of	O
multiple	O
estrogens	O
,	O
and	O
thus	O
are	O
important	O
for	O
maintaining	O
the	O
balance	O
of	O
estrogens	O
.	O

Epidemiologic	O
studies	O
also	O
discussed	O
the	O
relationship	O
between	O
CYP1A1	B
polymorphisms	O
and	O
prostate	O
cancer	O
risk	O
^	O
,	O
.	O

It	O
was	O
reported	O
that	O
CYP1A1	B
Single	O
Nucleotide	O
Polymorphisms	O
(	O
rs4646903	O
and	O
rs1048943	O
)	O
were	O
positively	O
correlated	O
with	O
prostate	O
cancer	O
^	O
,	O
^	O
,	O
.	O

CYP1A1	B
hydroxylates	O
testosterone	O
at	O
the	O
C	O
-	O
6	O
site	O
,	O
which	O
produces	O
hydrophilic	O
metabolites	O
and	O
promotes	O
the	O
excretion	O
of	O
testosterone	O
.	O

Therefore	O
,	O
CYP1A1	B
mutants	O
may	O
interfere	O
with	O
the	O
normal	O
physiological	O
concentration	O
of	O
testosterone	O
,	O
and	O
eventually	O
lead	O
to	O
the	O
occurrence	O
and	O
development	O
of	O
prostate	O
cancer	O
.	O

In	O
fact	O
,	O
CYP1A1	B
*	O
4	O
(	O
2453C	O
>	O
A	O
)	O
and	O
rs1048943	O
(	O
2455A	O
>	O
G	O
)	O
may	O
interfere	O
with	O
the	O
metabolism	O
of	O
testosterone	O
and	O
estrogen	O
,	O
and	O
are	O
reported	O
to	O
be	O
positively	O
correlated	O
with	O
male	O
infertility	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
CYP1A1	B
may	O
affect	O
the	O
biological	O
function	O
of	O
placenta	O
,	O
which	O
may	O
be	O
due	O
to	O
its	O
estrogen	O
metabolism	O
^	O
,	O
.	O

In	O
fact	O
,	O
it	O
is	O
reported	O
that	O
the	O
CYP1A1	B
SNP	O
rs4646903	O
(	O
3801T	O
>	O
C	O
)	O
is	O
positively	O
correlated	O
with	O
the	O
risk	O
of	O
recurrent	O
pregnancy	O
loss	O
in	O
humans	O
.	O

Epidemiological	O
analysis	O
showed	O
that	O
genetic	O
polymorphisms	O
of	O
the	O
CYP1A1	B
(	O
rs4646903	O
,	O
rs1048943	O
,	O
rs4986883	O
,	O
and	O
rs1799814	O
)	O
were	O
not	O
associated	O
with	O
the	O
high	O
risk	O
of	O
coronary	O
artery	O
disease	O
.	O

However	O
,	O
CYP1A1	B
SNP	O
(	O
rs1048943	O
)	O
and	O
CYP1A2	O
Single	O
Nucleotide	O
Polymorphisms	O
(	O
rs762551	O
,	O
rs1133323	O
,	O
and	O
rs1378942	O
)	O
are	O
positively	O
correlated	O
with	O
hypertension	O
susceptibility	O
^	O
,	O
.	O

In	O
this	O
part	O
,	O
the	O
Single	O
Nucleotide	O
Polymorphisms	O
of	O
CYP1A	O
(	O
11	O
for	O
CYP1A1	B
and	O
9	O
for	O
CYP1A2	O
)	O
studied	O
most	O
in	O
recent	O
10	O
years	O
are	O
reviewed	O
for	O
the	O
first	O
time	O
,	O
and	O
the	O
relationship	O
between	O
CYP1A	O
Single	O
Nucleotide	O
Polymorphisms	O
and	O
human	O
diseases	O
is	O
summarized	O
.	O

Treatment	O
of	O
antioxidant	O
,	O
CYP1A1	B
and	O
CYP2A6	O
inhibitors	O
,	O
and	O
chemodietary	O
agents	O
with	O
antioxidant	O
properties	O
significantly	O
reduced	O
the	O
Cell	O
Culture	O
Supernatant	O
and	O
CCS	O
-	O
EVs	O
mediated	O
HIV	O
-	O
1	O
replication	O
in	O
U1	O
cells	O
.	O

We	O
used	O
the	O
following	O
specific	O
TaqMan	O
TM	O
probes	O
(	O
CYP1A1	B
(	O
Hs01054794_m1	O
)	O
,	O
CYP2A6	O
(	O
Hs00430021_m1	O
)	O
,	O
SOD1	O
(	O
Hs00533490_m1	O
)	O
,	O
SOD2	O
(	O
Hs00167309_m1	O
)	O
,	O
catalase	O
(	O
Hs00156308_m1	O
)	O
,	O
and	O
PRDX6	O
(	O
Hs00705355_s1	O
)	O
)	O
and	O
Glyceraldehyde	O
3	O
-	O
Phosphate	O
Dehydrogenase	O
as	O
an	O
endogenous	O
control	O
.	O

We	O
used	O
Western	O
blotting	O
to	O
identify	O
the	O
presence	O
of	O
CYPs	O
,	O
antioxidants	O
,	O
and	O
Human	O
Papillomavirus	O
proteins	O
in	O
Caski	O
-	O
derived	O
Extracellular	O
Vesicles	O
and	O
to	O
calculate	O
the	O
relative	O
protein	O
fold	O
expression	O
level	O
of	O
CYPs	O
and	O
Antioxidant	O
Enzymes	O
in	O
U1	O
cells	O
upon	O
treatment	O
with	O
CCS	O
/	O
CCS	O
-	O
Eversus	O
We	O
used	O
the	O
following	O
primary	O
antibodies	O
:	O
Glyceraldehyde	O
3	O
-	O
Phosphate	O
Dehydrogenase	O
Rabbit	O
Mab	O
,	O
1	O
:	O
2000	O
dilution	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Danvers	O
,	O
MA	O
,	O
USA	O
)	O
,	O
catalogue	O
#	O
2118	O
;	O
CYP1A1	B
rabbit	O
Mab	O
,	O
1	O
:	O
200	O
dilution	O
(	O
Proteintech	O
Group	O
,	O
Inc	O
.	O
,	O
Rosemont	O
,	O
IL	O
,	O
USA	O
)	O
,	O
catalogue	O
#	O
13241	O
-	O
1	O
-	O
AP	O
;	O
CYP1B1	O
Rabbit	O
Mab	O
,	O
1	O
:	O
500	O
dilution	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Dallas	O
,	O
TX	O
,	O
USA	O
)	O
,	O
catalogue	O
#	O
sc	O
-	O
32882	O
;	O
CYP2A6	O
Mouse	O
Mab	O
,	O
1	O
:	O
200	O
dilution	O
(	O
Abcam	O
,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
,	O
catalogue	O
#	O
ab3570	O
;	O
SOD1	O
Mouse	O
Mab	O
,	O
1	O
:	O
1500	O
dilution	O
,	O
catalog	O
#	O
sc	O
-	O
101523	O
;	O
SOD2	O
Mouse	O
Mab	O
,	O
1	O
:	O
500	O
dilution	O
,	O
catalogue	O
#	O
sc	O
-	O
133254	O
;	O
Catalase	O
Mouse	O
Mab	O
,	O
1	O
:	O
1200	O
dilution	O
(	O
Santa	O
Cruz	O
Biotechnology	O
Inc	O
.	O
,	O
Dallas	O
,	O
TX	O
,	O
USA	O
)	O
,	O
catalog	O
#	O
21260	O
-	O
1	O
-	O
AP	O
;	O
PRDX6	O
Rabbit	O
Mab	O
,	O
1	O
:	O
500	O
dilution	O
(	O
LifeSpan	O
Biosciences	O
,	O
Inc	O
.	O
,	O
Seattle	O
,	O
WA	O
,	O
USA	O
)	O
,	O
catalog	O
#	O
LS	O
-	O
C162131	O
;	O
CD63	O
,	O
Rabbit	O
Pab	O
,	O
1	O
:	O
200	O
dilution	O
(	O
Proteintech	O
Group	O
,	O
Rosemont	O
,	O
IL	O
,	O
USA	O
)	O
,	O
catalog	O
#	O
25682	O
-	O
1	O
-	O
AP	O
.	O

The	O
four	O
-	O
day	O
exposure	O
of	O
Cell	O
Culture	O
Supernatant	O
significantly	O
increased	O
the	O
expression	O
of	O
CYP1A1	B
and	O
CYP2A6	O
at	O
the	O
mRNA	O
level	O
(	O
A	O
,	O
B	O
)	O
but	O
not	O
at	O
the	O
protein	O
level	O
(	O
C	O
,	O
D	O
;	O
.	O

To	O
confirm	O
that	O
HIV	O
-	O
1	O
replication	O
is	O
occurring	O
via	O
a	O
CYP	O
-	O
mediated	O
oxidative	O
stress	O
pathway	O
,	O
we	O
treated	O
the	O
CCS	O
-	O
EVs	O
exposed	O
U1	O
cells	O
with	O
an	O
antioxidant	O
(	O
resveratrol	O
)	O
CYP1A1	B
-	O
selective	O
inhibitor	O
(	O
ellipticine	O
)	O
,	O
and	O
CYP2A6	O
-	O
selective	O
inhibitor	O
(	O
tryptamine	O
)	O
.	O

We	O
particularly	O
examined	O
the	O
expression	O
of	O
CYP1A1	B
and	O
CYP2A6	O
,	O
because	O
these	O
enzymes	O
are	O
expressed	O
in	O
monocytic	O
cells	O
.	O

CYP1A1	B
and	O
CYP2A6	O
are	O
the	O
major	O
enzymes	O
for	O
metabolizing	O
polyaryl	O
hydrocarbons	O
and	O
nicotine	O
present	O
in	O
cigarette	O
smoke	O
,	O
respectively	O
,	O
as	O
well	O
as	O
environmental	O
contaminants	O
.	O

This	O
is	O
consistently	O
the	O
case	O
for	O
CYP1A1	B
expression	O
upon	O
exposure	O
to	O
cigarette	O
smoke	O
condensate	O
and	O
benzo	O
(	O
a	O
)	O
pyrene	O
.	O

Recently	O
,	O
we	O
confirmed	O
this	O
association	O
in	O
vitro	O
in	O
U1	O
cells	O
,	O
in	O
which	O
we	O
demonstrated	O
that	O
CYP1A1	B
metabolizes	O
benzo	O
(	O
a	O
)	O
pyrene	O
(	O
a	O
harmful	O
carcinogen	O
in	O
cigarette	O
smoke	O
)	O
and	O
causes	O
increased	O
production	O
of	O
Reactive	O
Oxygen	O
Species	O
,	O
which	O
subsequently	O
triggers	O
HIV	O
-	O
1	O
replication	O
in	O
the	O
U1	O
cells	O
.	O

In	O
flies	O
with	O
RNAi	O
-	O
mediated	O
silencing	O
of	O
Cyp307a2	O
(	O
human	O
orthologs	O
:	O
CYP1A1	B
and	O
CYP1A2	B
)	O
,	O
the	O
metabolite	O
3	O
-	O
OHCB	O
28	O
was	O
not	O
detected	O
and	O
3	O
-	O
OHCB	O
28	O
was	O
reduced	O
by	O
more	O
than	O
70	O
%	O
compared	O
to	O
control	O
levels	O
.	O

Feeding	O
experiments	O
on	O
rats	O
with	O
commercially	O
available	O
PCB	O
mixtures	O
such	O
as	O
Aroclor	O
1254	O
,	O
Fire	O
-	O
Master	O
Bp	O
-	O
6	O
or	O
individual	O
congeners	O
showed	O
the	O
induction	O
of	O
different	O
CYPs	O
depending	O
on	O
the	O
position	O
of	O
the	O
chlorine	O
atoms	O
on	O
the	O
phenyl	O
ring	O
^	O
:	O
Non	O
-	O
orthochlorinated	O
coplanar	O
PCBs	O
such	O
as	O
PCB	O
126	O
,	O
PCB	O
169	O
and	O
PCB	O
77	O
induce	O
the	O
expression	O
of	O
CYP1A1	B
and	O
CYP1A2	B
.	O

Other	O
structured	O
PCBs	O
such	O
as	O
PCB	O
118	O
,	O
PCB	O
138	O
and	O
PCB	O
170	O
induce	O
the	O
expression	O
of	O
both	O
CYP1A1	B
and	O
CYP2B	O
^	O
.	O

Virtually	O
no	O
metabolism	O
was	O
observed	O
for	O
CYP1A2	B
(	O
4	O
%	O
)	O
.	O

Incubation	O
with	O
rat	O
cytochromes	O
revealed	O
a	O
different	O
pattern	O
of	O
metabolism	O
compared	O
with	O
human	O
cytochromes	O
:	O
For	O
CYP1A2	B
,	O
petasin	O
was	O
higher	O
(	O
43	O
%	O
versus	O
4	O
%	O
)	O
,	O
and	O
neopetasin	O
(	O
22	O
%	O
versus	O
<	O
1	O
%	O
)	O
and	O
isopetasin	O
(	O
<	O
1	O
%	O
versus	O
21	O
%	O
)	O
lower	O
metabolized	O
,	O
respectively	O
.	O

On	O
the	O
other	O
hand	O
,	O
all	O
the	O
screened	O
molecules	O
emerged	O
as	O
non	O
-	O
inhibitors	O
of	O
the	O
cytochromes	O
CYP1A2	B
and	O
CYP2D6	O
.	O

Of	O
note	O
,	O
we	O
also	O
found	O
an	O
AAGLY	O
-	O
mediated	O
induction	O
of	O
CYP1A2	B
and	O
CYP2E1	B
in	O
the	O
embryonic	O
kidney	O
line	O
,	O
HEK293	O
(	O
Supplementary	O
Fig	O
.	O

Following	O
in	O
vitro	O
analysis	O
using	O
a	O
liver	O
-	O
like	O
CYP	O
-	O
cocktail	O
,	O
containing	O
human	O
orthologues	O
of	O
dCYP1A2	O
,	O
we	O
confirm	O
human	O
CYP1A2	B
as	O
a	O
PCB	O
28	O
metabolizing	O
enzyme	O
.	O

All	O
of	O
the	O
enzymatic	O
activity	O
on	O
PCB	O
28	O
was	O
found	O
in	O
the	O
fraction	O
containing	O
CYP1A2	B
,	O
CYP2E1	B
and	O
CYP3A4	B
.	O

Particularly	O
CYP1A2	B
as	O
a	O
single	O
enzyme	O
generated	O
high	O
levels	O
of	O
the	O
OH	O
-	O
CB28	O
metabolites	O
^	O
.	O

This	O
confirmed	O
CYP1A2	B
as	O
a	O
central	O
CYP	O
in	O
the	O
formation	O
of	O
reactive	O
OH	O
-	O
metabolites	O
from	O
PCB	O
28	O
.	O

Since	O
CYP1A2	B
is	O
a	O
human	O
orthologue	O
of	O
Drosophila	O
Cyp307a2	O
,	O
these	O
results	O
indicate	O
a	O
conservation	O
at	O
the	O
level	O
of	O
activity	O
against	O
PCB28	O
between	O
Drosophila	O
melanogaster	O
and	O
the	O
human	O
system	O
.	O

This	O
result	O
confirmed	O
CYP1A2	B
as	O
a	O
central	O
CYP	O
in	O
the	O
formation	O
of	O
reactive	O
OH	O
-	O
metabolites	O
from	O
PCB	O
28	O
,	O
since	O
CYP1A2	B
contained	O
in	O
the	O
liver	O
-	O
like	O
rhCYP	O
cocktail	O
is	O
a	O
human	O
orthologue	O
of	O
Cyp307a2	O
in	O
Drosophila	O
^	O
.	O

The	O
human	O
CYP1A2	B
,	O
identified	O
in	O
this	O
study	O
is	O
capable	O
of	O
oxidizing	O
estradiol	O
,	O
resulting	O
in	O
the	O
production	O
of	O
2	O
-	O
hydroxy	O
and	O
4	O
-	O
hydroxy	O
metabolites	O
^	O
.	O

Xenobiotic	O
substrates	O
of	O
CYP1A2	B
include	O
caffeine	O
^	O
,	O
aflatoxin	O
B1	O
^	O
and	O
paracetamol	O
^	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
increased	O
function	O
of	O
CYP1A2	B
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	O
cancer	O
^	O
,	O
which	O
could	O
ultimately	O
also	O
be	O
important	O
for	O
the	O
metabolism	O
of	O
PCBs	O
:	O
In	O
individual	O
cases	O
,	O
existing	O
exposure	O
of	O
PCBs	O
in	O
conjunction	O
with	O
genetic	O
polymorphisms	O
in	O
CYP1A2	B
could	O
lead	O
to	O
an	O
increase	O
in	O
biological	O
efficacy	O
of	O
PCBs	O
(	O
toxicity	O
/	O
mutagenicity	O
)	O
,	O
which	O
could	O
also	O
result	O
in	O
an	O
increased	O
risk	O
of	O
disease	O
.	O

Therefore	O
,	O
in	O
further	O
steps	O
,	O
CYP1A2	B
variants	O
might	O
be	O
identified	O
,	O
that	O
accelerate	O
the	O
metabolism	O
of	O
PCB	O
28	O
in	O
humans	O
.	O

Taking	O
only	O
neuroleptic	O
therapy	O
into	O
account	O
,	O
78	O
interactions	O
were	O
tested	O
,	O
most	O
of	O
which	O
occur	O
through	O
cytochromes	O
CYP3A4	B
(	O
n	O
=	O
27	O
)	O
,	O
CYP3A5	B
(	O
n	O
=	O
27	O
)	O
,	O
and	O
CYP1A2	B
(	O
n	O
=	O
17	O
)	O
.	O

The	O
CYP1A2	B
gene	O
was	O
studied	O
in	O
179	O
patients	O
,	O
with	O
the	O
most	O
prevalent	O
phenotype	O
being	O
HI	O
(	O
Higher	O
Inducibility	O
)	O
(	O
86	O
.	O
03	O
%	O
,	O
n	O
=	O
154	O
)	O
.	O

In	O
total	O
,	O
taking	O
into	O
account	O
the	O
liver	O
metabolism	O
,	O
mediated	O
through	O
the	O
previously	O
mentioned	O
CYP450	O
system	O
members	O
,	O
from	O
both	O
antipsychotic	O
therapy	O
and	O
concomitant	O
therapy	O
,	O
458	O
conflicts	O
were	O
discovered	O
between	O
the	O
patients	O
prescription	O
and	O
genotype	O
,	O
with	O
most	O
conflicts	O
associated	O
with	O
concomitant	O
therapy	O
occurring	O
through	O
cytochrome	O
CYP3A5	B
(	O
n	O
=	O
57	O
)	O
,	O
and	O
those	O
primarily	O
related	O
to	O
the	O
metabolism	O
of	O
neuroleptics	O
occurring	O
through	O
CYP1A2	B
(	O
n	O
=	O
80	O
)	O
;	O
taking	O
into	O
account	O
the	O
minor	O
metabolizers	O
of	O
the	O
studied	O
antipsychotics	O
,	O
the	O
cytochrome	O
with	O
the	O
highest	O
number	O
of	O
incidences	O
found	O
was	O
CYP3A5	B
(	O
n	O
=	O
93	O
)	O
.	O

The	O
pharmacogenetic	O
profile	O
of	O
the	O
population	O
(	O
CYP1A2	B
HI	O
:	O
0	O
.	O
86	O
;	O
CYP2D6	B
EM	O
:	O
0	O
.	O
85	O
;	O
CYP3A4	B
EM	O
:	O
0	O
.	O
91	O
)	O
could	O
explain	O
the	O
need	O
to	O
apply	O
a	O
higher	O
dose	O
with	O
its	O
consequent	O
adverse	O
effects	O
in	O
patients	O
treated	O
with	O
olanzapine	O
,	O
clozapine	O
,	O
or	O
asenapine	O
,	O
all	O
related	O
to	O
CYP1A2	B
,	O
while	O
favoring	O
the	O
use	O
of	O
aripiprazole	O
or	O
risperidone	O
in	O
those	O
who	O
have	O
a	O
wt	O
-	O
like	O
haplotype	O
in	O
CYP2D6	B
and	O
CYP3A4	B
cytochromes	O
,	O
a	O
situation	O
frequently	O
found	O
in	O
our	O
population	O
.	O

This	O
methodology	O
has	O
led	O
to	O
the	O
discovery	O
of	O
a	O
large	O
number	O
of	O
cases	O
in	O
which	O
there	O
was	O
a	O
problem	O
in	O
the	O
pharmacotherapy	O
due	O
to	O
the	O
metabolism	O
mainly	O
mediated	O
by	O
CYP1A2	B
.	O

For	O
CYP2C19	B
(	O
rs4244285	O
)	O
is	O
the	O
defining	O
polymorphism	O
of	O
the	O
CYP2C19	B
*	O
2	O
allele	O
and	O
is	O
a	O
synonymous	O
G	O
>	O
A	O
transition	O
in	O
exon	O
5	O
that	O
creates	O
an	O
aberrant	O
splice	O
site	O
,	O
and	O
this	O
change	O
alters	O
the	O
mRNA	O
reading	O
frame	O
,	O
which	O
results	O
in	O
a	O
truncated	O
,	O
non	O
-	O
functional	O
protein	O
.	O

This	O
CYP2C19	B
*	O
2	O
allele	O
is	O
the	O
most	O
common	O
CYP2C19	B
loss	O
-	O
of	O
-	O
function	O
allele	O
,	O
with	O
allele	O
frequencies	O
of	O
approximately	O
12	O
%	O
in	O
Caucasians	O
,	O
15	O
%	O
in	O
African	O
-	O
Americans	O
,	O
and	O
29	O
-	O
35	O
%	O
in	O
Asians	O
.	O

The	O
CYP2C19	B
poor	O
metabolism	O
phenotype	O
was	O
initially	O
discovered	O
by	O
studies	O
on	O
impaired	O
mephenytoin	O
metabolism	O
and	O
the	O
major	O
molecular	O
defect	O
responsible	O
for	O
the	O
trait	O
is	O
the	O
CYP2C19	B
*	O
2	O
(	O
rs4244285	O
)	O
loss	O
-	O
of	O
-	O
function	O
allele	O
.	O

For	O
CYP2C19	B
*	O
2	O
Single	O
Nucleotide	O
Polymorphisms	O
can	O
cause	O
a	O
40	O
-	O
nucleotide	O
deletion	O
and	O
a	O
frame	O
shift	O
which	O
leads	O
to	O
a	O
premature	O
stop	O
codon	O
,	O
result	O
in	O
the	O
production	O
of	O
a	O
truncated	O
protein	O
without	O
enzymatic	O
activity	O
.	O

For	O
CYP2C19	B
(	O
rs4986893	O
)	O
is	O
the	O
defining	O
polymorphism	O
of	O
the	O
CYP2C19	B
*	O
3	O
allele	O
and	O
is	O
a	O
G	O
>	O
A	O
transition	O
in	O
exon	O
4	O
that	O
results	O
in	O
a	O
premature	O
termination	O
codon	O
at	O
amino	O
acid	O
212	O
.	O

The	O
CYP2C19	B
*	O
3	O
allele	O
frequencies	O
in	O
most	O
populations	O
is	O
below	O
1	O
%	O
;	O
however	O
,	O
it	O
is	O
more	O
prevalent	O
among	O
Asians	O
(	O
2	O
-	O
9	O
%	O
)	O
.	O

Poor	O
CYP2C19	B
metabolizers	O
are	O
found	O
in	O
5	O
%	O
of	O
white	O
people	O
,	O
but	O
in	O
up	O
to	O
20	O
%	O
of	O
Asians	O
.	O

Here	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
the	O
number	O
of	O
miRNAs	O
that	O
targeting	O
the	O
CYP2C19	B
gene	O
,	O
which	O
includes	O
the	O
following	O
:	O
hsa	O
-	O
miR	O
-	O
1270	O
,	O
hsa	O
-	O
miR	O
-	O
455	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
4325	O
,	O
hsa	O
-	O
miR	O
-	O
7703	O
,	O
hsa	O
-	O
miR	O
-	O
6880	O
-	O
5p	O
,	O
hsa	O
-	O
miR	O
-	O
6851	O
-	O
5p	O
,	O
hsa	O
-	O
miR	O
-	O
3689d	O
,	O
hsa	O
-	O
miR	O
-	O
4683	O
,	O
hsa	O
-	O
miR	O
-	O
6499	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
767	O
-	O
5p	O
,	O
hsa	O
-	O
miR	O
-	O
6134	O
,	O
hsa	O
-	O
miR	O
-	O
4537	O
,	O
hsa	O
-	O
miR	O
-	O
5186	O
,	O
hsa	O
-	O
miR	O
-	O
665	O
,	O
hsa	O
-	O
miR	O
-	O
4459	O
,	O
hsa	O
-	O
miR	O
-	O
92b	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
92a	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
367	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
363	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
32	O
-	O
5p	O
,	O
hsa	O
-	O
miR	O
-	O
25	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
3180	O
-	O
5p	O
,	O
hsa	O
-	O
miR	O
-	O
3912	O
-	O
5p	O
,	O
hsa	O
-	O
miR	O
-	O
874	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
3157	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
5195	O
-	O
3p	O
,	O
hsa	O
-	O
miR	O
-	O
145	O
-	O
5p	O
,	O
and	O
hsa	O
-	O
miR	O
-	O
6886	O
-	O
3p	O
.	O

Since	O
,	O
about	O
28	O
miRNAs	O
can	O
target	O
the	O
CYP2C19	B
gene	O
,	O
we	O
believe	O
that	O
during	O
the	O
disease	O
status	O
in	O
children	O
with	O
epilepsy	O
,	O
or	O
during	O
treatment	O
with	O
phenobarbital	O
,	O
one	O
or	O
multiple	O
miRNA	O
may	O
be	O
involved	O
,	O
along	O
with	O
the	O
regulation	O
of	O
the	O
CYP2C19	B
gene	O
,	O
which	O
in	O
turn	O
up	O
-	O
regulates	O
or	O
down	O
regulates	O
the	O
genes	O
and	O
also	O
changes	O
the	O
genetic	O
variations	O
of	O
the	O
gene	O
.	O

Genomic	O
variation	O
of	O
CYP2C19	B
was	O
considered	O
in	O
drug	O
pharmacokinetic	O
proteins	O
,	O
in	O
drug	O
target	O
proteins	O
and	O
finally	O
across	O
multiple	O
candidate	O
genes	O
,	O
thus	O
providing	O
three	O
broad	O
hypotheses	O
as	O
sources	O
,	O
housing	O
potential	O
influential	O
genomic	O
variations	O
.	O

Metoprolol	O
metabolites	O
segregated	O
very	O
well	O
with	O
CYP2D6	B
phenotype	O
,	O
suggesting	O
that	O
drug	O
metabolism	O
can	O
be	O
predicted	O
based	O
upon	O
knowledge	O
of	O
CYP2D6	B
genotype	O
and	O
the	O
presence	O
of	O
drug	O
-	O
drug	O
interactions	O
.	O

This	O
may	O
have	O
contributed	O
to	O
our	O
inability	O
to	O
identify	O
endogenous	O
metabolites	O
predictive	O
of	O
clinical	O
effectiveness	O
,	O
if	O
CYP2D6	B
drug	O
metabolism	O
plays	O
a	O
major	O
role	O
in	O
drug	O
effectiveness	O
,	O
as	O
hypothesized	O
.	O

CYP2D6	B
was	O
genotyped	O
using	O
the	O
Multiplex	O
SNaPshot	O
technique	O
previously	O
described	O
.	O

This	O
assay	O
detects	O
20	O
CYP2D6	B
clinically	O
significant	O
variants	O
and	O
identifies	O
copy	O
number	O
variants	O
.	O

Genotyping	O
was	O
performed	O
after	O
subjects	O
completed	O
the	O
protocol	O
;	O
thus	O
,	O
the	O
investigators	O
were	O
blinded	O
to	O
the	O
CYP2D6	B
genotype	O
during	O
treatment	O
.	O

Predicted	O
phenotypes	O
were	O
determined	O
utilizing	O
CYP2D6	B
activity	O
score	O
,	O
as	O
described	O
by	O
Gaedigk	O
et	O
al	O
.	O
.	O
Each	O
identified	O
CYP2D6	B
SNV	O
was	O
assigned	O
a	O
predicted	O
enzyme	O
activity	O
score	O
[	O
,	O
.	O

Human	O
P450	O
polymorphisms	O
in	O
what	O
is	O
now	O
known	O
as	O
CYP2D6	B
were	O
identified	O
in	O
the	O
1970s	O
and	O
in	O
the	O
1980s	O
in	O
P450	O
2C19	O
[	O
,	O
.	O

(	O
Note	O
:	O
by	O
definition	O
a	O
polymorphism	O
is	O
present	O
at	O
1	O
%	O
incidence	O
in	O
a	O
population	O
,	O
and	O
the	O
term	O
variant	O
includes	O
not	O
only	O
polymorphisms	O
but	O
all	O
rare	O
changes	O
,	O
and	O
the	O
term	O
single	O
nucleotide	O
variant	O
(	O
SNV	O
)	O
is	O
probably	O
more	O
generally	O
appropriate	O
,	O
ie	O
,	O
160	O
CYP2D6	B
SNVs	O
are	O
known	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
pharmvar	O
.	O
org	O
/	O
gene	O
/	O
CYP2D6	B
)	O
.	O
)	O

Today	O
we	O
realize	O
that	O
SNVs	O
are	O
seen	O
in	O
all	O
human	O
P450s	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
pharmvar	O
.	O
org	O
/	O
gene	O
/	O
CYP2D6	B
)	O
.	O

This	O
is	O
,	O
for	O
instance	O
,	O
how	O
the	O
CYP2D6	B
polymorphism	O
was	O
discovered	O
,	O
in	O
that	O
Robert	O
Smith	O
(	O
personally	O
)	O
experienced	O
a	O
strong	O
hypotensive	O
effect	O
of	O
debrisoquine	O
.	O

Conversely	O
,	O
some	O
drugs	O
are	O
activated	O
by	O
P450s	O
,	O
and	O
there	O
are	O
SNVs	O
that	O
involve	O
higher	O
activity	O
than	O
wild	O
type	O
enzyme	O
,	O
eg	O
,	O
CYP2D6	B
*	O
53	O
[	O
,	O
.	O

One	O
deficiency	O
is	O
predicting	O
the	O
in	O
vivo	O
magnitude	O
of	O
P450	O
SNversus	O
For	O
instance	O
,	O
even	O
the	O
CYP2D6	B
*	O
3	O
polymorphism	O
,	O
which	O
results	O
in	O
loss	O
of	O
the	O
entire	O
enzyme	O
due	O
to	O
aberrant	O
mRNA	O
splicing	O
,	O
has	O
varying	O
effects	O
in	O
vivo	O
with	O
different	O
drugs	O
,	O
and	O
the	O
results	O
cannot	O
be	O
explained	O
simply	O
by	O
the	O
contribution	O
of	O
other	O
P450s	O
.	O

Tested	O
extracts	O
and	O
mitragynine	O
were	O
generally	O
stronger	O
inhibitors	O
of	O
CYP2D6	B
activity	O
relative	O
to	O
the	O
other	O
isoforms	O
^	O
,	O
.	O

Most	O
patients	O
had	O
an	O
EM	O
phenotype	O
(	O
85	O
.	O
95	O
%	O
,	O
n	O
=	O
159	O
;	O
91	O
.	O
49	O
%	O
,	O
n	O
=	O
172	O
)	O
with	O
respect	O
to	O
CYP2D6	B
cytochromes	O
(	O
n	O
=	O
183	O
)	O
and	O
CYP3A4	B
(	O
n	O
=	O
188	O
)	O
,	O
and	O
PM	O
(	O
Poor	O
Metabolizer	O
)	O
phenotype	O
(	O
87	O
.	O
85	O
%	O
,	O
n	O
=	O
159	O
)	O
was	O
the	O
most	O
frequent	O
with	O
respect	O
to	O
CYP3A5	B
cytochrome	O
(	O
n	O
=	O
187	O
)	O
.	O

Aripiprazole	O
is	O
a	O
neuroleptic	O
whose	O
metabolism	O
develops	O
predominantly	O
in	O
the	O
liver	O
,	O
through	O
the	O
CYP450	O
system	O
,	O
specifically	O
by	O
CYP2D6	B
and	O
CYP3A4	B
cytochromes	O
which	O
,	O
in	O
the	O
vast	O
majority	O
of	O
our	O
patients	O
(	O
more	O
than	O
80	O
%	O
)	O
,	O
presented	O
an	O
EM	O
phenotype	O
,	O
favoring	O
its	O
use	O
.	O

This	O
finding	O
strongly	O
suggests	O
that	O
hepatic	O
CYP2E1	B
-	O
dependent	O
ROS	O
-	O
elicited	O
lipid	O
peroxidation	O
with	O
consequent	O
JNK1	O
activation	O
and	O
insulin	O
resistance	O
occur	O
only	O
when	O
hepatic	O
lipid	O
is	O
markedly	O
elevated	O
and	O
available	O
for	O
peroxidation	O
.	O

and	O
Jiang	O
et	O
al	O
.	O
,	O
we	O
conclude	O
that	O
a	O
major	O
determinant	O
of	O
the	O
differential	O
responses	O
observed	O
upon	O
comparable	O
CYP2E1	B
-	O
functional	O
stabilization	O
in	O
Chip	O
-	O
KO	O
and	O
Gp78	O
-	O
KO	O
mouse	O
livers	O
is	O
the	O
ER	O
-	O
stability	O
of	O
the	O
Insig	O
-	O
SCAP	O
-	O
SREBP	O
-	O
1c	O
complex	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
Chip	O
-	O
KO	O
mice	O
,	O
although	O
the	O
adiponectin	O
-	O
AMPK1ALPHA	O
-	O
FOXO1	O
/	O
3	O
signaling	O
initially	O
protects	O
the	O
livers	O
,	O
this	O
beneficial	O
signaling	O
is	O
suppressed	O
as	O
progressively	O
augmented	O
CYP2E1	B
-	O
dependent	O
oxidative	O
injury	O
and	O
sustained	O
JNK	O
-	O
signaling	O
activation	O
trigger	O
hepatic	O
injury	O
and	O
hepatocyte	O
dropout	O
with	O
age	O
.	O

Thus	O
,	O
in	O
principle	O
,	O
ALD	O
-	O
targeted	O
CYP2E1	B
given	O
its	O
critical	O
role	O
in	O
acetaminophen	O
-	O
mediated	O
hepatotoxicity	O
and	O
contribution	O
to	O
alcoholic	O
liver	O
disease	O
could	O
be	O
a	O
prime	O
candidate	O
.	O

However	O
,	O
while	O
the	O
protective	O
effects	O
of	O
rapamycin	O
-	O
induced	O
Autophagic	O
-	O
Lysosomal	O
Degradation	O
and	O
the	O
worsening	O
effects	O
of	O
chloroquine	O
-	O
suppressed	O
Autophagic	O
-	O
Lysosomal	O
Degradation	O
on	O
acetaminophen	O
-	O
elicited	O
hepatotoxicity	O
seemingly	O
reflect	O
an	O
inherent	O
role	O
of	O
CYP2E1	B
in	O
acetaminophen	O
bioactivation	O
,	O
they	O
are	O
exerted	O
at	O
a	O
stage	O
beyond	O
CYP2E1	B
-	O
dependent	O
metabolic	O
activation	O
,	O
and	O
thus	O
,	O
quite	O
independent	O
of	O
corresponding	O
effects	O
on	O
CYP2E1	B
-	O
proteolytic	O
stability	O
.	O

This	O
apparent	O
discrepancy	O
is	O
due	O
not	O
only	O
to	O
reduced	O
CYP2E1	B
content	O
but	O
also	O
a	O
persistent	O
,	O
compensatory	O
activation	O
of	O
NRF2	O
that	O
triggers	O
the	O
transcriptional	O
activation	O
of	O
drug	O
detoxification	O
enzymes	O
and	O
GSH	O
synthesis	O
,	O
as	O
well	O
as	O
greater	O
hepatocyte	O
proliferation	O
in	O
the	O
liver	O
-	O
specific	O
Atg5	O
-	O
KO	O
mice	O
.	O

Interestingly	O
,	O
CYP2E1	B
-	O
stabilization	O
upon	O
chemically	O
-	O
induced	O
autophagic	O
disruption	O
in	O
HepG2	O
cells	O
promotes	O
,	O
as	O
expected	O
,	O
CYP2E1	B
-	O
dependent	O
oxidative	O
stress	O
,	O
mitochondrial	O
dysfunction	O
,	O
JNK	O
and	O
p38	O
MAPK	O
-	O
activation	O
,	O
and	O
consequent	O
cytotoxicity	O
.	O

Thus	O
,	O
CYP2E1	B
functional	O
stabilization	O
upon	O
Chip	O
-	O
KO	O
results	O
in	O
hepatic	O
oxidative	O
stress	O
,	O
JNK1	O
-	O
activation	O
,	O
insulin	O
resistance	O
,	O
FA	O
-	O
and	O
TG	O
-	O
accumulation	O
and	O
liver	O
injury	O
that	O
contribute	O
to	O
NASH	O
.	O

By	O
contrast	O
,	O
despite	O
comparable	O
CYP2E1	B
functional	O
stabilization	O
,	O
no	O
significant	O
hepatic	O
FA	O
-	O
and	O
TG	O
-	O
accumulation	O
is	O
observed	O
upon	O
Gp78	O
-	O
KO	O
due	O
to	O
the	O
ER	O
-	O
stabilization	O
of	O
the	O
Insig	O
proteins	O
that	O
prevents	O
SREBP	O
-	O
1c	O
-	O
elicited	O
transcriptional	O
activation	O
of	O
hepatic	O
lipogenesis	O
.	O

In	O
addition	O
,	O
the	O
hydroxylation	O
of	O
some	O
tri	O
-	O
and	O
tetrachlorobiphenyls	O
(	O
PCB	O
20	O
,	O
22	O
,	O
52	O
and	O
74	O
)	O
by	O
CYP2E1	B
^	O
and	O
the	O
formation	O
of	O
4	O
-	O
OHCB	O
101	O
from	O
PCB	O
101	O
by	O
CYP2A6	O
was	O
detected	O
in	O
vitro	O
^	O
.	O

were	O
altering	O
N	O
-	O
oxidation	O
of	O
3	O
,	O
5	O
-	O
DCA	O
,	O
the	O
ability	O
of	O
diethyldithiocarbamate	O
(	O
DEDTCA	O
)	O
,	O
an	O
inhibitor	O
of	O
CYP2C	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
CYP2E1	B
,	O
to	O
reduce	O
DCNB	O
formation	O
was	O
examined	O
.	O

Since	O
the	O
CYP2E1	B
inhibitor	O
isoniazid	O
had	O
no	O
effect	O
on	O
3	O
,	O
5	O
-	O
DCA	O
cytotoxicity	O
,	O
it	O
appears	O
that	O
CYP2C	O
enzymes	O
are	O
bioactivating	O
3	O
,	O
5	O
-	O
DCA	O
to	O
toxic	O
metabolites	O
via	O
3	O
,	O
5	O
-	O
DCPHA	O
formation	O
.	O

In	O
vitro	O
functional	O
reconstitution	O
studies	O
,	O
of	O
E1	O
/	O
E2	O
/	O
E3	O
-	O
mediated	O
CYP3A4	B
and	O
CYP2E1	O
ubiquitination	O
have	O
identified	O
UbcH5a	O
/	O
Hsc70	O
/	O
Hsp40	O
/	O
CHIP	O
and	O
UBC7	O
/	O
AMFR	O
/	O
gp78	O
complexes	O
as	O
two	O
relevant	O
E2	O
/	O
E3	O
systems	O
in	O
CYP3A4	B
and	O
CYP2E1	O
ubiquitination	O
:	O
(	O
i	O
)	O
CHIP	O
(	O
carboxy	O
-	O
terminus	O
of	O
Hsc70	O
-	O
interacting	O
protein	O
)	O
,	O
a	O
cytoplasmic	O
Hsc70	O
-	O
cochaperone	O
,	O
functions	O
with	O
its	O
cognate	O
UbcH5a	O
E2	O
and	O
Hsc70	O
/	O
Hsp40	O
co	O
-	O
chaperones	O
in	O
substrate	O
ubiquitination	O
,	O
.	O

The	O
individual	O
roles	O
of	O
CHIP	O
and	O
gp78	O
in	O
CYP3A	B
and	O
CYP2E1	O
ubiquitination	O
and	O
Endoplasmic	O
Reticulum	O
-	O
Associated	O
Degradation	O
were	O
verified	O
upon	O
lentiviral	O
shRNA	O
interference	O
analyses	O
targeted	O
individually	O
against	O
each	O
of	O
these	O
E3s	O
in	O
cultured	O
rat	O
hepatocytes	O
,	O
.	O

Thus	O
,	O
upon	O
CHIP	O
-	O
knockdown	O
,	O
CYP3A	B
was	O
stabilized	O
largely	O
as	O
the	O
parent	O
(	O
55	O
kDa	O
)	O
species	O
along	O
with	O
a	O
minor	O
CYP3A	B
fraction	O
consisting	O
of	O
its	O
high	O
molecular	O
mass	O
ubiquitinated	O
species	O
.	O

Upon	O
gp78	O
knockdown	O
,	O
CYP3A	B
was	O
largely	O
found	O
as	O
its	O
parent	O
species	O
along	O
with	O
a	O
significant	O
amount	O
of	O
its	O
ubiquitinated	O
species	O
.	O

However	O
,	O
upon	O
either	O
E3	O
-	O
knockdown	O
,	O
the	O
functionally	O
active	O
CYP3A	B
fraction	O
not	O
only	O
was	O
proportional	O
to	O
the	O
relative	O
amount	O
of	O
the	O
stabilized	O
unmodified	O
parent	O
species	O
,	O
but	O
also	O
considerably	O
greater	O
than	O
that	O
in	O
the	O
corresponding	O
non	O
-	O
targeting	O
shRNA	O
-	O
treated	O
control	O
hepatocytes	O
,	O
indicating	O
that	O
CYP3A	B
-	O
ERAD	O
disruption	O
could	O
be	O
therapeutically	O
relevant	O
.	O

Furthermore	O
,	O
each	O
system	O
by	O
itself	O
was	O
capable	O
of	O
CYP3A4	B
-	O
ubiquitination	O
as	O
determined	O
upon	O
in	O
vitro	O
reconstitution	O
studies	O
of	O
each	O
individual	O
CYP3A4	B
E2	O
/	O
E3	O
-	O
ubiquitination	O
system	O
.	O

However	O
,	O
CYP3A4	B
ubiquitination	O
was	O
both	O
greatly	O
accelerated	O
and	O
magnified	O
when	O
both	O
E2	O
/	O
E3	O
systems	O
were	O
present	O
simultaneously	O
.	O

The	O
CYP3A4	B
ubiquitination	O
profile	O
observed	O
upon	O
sequential	O
introduction	O
of	O
each	O
E2	O
/	O
E3	O
in	O
the	O
reconstituted	O
system	O
suggested	O
that	O
UbcH5a	O
/	O
CHIP	O
most	O
likely	O
serves	O
as	O
the	O
E3	O
,	O
with	O
UBC7	O
/	O
gp78	O
serving	O
as	O
the	O
E4	O
involved	O
in	O
the	O
elongation	O
of	O
CYP3A4	B
polyUb	O
chains	O
.	O

This	O
heterotrimeric	O
p97	O
-	O
complex	O
was	O
documented	O
to	O
be	O
required	O
for	O
CYP3A	B
Ubiquitin	O
-	O
Dependent	O
Proteasomal	O
Degradation	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Through	O
chemical	O
(	O
formaldehyde	O
)	O
-	O
crosslinking	O
,	O
immune	O
affinity	O
-	O
purification	O
and	O
LC	O
-	O
MS	O
/	O
MS	O
analyses	O
,	O
its	O
close	O
cellular	O
association	O
with	O
ubiquitinated	O
CYP3A23	O
in	O
cultured	O
rat	O
hepatocytes	O
was	O
also	O
documented	O
,	O
a	O
finding	O
subsequently	O
verified	O
by	O
p97	O
-	O
targeted	O
lentiviral	O
Shrna	O
Interference	O
analyses	O
in	O
cultured	O
rat	O
hepatocytes	O
.	O

Lentiviral	O
shRNAi	O
-	O
elicited	O
p97	O
-	O
knockdown	O
led	O
to	O
the	O
accumulation	O
of	O
parent	O
and	O
ubiquitinated	O
CYP3A23	O
species	O
that	O
remained	O
largely	O
anchored	O
to	O
the	O
ER	O
-	O
membrane	O
,	O
unlike	O
those	O
from	O
control	O
shRNA	O
-	O
treated	O
hepatocytes	O
that	O
were	O
largely	O
extracted	O
into	O
the	O
cytosol	O
.	O

The	O
serious	O
,	O
life	O
-	O
threatening	O
Drug	O
-	O
Drug	O
Interactions	O
observed	O
with	O
the	O
CYP3A4	B
mechanism	O
-	O
based	O
inactivators	O
grapefruit	O
juice	O
furanocoumarins	O
and	O
terfenadine	O
,	O
astemizole	O
or	O
amiodarone	O
are	O
some	O
illustrative	O
examples	O
,	O
.	O

Similar	O
hepatic	O
stabilization	O
of	O
CYP3A	B
-	O
enzymes	O
in	O
these	O
mice	O
can	O
significantly	O
enhance	O
the	O
bioactivation	O
of	O
the	O
breast	O
cancer	O
chemotherapeutic	O
prodrug	O
tamoxifen	O
to	O
its	O
pharmacologically	O
active	O
end	O
-	O
product	O
endoxifen	O
.	O

We	O
find	O
it	O
intriguing	O
that	O
serum	O
antibodies	O
to	O
one	O
of	O
the	O
CYP3A	B
peptides	O
detected	O
in	O
clinical	O
CBZ	O
-	O
elicited	O
acute	O
hypersensitivity	O
reactions	O
,	O
corresponds	O
to	O
the	O
same	O
CYP3A4	B
helix	O
K	O
-	O
region	O
that	O
is	O
heme	O
-	O
modified	O
upon	O
cumene	O
-	O
hydroperoxide	O
-	O
elicited	O
peroxidative	O
CYP3A4	B
heme	O
-	O
fragmentation	O
.	O

The	O
magnitude	O
of	O
CYP2E1	O
and	O
CYP3A	B
functional	O
stabilization	O
is	O
comparable	O
in	O
Gp78	O
-	O
KO	O
and	O
Chip	O
-	O
KO	O
mouse	O
livers	O
,	O
.	O

CYP3A	B
showed	O
a	O
similar	O
pattern	O
:	O
petasin	O
/	O
neopetasin	O
/	O
isopetasin	O
metabolism	O
with	O
CYP3A4	B
(	O
human	O
)	O
was	O
34	O
%	O
/	O
87	O
%	O
/	O
86	O
%	O
versus	O
CYP3A1	O
(	O
rat	O
)	O
:	O
37	O
%	O
/	O
78	O
%	O
/	O
86	O
%	O
versus	O
CYP3A2	O
(	O
rat	O
)	O
:	O
34	O
%	O
/	O
46	O
%	O
/	O
73	O
%	O
.	O

By	O
day	O
20	O
,	O
hepatic	O
transcripts	O
,	O
such	O
as	O
alpha1	O
-	O
antitrypsin	O
and	O
Na	O
^	O
+	O
-	O
taurocholate	O
cotransporting	O
polypeptide	O
,	O
reached	O
levels	O
found	O
in	O
PHHs4A	O
and	O
Alpha1	O
-	O
Antitrypsin	O
and	O
activity	O
of	O
mature	O
genes	O
such	O
as	O
albumin	O
or	O
CYP3A4	B
,	O
the	O
most	O
important	O
drug	O
-	O
biotransforming	O
enzyme	O
,	O
remained	O
lower	O
than	O
in	O
Primary	O
Human	O
Hepatocytes	O
or	O
even	O
12	O
h	O
plated	O
Primary	O
Human	O
Hepatocytes	O
(	O
PHH	O
12	O
h	O
)	O
.	O

Induction	O
of	O
HNF1A	O
,	O
FOXA3	O
,	O
and	O
PROX1	O
from	O
D4	O
until	O
D20	O
induced	O
their	O
expression	O
to	O
levels	O
near	O
those	O
of	O
Primary	O
Human	O
Hepatocytes	O
and	O
increased	O
both	O
Albumin	O
and	O
CYP3A4	B
mRNA	O
.	O

Transcript	O
levels	O
of	O
Albumin	O
now	O
reached	O
those	O
of	O
PHH	O
12	O
h	O
and	O
CYP3A4	B
expression	O
was	O
increased	O
50	O
-	O
fold	O
was	O
still	O
very	O
low	O
or	O
increased	O
OCR	O
was	O
observed	O
.	O

Surprisingly	O
,	O
despite	O
the	O
clear	O
correlation	O
between	O
metabolism	O
,	O
AA	O
catabolism	O
,	O
and	O
Cytochrome	O
P450	O
expression	O
observed	O
in	O
the	O
WGCNA	O
,	O
AA3	O
only	O
marginally	O
induced	O
the	O
expression	O
of	O
CYP3A4	B
when	O
exceeding	O
the	O
nutritional	O
need	O
(	O
Supplementary	O
Fig	O
,	O
C	O
)	O
.	O

We	O
observed	O
a	O
concentration	O
-	O
dependent	O
increase	O
in	O
CYP3A4	B
expression	O
when	O
HLC	O
D20	O
or	O
HC3X	O
D20	O
were	O
differentiated	O
in	O
AA3	O
medium	O
supplemented	O
with	O
2	O
%	O
glycine	O
present	O
in	O
the	O
media	O
was	O
replaced	O
by	O
2	O
%	O
of	O
a	O
single	O
AA	O
,	O
as	O
the	O
combination	O
increased	O
the	O
osmolarity	O
of	O
the	O
media	O
to	O
lethal	O
levels	O
(	O
Supplementary	O
Fig	O
.	O

Importantly	O
,	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
medium	O
induced	O
a	O
gradual	O
maturation	O
of	O
HLC	O
and	O
HC3X	O
progeny	O
,	O
as	O
extended	O
culture	O
resulted	O
in	O
a	O
continuous	O
increase	O
in	O
CYP3A4	B
expression	O
and	O
function	O
to	O
levels	O
that	O
were	O
in	O
the	O
range	O
of	O
gold	O
standard	O
,	O
freshly	O
thawed	O
Primary	O
Human	O
Hepatocytes	O
.	O

As	O
we	O
observed	O
for	O
Hepatocyte	O
-	O
Like	O
Cells	O
,	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
also	O
induced	O
a	O
gradual	O
increase	O
in	O
CYP3A4	B
expression	O
and	O
function	O
of	O
HepG2	O
cells	O
over	O
time	O
.	O

Based	O
on	O
the	O
Rna	O
-	O
Sequencing	O
data	O
,	O
we	O
next	O
analyzed	O
the	O
activity	O
of	O
the	O
AKT	O
-	O
mTORC1	O
,	O
Amp	O
-	O
Activated	O
Protein	O
Kinase	O
,	O
and	O
eIF2alpha	O
pathways	O
in	O
HepG2	O
cultured	O
with	O
AA3	O
ALA	O
or	O
AA3GLY	O
(	O
strong	O
inducers	O
of	O
CYP3A4	B
)	O
versus	O
AA3	O
VAL	O
(	O
weak	O
induction	O
of	O
CYP3A4	B
)	O
.	O

This	O
analysis	O
linked	O
induction	O
of	O
mature	O
hepatic	O
markers	O
such	O
as	O
CYP3A4	B
,	O
Phosphoenolpyruvate	O
Carboxykinase	O
,	O
and	O
glutamine	O
synthetase	O
to	O
an	O
increased	O
phosphorylation	O
of	O
S6	O
,	O
Amp	O
-	O
Activated	O
Protein	O
Kinase	O
,	O
and	O
AKT	O
.	O

From	O
these	O
pathways	O
,	O
we	O
were	O
able	O
to	O
specifically	O
link	O
mTORC1	O
signaling	O
to	O
the	O
induction	O
of	O
CYP3A4	B
,	O
as	O
addition	O
of	O
the	O
mTORC1	O
inhibitor	O
rapamycin	O
blocked	O
the	O
induction	O
of	O
CYP3A4	B
,	O
while	O
Amp	O
-	O
Activated	O
Protein	O
Kinase	O
phosphorylation	O
and	O
ATF4	O
levels	O
remained	O
unchanged	O
(	O
Supplementary	O
Fig	O
.	O

Furthermore	O
,	O
knockout	O
of	O
the	O
upstream	O
regulators	O
of	O
Amp	O
-	O
Activated	O
Protein	O
Kinase	O
and	O
eIF2alpha	O
,	O
LKB1	O
and	O
GCN2	O
,	O
did	O
not	O
affect	O
CYP3A4	B
levels	O
both	O
in	O
control	O
media	O
or	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
media	O
(	O
Supplementary	O
Fig	O
B	O
,	O
C	O
)	O
.	O

In	O
both	O
HepG2	O
,	O
HLC	O
and	O
HC3X	O
,	O
mTORC1	O
appeared	O
to	O
regulate	O
CYP3A4	B
expression	O
rather	O
than	O
translation	O
.	O

Finally	O
,	O
although	O
Knockout	O
of	O
the	O
mTORC1	O
inhibitor	O
Tuberous	O
sclerosis	O
(	O
TSC	O
)	O
1	O
was	O
not	O
sufficient	O
for	O
driving	O
maturation	O
in	O
HepG2	O
,	O
culture	O
of	O
TSC1	O
Knockout	O
HepG2	O
in	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
medium	O
yielded	O
an	O
even	O
greater	O
induction	O
of	O
CYP3A4	B
compared	O
with	O
wild	O
-	O
type	O
HepG2	O
^	O
.	O

However	O
,	O
we	O
only	O
found	O
an	O
increase	O
in	O
CYP3A4	B
and	O
the	O
gluconeogenic	O
genes	O
,	O
G6PC	O
and	O
Phosphoenolpyruvate	O
Carboxykinase	O
,	O
when	O
HC6X	O
were	O
also	O
cultured	O
with	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
,	O
indicating	O
that	O
mitochondrial	O
biogenesis	O
is	O
not	O
sufficient	O
to	O
drive	O
maturation	O
(	O
Supplementary	O
Fig	O
E	O
,	O
F	O
)	O
.	O

The	O
transcriptome	O
of	O
HC6X	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
D40	O
was	O
similar	O
to	O
that	O
of	O
HC3X	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
D40	O
,	O
even	O
if	O
perhaps	O
slightly	O
closer	O
to	O
that	O
of	O
Primary	O
Human	O
Hepatocytes	O
caused	O
a	O
significant	O
decrease	O
in	O
CYP3A4	B
activity	O
and	O
to	O
a	O
lesser	O
extent	O
also	O
decreased	O
global	O
maturity	O
(	O
Fig	O
.	O

In	O
accordance	O
,	O
we	O
found	O
that	O
HC6X	O
Aa3	O
Medium	O
Supplemented	O
With	O
2	O
%	O
Glycine	O
D40	O
stained	O
positive	O
for	O
CYP3A4	B
,	O
with	O
several	O
cells	O
displaying	O
a	O
binucleated	O
phenotype	O
(	O
Supplementary	O
Fig	O
.	O

Of	O
the	O
investigated	O
signaling	O
pathways	O
,	O
we	O
only	O
found	O
inhibition	O
of	O
mTORC1	O
to	O
be	O
able	O
to	O
prevent	O
the	O
induction	O
of	O
CYP3A4	B
under	O
conditions	O
of	O
AA	O
supplementation	O
.	O

Nevertheless	O
,	O
the	O
sole	O
activation	O
of	O
mTORC1	O
through	O
the	O
genetic	O
deletion	O
of	O
TSC1	O
was	O
not	O
sufficient	O
to	O
induce	O
CYP3A4	B
expression	O
.	O

CYP3A4	B
-	O
dependent	O
metabolization	O
was	O
determined	O
using	O
the	O
fluorometric	O
probe	O
BFC	O
as	O
previously	O
described	O
^	O
.	O

Moreover	O
it	O
is	O
important	O
to	O
emphasize	O
that	O
tocilizumab	O
decreases	O
the	O
concentration	O
of	O
several	O
medications	O
as	O
a	O
cytochrome	O
P450	O
,	O
isoenzyme	O
CYP3A4	B
inducer	O
in	O
terms	O
of	O
antagonisms	O
or	O
synergy	O
but	O
this	O
is	O
not	O
yet	O
entirely	O
clear	O
(	O
;	O
.	O

Several	O
drugs	O
,	O
such	O
as	O
CYP3A4	B
inhibitors	O
,	O
increase	O
concentration	O
of	O
colchicine	O
and	O
attention	O
should	O
be	O
paid	O
when	O
the	O
latter	O
is	O
used	O
with	O
cisplatin	O
or	O
vinca	O
alkaloids	O
.	O

One	O
main	O
source	O
of	O
risk	O
is	O
inhibition	O
of	O
CYP3A4	B
by	O
lopinavir	O
/	O
ritonavir	O
(	O
perpetrator	O
)	O
.	O

Given	O
that	O
ritonavir	O
irreversibly	O
inhibits	O
CYP3A4	B
,	O
the	O
inhibitory	O
effect	O
may	O
last	O
up	O
to	O
5	O
days	O
after	O
stopping	O
ritonavir	O
.	O

Interestingly	O
,	O
we	O
observed	O
the	O
same	O
trend	O
as	O
with	O
CYP3A	B
enzymes	O
:	O
a	O
diminished	O
difference	O
between	O
the	O
sexes	O
in	O
GF	O
mice	O
.	O

The	O
enzymatic	O
activity	O
of	O
CYP3A	B
was	O
significantly	O
decreased	O
in	O
GF	O
mice	O
compared	O
to	O
SPF	O
mice	O
.	O

In	O
the	O
female	O
groups	O
,	O
the	O
activity	O
of	O
CYP3A	B
did	O
not	O
differ	O
significantly	O
from	O
the	O
male	O
groups	O
but	O
had	O
a	O
tendency	O
to	O
decrease	O
.	O

Even	O
though	O
in	O
humans	O
the	O
differences	O
are	O
subtler	O
,	O
it	O
is	O
known	O
that	O
the	O
CYP3A4	B
activity	O
features	O
apparent	O
sexual	O
dimorphism	O
with	O
higher	O
activity	O
in	O
women	O
due	O
to	O
differences	O
in	O
growth	O
hormone	O
patterns	O
.	O

The	O
enzymatic	O
activity	O
of	O
CYP3A	B
(	O
using	O
midazolam	O
as	O
a	O
substrate	O
)	O
in	O
both	O
the	O
male	O
and	O
female	O
mice	O
lacking	O
the	O
microbiota	O
was	O
significantly	O
decreased	O
compared	O
to	O
their	O
SPF	O
counterparts	O
.	O

Further	O
we	O
have	O
found	O
that	O
the	O
activity	O
of	O
CYP3A	B
did	O
not	O
differ	O
significantly	O
in	O
female	O
groups	O
from	O
the	O
male	O
groups	O
,	O
but	O
had	O
a	O
tendency	O
to	O
decrease	O
.	O

This	O
data	O
suggests	O
that	O
the	O
down	O
-	O
regulation	O
of	O
CYP3A	B
enzymes	O
may	O
not	O
be	O
sex	O
-	O
specific	O
and	O
,	O
above	O
all	O
,	O
that	O
the	O
gut	O
microbiome	O
is	O
crucial	O
in	O
the	O
synthesis	O
of	O
CYP3A	B
in	O
both	O
sexes	O
.	O

Interestingly	O
,	O
we	O
observed	O
the	O
same	O
trend	O
as	O
with	O
CYP3A	B
enzymes	O
:	O
diminishing	O
the	O
changes	O
between	O
sexes	O
in	O
GF	O
mice	O
.	O

In	O
humans	O
,	O
CYP2C	O
and	O
CYP3A	B
enzymes	O
are	O
abundantly	O
present	O
in	O
the	O
liver	O
and	O
,	O
completely	O
or	O
partially	O
,	O
metabolize	O
a	O
large	O
fraction	O
of	O
all	O
prescribed	O
drugs	O
.	O

CYP3A4	B
contributes	O
to	O
the	O
oxidation	O
of	O
many	O
steroids	O
,	O
and	O
its	O
activity	O
in	O
humans	O
is	O
sexually	O
dimorphic	O
.	O

The	O
exact	O
mechanism	O
for	O
sex	O
differences	O
in	O
CYP3A4	B
(	O
and	O
other	O
CYPs	O
)	O
remains	O
elusive	O
but	O
may	O
include	O
altered	O
growth	O
hormone	O
signalling	O
.	O

In	O
addition	O
,	O
because	O
CYP3A	B
is	O
also	O
expressed	O
in	O
the	O
intestine	O
,	O
mitragynine	O
concentrations	O
in	O
the	O
intestine	O
could	O
well	O
exceed	O
10	O
M	O
,	O
increasing	O
the	O
possibility	O
of	O
CYP3A	B
-	O
mediated	O
kratom	O
-	O
drug	O
interactions	O
.	O

In	O
the	O
context	O
of	O
Hepatocellular	O
Carcinoma	O
,	O
treatment	O
with	O
5	O
-	O
AZA	O
conduced	O
to	O
tumor	O
regression	O
and	O
a	O
shift	O
to	O
a	O
more	O
differentiated	O
phenotype	O
,	O
which	O
was	O
associated	O
with	O
regional	O
demethylation	O
of	O
CpG	O
regions	O
upstream	O
of	O
the	O
liver	O
-	O
specific	O
genes	O
SLC10A1	O
,	O
CYP3A4	B
,	O
ALB	O
,	O
and	O
miR	O
-	O
122	O
,	O
which	O
were	O
downregulated	O
pretreatments	O
.	O

The	O
cytochrome	O
through	O
which	O
more	O
conflicts	O
occur	O
was	O
CYP3A4	B
(	O
n	O
=	O
67	O
)	O
,	O
followed	O
by	O
3A5	O
(	O
n	O
=	O
27	O
)	O
and	O
1A2	O
(	O
n	O
=	O
27	O
)	O
.	O

As	O
can	O
be	O
seen	O
,	O
the	O
prescription	O
of	O
oral	O
drugs	O
whose	O
metabolism	O
is	O
related	O
to	O
enzymes	O
frequently	O
altered	O
in	O
the	O
study	O
population	O
,	O
is	O
reduced	O
by	O
between	O
20	O
and	O
100	O
%	O
,	O
in	O
favor	O
of	O
intramuscular	O
prescriptions	O
that	O
either	O
do	O
not	O
have	O
liver	O
metabolism	O
,	O
such	O
as	O
Paliperidone	O
,	O
which	O
increases	O
by	O
186	O
.	O
95	O
%	O
,	O
or	O
whose	O
main	O
route	O
of	O
metabolism	O
is	O
associated	O
with	O
an	O
enzyme	O
that	O
usually	O
has	O
no	O
alterations	O
,	O
such	O
as	O
Aripiprazole	O
,	O
whose	O
prescriptions	O
increase	O
by	O
100	O
%	O
,	O
predominantly	O
metabolized	O
by	O
CYP3A4	B
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
use	O
of	O
DEPOT	O
presentations	O
of	O
drugs	O
such	O
as	O
paliperidone	O
(	O
not	O
metabolized	O
by	O
the	O
CYP450	O
system	O
)	O
or	O
aripiprazole	O
(	O
whose	O
predominant	O
pathway	O
within	O
the	O
CYP450	O
system	O
is	O
CYP3A4	B
,	O
which	O
presents	O
a	O
wt	O
-	O
like	O
genotype	O
in	O
the	O
vast	O
majority	O
of	O
the	O
study	O
population	O
)	O
has	O
been	O
the	O
solution	O
for	O
the	O
majority	O
of	O
problematic	O
cases	O
,	O
because	O
of	O
the	O
pharmacogenetic	O
profile	O
of	O
the	O
sample	O
,	O
even	O
considering	O
that	O
each	O
patient	O
was	O
studied	O
individually	O
attending	O
its	O
personal	O
genetic	O
implications	O
.	O

The	O
lowest	O
counts	O
of	O
variants	O
were	O
found	O
in	O
CYP21A2	O
(	O
one	O
variant	O
)	O
,	O
CYP26C1	O
(	O
seven	O
)	O
,	O
CYP3A4	B
,	O
and	O
CYP19A1	O
(	O
both	O
eight	O
variants	O
)	O
.	O

CYP3A5	B
catalyzes	O
a	O
comparable	O
range	O
of	O
reactions	O
as	O
CYP3A4	B
but	O
its	O
role	O
in	O
drug	O
and	O
steroid	O
metabolism	O
is	O
limited	O
due	O
to	O
its	O
generally	O
low	O
activity	O
and	O
expression	O
in	O
a	O
relatively	O
small	O
percentage	O
of	O
individuals	O
[	O
,	O
.	O

CYP3A7	O
is	O
the	O
major	O
CYP3A	O
isoform	O
in	O
prenatal	O
and	O
early	O
postnatal	O
life	O
and	O
differs	O
from	O
CYP3A4	B
in	O
terms	O
of	O
expression	O
and	O
function	O
.	O

CYP3A4	B
-	O
catalyzed	O
6BETA	O
-	O
hydroxylation	O
is	O
the	O
most	O
common	O
hydroxylation	O
for	O
^	O
4	O
steroids	O
,	O
eg	O
cortisol	O
(	O
(	O
e	O
)	O
)	O
,	O
while	O
6ALPHA	O
-	O
hydroxylated	O
pregnanolones	O
are	O
quantitatively	O
important	O
urine	O
steroid	O
metabolites	O
during	O
pregnancy	O
.	O

The	O
differential	O
substrate	O
specificity	O
,	O
regioselectivity	O
and	O
catalytic	O
activity	O
of	O
CYP3A4	B
and	O
CYP3A7	O
and	O
the	O
dynamic	O
expression	O
pattern	O
of	O
the	O
two	O
isoforms	O
throughout	O
fetal	O
development	O
and	O
the	O
first	O
year	O
of	O
life	O
lead	O
to	O
substantial	O
changes	O
in	O
the	O
hepatic	O
steroid	O
metabolome	O
during	O
this	O
period	O
of	O
life	O
.	O

CYP3A4	B
levels	O
are	O
low	O
in	O
the	O
fetus	O
and	O
newborn	O
compared	O
to	O
the	O
adult	O
.	O

Thus	O
,	O
there	O
is	O
a	O
switch	O
from	O
CYP3A7	O
to	O
CYP3A4	B
during	O
the	O
first	O
months	O
after	O
birth	O
.	O

In	O
fact	O
,	O
CYP2C19	O
and	O
CYP3A4	B
can	O
21	O
-	O
hydroxylate	O
progesterone	O
and	O
pregnenolone	O
,	O
possibly	O
partially	O
compensating	O
mineralocorticoid	O
deficiency	O
in	O
CAH	O
due	O
to	O
21	O
-	O
hydroxylase	O
deficiency	O
;	O
however	O
,	O
the	O
two	O
enzymes	O
are	O
not	O
capable	O
of	O
catalyzing	O
the	O
21	O
-	O
hydroxylation	O
of	O
17OHP	O
to	O
11	O
-	O
deoxycortisol	O
.	O

Cortisol	O
can	O
also	O
be	O
6BETA	O
-	O
hydroxylated	O
by	O
CYP3A4	B
expressed	O
in	O
the	O
liver	O
,	O
resulting	O
in	O
6BETA	O
-	O
hydroxycortisol	O
(	O
6BETA	O
-	O
OHF	O
)	O
.	O

Circulating	O
Dehydroepiandrosterone	O
is	O
readily	O
16ALPHA	O
-	O
hydroxylated	O
by	O
CYP3A4	B
/	O
7	O
within	O
the	O
liver	O
.	O

CYP3A4	B
is	O
the	O
major	O
enzyme	O
responsible	O
for	O
the	O
16ALPHA	O
-	O
hydroxylation	O
of	O
estrone	O
in	O
adults	O
,	O
though	O
CYP1A1	O
,	O
CYP2C19	O
and	O
CYP3A5	B
can	O
also	O
catalyze	O
the	O
reaction	O
.	O

Conversely	O
,	O
CYP1A2	O
is	O
the	O
dominant	O
enzyme	O
catalyzing	O
the	O
16ALPHA	O
-	O
hydroxylation	O
of	O
17BETA	O
-	O
estradiol	O
,	O
with	O
CYP3A4	B
,	O
CYP1A1	O
and	O
CYP1B1	O
also	O
demonstrating	O
this	O
activity	O
.	O

These	O
reactions	O
are	O
catalyzed	O
by	O
a	O
variety	O
of	O
CYPs	O
,	O
including	O
CYP3A4	B
and	O
CYP1A2	O
in	O
the	O
liver	O
,	O
or	O
CYP1A1	O
and	O
CYP3A4	B
in	O
peripheral	O
tissues	O
.	O

There	O
are	O
more	O
than	O
50	O
Cytochrome	O
P450	O
enzymes	O
,	O
but	O
the	O
CYP1A2	O
,	O
CYP2C9	O
,	O
CYP2C19	O
,	O
CYP2D6	O
,	O
CYP3A4	B
,	O
and	O
CYP3A5	B
enzymes	O
metabolize	O
90	O
percent	O
of	O
drugs	O
.	O

Accordingly	O
,	O
the	O
dominant	O
human	O
liver	O
/	O
intestinal	O
CYP3A4	B
and	O
human	O
liver	O
CYP2E1	O
are	O
found	O
to	O
be	O
prototypic	O
ERAD	O
-	O
C	O
substrates	O
.	O

CYP3A4	B
,	O
accounting	O
for	O
30	O
%	O
of	O
the	O
hepatic	O
P450	O
content	O
,	O
is	O
engaged	O
in	O
the	O
metabolism	O
of	O
>	O
50	O
%	O
of	O
clinically	O
relevant	O
drugs	O
and	O
other	O
xenobiotics	O
,	O
whereas	O
CYP2E1	O
biotransforms	O
clinically	O
relevant	O
drugs	O
(	O
acetaminophen	O
,	O
halothane	O
)	O
,	O
EtOH	O
,	O
and	O
other	O
xenobiotics	O
,	O
carcinogens	O
(	O
nitrosamines	O
)	O
,	O
endogenous	O
acetone	O
and	O
fatty	O
acids	O
(	O
arachidonic	O
acid	O
)	O
to	O
toxic	O
/	O
reactive	O
intermediates	O
,	O
.	O

Therefore	O
,	O
further	O
elucidation	O
of	O
the	O
function	O
of	O
rs17102977	O
and	O
mainly	O
the	O
whole	O
gene	O
locus	O
1p33	O
containing	O
also	O
CYP4B1	O
,	O
CYP4A11	O
,	O
CYP4Z1	O
,	O
and	O
CYP4A22	O
genes	O
is	O
needed	O
.	O

Thus	O
,	O
although	O
previous	O
studies	O
identified	O
Amino	O
Acids	O
as	O
important	O
for	O
hepatocyte	O
survival	O
,	O
proliferation	O
,	O
and	O
protein	O
synthesis	O
^	O
,	O
,	O
we	O
here	O
demonstrate	O
that	O
increasing	O
Amino	O
Acids	O
to	O
levels	O
30	O
-	O
fold	O
above	O
that	O
of	O
typical	O
hepatocyte	O
media	O
,	O
actively	O
induces	O
a	O
metabolic	O
switch	O
,	O
as	O
well	O
as	O
Cytochrome	B
P450	I
enzyme	O
expression	O
and	O
function	O
(	O
Supplementary	O
Table	O
.	O

Comparative	O
Cytochrome	B
P450	I
biotransformation	O
studies	O
were	O
performed	O
to	O
assess	O
functionality	O
across	O
a	O
number	O
of	O
gold	O
standard	O
primary	O
hepatocyte	O
models	O
.	O

Tocilizumab	O
decreases	O
concentrations	O
of	O
many	O
anticancer	O
drugs	O
due	O
to	O
interference	O
with	O
Cytochrome	B
P450	I
.	O

Cytochrome	B
P450	I
monooxygenases	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
biosynthesis	O
of	O
numerous	O
secondary	O
metabolites	O
and	O
stress	O
responses	O
of	O
plants	O
to	O
herbicides	O
and	O
pathogens	O
^	O
-	O
.	O

Previous	O
studies	O
reported	O
that	O
Mycophenolic	O
Acid	O
metabolized	O
in	O
inactive	O
MPAG	O
and	O
AcMPAG	O
metabolites	O
by	O
Cytochrome	B
P450	I
.	O

Meanwhile	O
QC	O
further	O
improved	O
the	O
therapeutic	O
efficacy	O
by	O
increasing	O
the	O
bioavailability	O
of	O
Mycophenolic	O
Acid	O
through	O
inhibiting	O
Cytochrome	B
P450	I
enzyme	I
.	O

Thus	O
,	O
we	O
investigated	O
the	O
potential	O
of	O
naturally	O
occurring	O
Alternaria	O
toxin	O
mixtures	O
to	O
induce	O
Cytochrome	B
P450	I
1A1	O
/	O
1A2	O
/	O
1B1	O
activity	O
.	O

Sub	O
-	O
cytotoxic	O
concentrations	O
of	O
the	O
two	O
toxin	O
mixtures	O
,	O
as	O
well	O
as	O
ATX	O
-	O
I	O
,	O
ATX	O
-	O
II	O
and	O
AOH	O
,	O
exhibited	O
dose	O
-	O
dependent	O
enhancements	O
of	O
Cytochrome	B
P450	I
1	O
activity	O
.	O

Besides	O
,	O
several	O
Cytochrome	B
P450	I
isoforms	O
are	O
frequently	O
induced	O
by	O
their	O
own	O
substrates	O
.	O

Hence	O
,	O
prominent	O
ligands	O
of	O
the	O
Aryl	O
Hydrocarbon	O
Receptor	O
behave	O
also	O
as	O
inducers	O
of	O
Cytochrome	B
P450	I
1A1	O
activity	O
,	O
such	O
as	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
and	O
benzo	O
[	O
a	O
]	O
pyrene	O
(	O
B	O
[	O
a	O
]	O
P	O
)	O
,	O
which	O
are	O
suggested	O
to	O
be	O
involved	O
in	O
increased	O
breast	O
cancer	O
risk	O
.	O

Furthermore	O
,	O
distinctively	O
elevated	O
Cytochrome	B
P450	I
1A1	O
and	O
Cytochrome	B
P450	I
1B1	O
protein	O
expression	O
as	O
well	O
as	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
activity	O
were	O
previously	O
reported	O
for	O
breast	O
cancer	O
tissues	O
in	O
comparison	O
to	O
adjacent	O
non	O
-	O
tumor	O
tissues	O
.	O

A	O
standard	O
method	O
used	O
to	O
determine	O
Cytochrome	B
P450	I
1A1	O
enzyme	O
activity	O
induction	O
upon	O
exposure	O
to	O
Aryl	O
Hydrocarbon	O
Receptor	O
ligands	O
is	O
the	O
7	O
-	O
ethoxyresorufin	O
-	O
O	O
-	O
deethylase	O
assay	O
.	O

The	O
dealkylation	O
of	O
7	O
-	O
ethoxyresorufin	O
(	O
7	O
-	O
ER	O
)	O
yielding	O
the	O
fluorescent	O
substance	O
resorufin	O
was	O
shown	O
to	O
be	O
primarily	O
exerted	O
through	O
Cytochrome	B
P450	I
1A1	O
,	O
followed	O
by	O
Cytochrome	B
P450	I
1A2	O
and	O
Cytochrome	B
P450	I
1B1	O
.	O

Previous	O
studiesuncovered	O
the	O
induction	O
of	O
Cytochrome	B
P450	I
1A1	O
expression	O
to	O
be	O
Aryl	O
Hydrocarbon	O
Receptor	O
dependent	O
for	O
both	O
dibenzo	O
-	O
ALPHA	O
-	O
pyrones	O
in	O
murine	O
hepatoma	O
cells	O
and	O
AOH	O
in	O
human	O
esophageal	O
cancer	O
cells	O
,	O
whereas	O
the	O
latter	O
turned	O
out	O
to	O
be	O
irrelevant	O
for	O
the	O
genotoxic	O
capabilities	O
of	O
AOH	O
.	O

Although	O
data	O
on	O
the	O
metabolism	O
of	O
altertoxins	O
is	O
scarce	O
,	O
ATX	O
-	O
II	O
was	O
reported	O
to	O
induce	O
Cytochrome	B
P450	I
1A1	O
activity	O
and	O
raise	O
Cytochrome	B
P450	I
1A1	O
transcript	O
levels	O
in	O
KYSE	O
510	O
cells	O
.	O

Hence	O
,	O
this	O
study	O
aimed	O
to	O
uncover	O
the	O
potential	O
of	O
naturally	O
occurring	O
mixtures	O
of	O
Alternaria	O
toxins	O
to	O
enhance	O
Cytochrome	B
P450	I
1	O
activity	O
and	O
their	O
combinatory	O
effects	O
in	O
this	O
respect	O
applying	O
the	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
assay	O
.	O

Further	O
,	O
the	O
Cytochrome	B
P450	I
1	O
activating	O
potential	O
of	O
single	O
Alternaria	O
toxins	O
,	O
as	O
well	O
as	O
binary	O
mixtures	O
according	O
to	O
the	O
complex	O
extracts	O
,	O
was	O
investigated	O
utilizing	O
the	O
estrogen	O
-	O
sensitive	O
mammary	O
adenocarcinoma	O
cell	O
line	O
MCF	O
-	O
7	O
.	O

Thus	O
,	O
the	O
study	O
at	O
hand	O
investigated	O
the	O
potential	O
of	O
complex	O
Alternaria	O
toxin	O
mixtures	O
as	O
well	O
as	O
selected	O
single	O
toxins	O
in	O
corresponding	O
binary	O
mixtures	O
to	O
affect	O
Cytochrome	B
P450	I
1	O
enzyme	O
activity	O
in	O
estrogen	O
-	O
sensitive	O
MCF	O
-	O
7	O
mammary	O
cancer	O
cells	O
.	O

The	O
induction	O
of	O
both	O
Cytochrome	B
P450	I
1A1	O
mRNA	O
transcription	O
and	O
the	O
according	O
enzymatic	O
activity	O
was	O
reported	O
to	O
serve	O
as	O
indicators	O
for	O
Aryl	O
Hydrocarbon	O
Receptor	O
activation	O
.	O

In	O
contrast	O
,	O
E2	O
showed	O
no	O
estrogen	O
-	O
related	O
induction	O
of	O
Cytochrome	B
P450	I
1	O
activity	O
in	O
our	O
MCF	O
-	O
7	O
cell	O
model	O
(	O
a	O
)	O
,	O
which	O
was	O
suggested	O
in	O
a	O
previously	O
published	O
study	O
.	O

Both	O
,	O
the	O
Complete	O
Extract	O
and	O
the	O
Reduced	O
Extract	O
(	O
stripped	O
from	O
the	O
two	O
perylene	O
quinones	O
ATX	O
-	O
II	O
and	O
STTX	O
-	O
III	O
)	O
,	O
led	O
to	O
dose	O
-	O
dependent	O
enhancements	O
of	O
Cytochrome	B
P450	I
1A1	O
activity	O
(	O
a	O
)	O
.	O

This	O
is	O
in	O
line	O
with	O
a	O
previous	O
report	O
of	O
the	O
Complete	O
Extract	O
to	O
increase	O
Cytochrome	B
P450	I
1A1	O
expression	O
levels	O
in	O
Ishikawa	O
cells	O
at	O
concentrations	O
comparable	O
to	O
the	O
extracts	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
enzyme	O
activity	O
induction	O
in	O
MCF	O
-	O
7	O
.	O

Notably	O
,	O
the	O
REs	O
capability	O
to	O
induce	O
Cytochrome	B
P450	I
1	O
activity	O
surpassed	O
the	O
potent	O
activity	O
of	O
the	O
Complete	O
Extract	O
at	O
higher	O
concentrations	O
.	O

Single	O
known	O
extracts	O
constituents	O
,	O
such	O
as	O
ATX	O
-	O
II	O
and	O
AOH	O
were	O
previously	O
shown	O
to	O
activate	O
the	O
Aryl	O
Hydrocarbon	O
Receptor	O
,	O
increase	O
Cytochrome	B
P450	I
1A1	O
enzyme	O
activity	O
,	O
which	O
was	O
shown	O
via	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
assay	O
and	O
impact	O
Cytochrome	B
P450	I
1A1	O
mRNA	O
transcription	O
at	O
corresponding	O
concentrations	O
in	O
KYSE	O
510	O
oesophageal	O
cancer	O
cells	O
,	O
while	O
Alternariol	O
Monomethyl	O
Ether	O
exhibited	O
its	O
potency	O
primarily	O
in	O
HepG2	O
cells	O
.	O

Testing	O
single	O
toxins	O
revealed	O
dose	O
-	O
dependent	O
enzyme	O
activation	O
for	O
ATX	O
-	O
I	O
,	O
ATX	O
-	O
II	O
and	O
AOH	O
;	O
in	O
contrast	O
,	O
no	O
evident	O
induction	O
of	O
Cytochrome	B
P450	I
1	O
enzyme	O
activity	O
was	O
exerted	O
by	O
Alternariol	O
Monomethyl	O
Ether	O
(	O
b	O
)	O
.	O

Previously	O
,	O
ATX	O
-	O
II	O
was	O
found	O
to	O
increase	O
Cytochrome	B
P450	I
1	O
transcription	O
and	O
activity	O
in	O
oesophageal	O
cancer	O
cells	O
starting	O
at	O
a	O
concentration	O
of	O
0	O
.	O
05	O
M	O
and	O
0	O
.	O
1	O
M	O
,	O
respectively	O
,	O
indicating	O
a	O
higher	O
sensitivity	O
to	O
Aryl	O
Hydrocarbon	O
Receptor	O
activation	O
compared	O
to	O
the	O
breast	O
cancer	O
cell	O
line	O
MCF	O
-	O
7	O
.	O

This	O
enhancement	O
of	O
Cytochrome	B
P450	I
1	O
enzyme	O
activity	O
was	O
linked	O
to	O
Aryl	O
Hydrocarbon	O
Receptor	O
activation	O
.	O

Preceding	O
published	O
experiments	O
showed	O
inconclusive	O
efficacy	O
of	O
Alternariol	O
Monomethyl	O
Ether	O
towards	O
Cytochrome	B
P450	I
1	O
enzyme	O
activity	O
alteration	O
,	O
increasing	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
activity	O
in	O
HepG2	O
cells	O
at	O
10	O
M	O
and	O
in	O
KYSE	O
510	O
at	O
50	O
M	O
.	O
This	O
effect	O
was	O
diminished	O
again	O
at	O
50	O
M	O
in	O
HepG2	O
,	O
possibly	O
due	O
to	O
the	O
onset	O
of	O
cytotoxicity	O
.	O

Of	O
note	O
,	O
B	O
[	O
a	O
]	O
P	O
was	O
shown	O
to	O
elevate	O
Cytochrome	B
P450	I
1A1	O
and	O
Cytochrome	B
P450	I
1B1	O
mRNA	O
in	O
MCF	O
-	O
7	O
cells	O
;	O
therefore	O
,	O
enhanced	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
enzyme	O
activity	O
cannot	O
exclusively	O
be	O
ascribed	O
to	O
a	O
single	O
Cytochrome	B
P450	I
1	O
enzyme	O
as	O
7	O
-	O
ER	O
poses	O
a	O
substrate	O
for	O
several	O
above	O
mentioned	O
isoforms	O
.	O

Nonetheless	O
,	O
previous	O
studies	O
on	O
AOH	O
,	O
Alternariol	O
Monomethyl	O
Ether	O
,	O
and	O
ATX	O
-	O
II	O
as	O
well	O
as	O
on	O
the	O
Alternaria	O
extracts	O
used	O
showed	O
Cytochrome	B
P450	I
1A1	O
mRNA	O
enhancements	O
in	O
various	O
cell	O
lines	O
.	O

Therefore	O
,	O
a	O
high	O
correlation	O
of	O
7	O
-	O
Ethoxy	O
-	O
Resorufin	O
-	O
O	O
-	O
Deethylase	O
enzyme	O
activity	O
towards	O
Cytochrome	B
P450	I
1A1	O
could	O
be	O
assumed	O
for	O
the	O
toxins	O
and	O
mixtures	O
applied	O
here	O
as	O
well	O
.	O

Nonetheless	O
,	O
further	O
interference	O
by	O
other	O
compounds	O
not	O
tested	O
(	O
or	O
not	O
identified	O
)	O
within	O
the	O
complex	O
mixture	O
affecting	O
the	O
Cytochrome	B
P450	I
1	O
enzyme	O
activity	O
needs	O
to	O
be	O
considered	O
for	O
interpretation	O
of	O
the	O
current	O
data	O
.	O

We	O
could	O
decipher	O
the	O
two	O
perylene	O
quinone	O
derivates	O
ATX	O
-	O
I	O
and	O
ATX	O
-	O
II	O
,	O
as	O
well	O
as	O
the	O
dibenzo	O
-	O
ALPHA	O
-	O
pyrone	O
AOH	O
,	O
as	O
participants	O
towards	O
the	O
Cytochrome	B
P450	I
1A1	O
activity	O
induction	O
exerted	O
by	O
complex	O
Alternaria	O
extracts	O
in	O
mammary	O
cancer	O
cells	O
and	O
their	O
combinatory	O
effects	O
to	O
be	O
major	O
contributors	O
.	O

Issues	O
addressed	O
at	O
these	O
research	O
meetings	O
(	O
International	O
Conferences	O
on	O
Cytochrome	B
P450	I
,	O
https	O
:	O
/	O
/	O
www	O
.	O
p450meetings	O
.	O
com	O
)	O
include	O
biochemistry	O
,	O
biophysics	O
,	O
gene	O
regulation	O
,	O
and	O
pharmaceutical	O
and	O
biotechnology	O
applications	O
.	O

Increase	O
in	O
Cytochrome	B
P450	I
activity	O
has	O
been	O
observed	O
even	O
after	O
short	O
-	O
course	O
treatment	O
with	O
lopinavir	O
/	O
ritonavir	O
.	O

Cytochrome	B
P450	I
genes	O
,	O
which	O
are	O
involved	O
in	O
plant	O
development	O
,	O
antioxidant	O
,	O
and	O
detoxification	O
of	O
pollutants	O
,	O
are	O
also	O
involved	O
in	O
plant	O
defense	O
by	O
protecting	O
from	O
various	O
biotic	O
and	O
abiotic	O
stresses	O
.	O

Therefore	O
,	O
we	O
searched	O
the	O
genome	O
of	O
F	O
.	O
filiformis	O
for	O
proteins	O
with	O
a	O
P450	O
conserved	O
domain	O
using	O
the	O
NCBI	O
CDD	O
tool	O
and	O
BLASTp	O
and	O
also	O
by	O
homology	O
BLAST	O
in	O
the	O
Fungal	O
Cytochrome	B
P450	I
Database	O
(	O
p450	O
.	O
riceblast	O
.	O
snu	O
.	O
ac	O
.	O
kr	O
/	O
index	O
.	O
php	O
?	O

The	O
homolog	O
of	O
MaCYP71CD2	O
in	O
neem	O
(	O
AiCYP71CD2	O
)	O
was	O
identified	O
,	O
the	O
homolog	O
of	O
MaCYP71BQ5	O
(	O
a	O
characterized	O
Cytochrome	B
P450	I
from	O
M	O
.	O
azedarach	O
)	O
in	O
neem	O
was	O
fragmented	O
.	O

Extensive	O
bioinformatic	O
analysis	O
of	O
unigenes	O
involving	O
phylogenetic	O
analysis	O
,	O
domain	O
prediction	O
,	O
and	O
molecular	O
docking	O
further	O
provided	O
22	O
candidates	O
for	O
the	O
putative	O
biosynthetic	O
pathway	O
,	O
including	O
1	O
2	O
,	O
3	O
-	O
Oxidosqualene	O
Cyclase	O
unigene	O
,	O
2	O
Alcohol	O
Dehydrogenase	O
unigenes	O
,	O
12	O
Cytochrome	B
P450	I
unigenes	O
,	O
2	O
Acyltransferase	O
unigenes	O
,	O
and	O
5	O
Esterase	O
unigenes	O
.	O

The	O
length	O
of	O
two	O
Cytochrome	B
P450	I
unigenes	O
(	O
transcript	O
/	O
16971	O
and	O
transcript	O
/	O
16742	O
)	O
was	O
1536	O
bp	O
and	O
1527	O
bp	O
,	O
and	O
they	O
encoded	O
proteins	O
consisting	O
of	O
511	O
and	O
508	O
amino	O
acids	O
,	O
respectively	O
.	O

Alcohol	O
Dehydrogenase	O
,	O
Cytochrome	B
P450	I
,	O
Acyltransferase	O
,	O
and	O
Esterase	O
are	O
supposed	O
to	O
be	O
involved	O
in	O
azadirachtin	O
downstream	O
pathway	O
and	O
thus	O
their	O
encoding	O
-	O
unigenes	O
were	O
chosen	O
as	O
candidates	O
.	O

Among	O
all	O
the	O
Differentially	O
Expressed	O
Genes	O
in	O
fruit	O
and	O
leaf	O
transcriptome	O
data	O
,	O
Differentially	O
Expressed	O
Genes	O
encoding	O
Alcohol	O
Dehydrogenase	O
,	O
Cytochrome	B
P450	I
,	O
Acyltransferase	O
and	O
Esterase	O
were	O
discovered	O
.	O

As	O
for	O
Cytochrome	B
P450	I
,	O
sixteen	O
Differentially	O
Expressed	O
Genes	O
encoded	O
Cytochrome	B
P450	I
and	O
ten	O
Differentially	O
Expressed	O
Genes	O
were	O
selected	O
.	O

Among	O
all	O
the	O
Differentially	O
Expressed	O
Genes	O
in	O
fruit	O
and	O
leaf	O
transcriptome	O
data	O
,	O
Differentially	O
Expressed	O
Genes	O
encoding	O
Alcohol	O
Dehydrogenase	O
,	O
Cytochrome	B
P450	I
,	O
Acyltransferase	O
,	O
and	O
Esterase	O
were	O
identified	O
.	O

There	O
were	O
16	O
Differentially	O
Expressed	O
Genes	O
encoding	O
Cytochrome	B
P450	I
,	O
10	O
out	O
of	O
these	O
Differentially	O
Expressed	O
Genes	O
were	O
selected	O
.	O

According	O
to	O
the	O
phylogenetic	O
analysis	O
of	O
unigenes	O
encoding	O
Cytochrome	B
P450	I
,	O
5	O
transcripts	O
(	O
transcript	O
/	O
16057	O
,	O
transcript	O
/	O
16577	O
,	O
transcript	O
/	O
16950	O
,	O
transcript	O
/	O
16777	O
,	O
and	O
transcript	O
/	O
17001	O
)	O
were	O
grouped	O
with	O
members	O
in	O
CYP71	O
and	O
CYP72	O
clades	O
,	O
whose	O
members	O
are	O
reported	O
to	O
be	O
involved	O
in	O
terpenoid	O
biosynthesis	O
.	O

According	O
to	O
Cytochrome	B
P450	I
domain	O
analysis	O
,	O
transcript	O
/	O
17636	O
and	O
transcript	O
/	O
16971	O
contained	O
the	O
same	O
CypX	O
domain	O
as	O
CYP81B1	O
.	O

Therefore	O
,	O
5	O
Differentially	O
Expressed	O
Genes	O
(	O
transcript	O
/	O
16057	O
,	O
transcript	O
/	O
16	O
,	O
577	O
,	O
transcript	O
/	O
17057	O
,	O
transcript	O
/	O
16777	O
,	O
and	O
transcript	O
/	O
17001	O
)	O
contained	O
domains	O
found	O
within	O
Cytochrome	B
P450	I
oxidases	O
and	O
the	O
others	O
contained	O
domain	O
found	O
within	O
Cytochrome	B
P450	I
hydroxylase	O
.	O

Upon	O
bioinformatic	O
analysis	O
of	O
these	O
Differentially	O
Expressed	O
Genes	O
,	O
2	O
transcripts	O
(	O
transcript	O
/	O
18833	O
and	O
transcript	O
/	O
19291	O
)	O
encoding	O
Alcohol	O
Dehydrogenase	O
,	O
12	O
transcripts	O
encoding	O
Cytochrome	B
P450	I
,	O
2	O
Acyltransferase	O
transcripts	O
(	O
transcript	O
/	O
17792	O
and	O
transcript	O
/	O
18214	O
)	O
,	O
and	O
5	O
transcripts	O
encoding	O
Esterase	O
,	O
were	O
selected	O
as	O
candidates	O
in	O
the	O
azadirachtin	O
A	O
downstream	O
pathway	O
.	O

MaCYP71BQ5	O
is	O
the	O
Cytochrome	B
P450	I
found	O
to	O
be	O
involved	O
in	O
melianol	O
formation	O
.	O

Finally	O
,	O
22	O
unigenes	O
encoding	O
enzymes	O
including	O
2	O
,	O
3	O
-	O
Oxidosqualene	O
Cyclase	O
,	O
Alcohol	O
Dehydrogenase	O
,	O
Cytochrome	B
P450	I
,	O
Acyltransferase	O
,	O
and	O
Esterase	O
were	O
selected	O
as	O
candidates	O
involved	O
in	O
azadirachtin	O
A	O
downstream	O
pathway	O
.	O

The	O
SwissProt	O
database	O
was	O
queried	O
to	O
retrieve	O
all	O
reviewed	O
sequences	O
of	O
alcohol	O
dehydrogenase	O
,	O
Cytochrome	B
P450	I
,	O
acyltransferase	O
,	O
and	O
esterase	O
.	O

Next	O
,	O
molecular	O
docking	O
was	O
performed	O
with	O
Autodock	O
4	O
.	O
0	O
to	O
predict	O
the	O
interactions	O
of	O
four	O
triterpenoids	O
(	O
tirucalla	O
-	O
7	O
,	O
24	O
-	O
dien	O
-	O
3BETA	O
-	O
ol	O
,	O
azadirone	O
,	O
nimbin	O
,	O
and	O
nimbolide	O
)	O
as	O
substrates	O
for	O
the	O
Cytochrome	B
P450	I
proteins	O
.	O

For	O
covering	O
acting	O
domains	O
present	O
in	O
Cytochrome	B
P450	I
protein	O
,	O
grid	O
spacing	O
was	O
maintained	O
at	O
0	O
.	O
375	O
.	O

In	O
addition	O
to	O
the	O
conjugation	O
pathway	O
and	O
17	O
-	O
ketosteroid	O
pathway	O
,	O
hydroxylation	O
and	O
oxidation	O
of	O
hepatic	O
Cytochrome	B
P450	I
enzymes	I
are	O
additional	O
pathways	O
for	O
testosterone	O
metabolism	O
.	O

The	O
expression	O
of	O
additional	O
CYPs	O
(	O
Cyp1a1	O
,	O
Cyp1b1	O
,	O
Cyp2e1	B
)	O
was	O
observed	O
in	O
the	O
skin	O
of	O
C57BL	O
/	O
6J	O
mice	O
by	O
Flowers	O
et	O
al	O
.	O
.	O
In	O
the	O
mouse	O
skin	O
the	O
expression	O
of	O
several	O
Cyp	O
genes	O
was	O
demonstrated	O
on	O
the	O
RNA	O
level	O
.	O

Determination	O
of	O
(	O
CD	O
-	O
1	O
)	O
mouse	O
cutaneous	O
RNA	O
levels	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
showed	O
transcripts	O
arising	O
from	O
Cyp4f13	O
and	O
4f16	O
(	O
most	O
abundant	O
)	O
,	O
Cyp4f18	O
and	O
4f39	O
(	O
intermediate	O
)	O
,	O
Cyp4f14	O
,	O
4f17	O
,	O
and	O
4f37	O
(	O
low	O
)	O
,	O
and	O
from	O
Cyp4f15	O
and	O
Cyp4f40	O
(	O
highly	O
variable	O
or	O
too	O
low	O
to	O
measure	O
in	O
some	O
animals	O
)	O
(	O
Du	O
et	O
al	O
.	O
.	O
In	O
addition	O
,	O
the	O
expression	O
of	O
the	O
Cyp1a1	O
,	O
Cyp1b1	O
,	O
Cyp2e1	B
genes	O
was	O
observed	O
in	O
(	O
C57BL	O
/	O
6J	O
)	O
mouse	O
skin	O
(	O
Flowers	O
et	O
al	O
.	O
.	O
Interestingly	O
,	O
recent	O
studies	O
by	O
Borland	O
et	O
al	O
.	O

Expression	O
of	O
Cyp1b1	O
and	O
Cyp1a1	B
mRNAs	O
peaked	O
at	O
4	O
h	O
,	O
expression	O
of	O
Cyp3a11	O
mRNA	O
peaked	O
at	O
24	O
h	O
(	O
upregulation	O
of	O
Pregnane	O
X	O
Receptor	O
in	O
the	O
DMBA	O
-	O
treated	O
skin	O
was	O
confirmed	O
at	O
the	O
protein	O
level	O
)	O
.	O

Western	O
diet	O
and	O
benzo	O
[	O
a	O
]	O
pyrene	O
can	O
induce	O
fatty	O
liver	O
in	O
Cyp1a1	B
deficiency	O
mice	O
,	O
but	O
not	O
in	O
Wild	O
Type	O
mice	O
.	O

In	O
agreement	O
with	O
previous	O
studies	O
,	O
the	O
mRNA	O
levels	O
of	O
Cyp4a12	O
and	O
Cyp4a14	O
were	O
below	O
the	O
levels	O
of	O
detection	O
in	O
the	O
hearts	O
of	O
both	O
male	O
and	O
female	O
mice	O
in	O
the	O
current	O
study	O
(	O
data	O
not	O
shown	O
)	O
.	O

ZHX2	O
,	O
described	O
earlier	O
as	O
the	O
repressor	O
that	O
targets	O
H19	O
for	O
silencing	O
in	O
postnatal	O
liver	O
,	O
also	O
regulates	O
sexually	O
dimorphic	O
,	O
developmentally	O
-	O
regulated	O
P450	O
genes	O
in	O
the	O
liver	O
,	O
including	O
Cyp2a4	O
,	O
Cyp2b13	O
and	O
Cyp4a12	O
.	O

showed	O
that	O
the	O
metabolism	O
of	O
a	O
particular	O
drug	O
could	O
be	O
dominated	O
by	O
a	O
single	O
(	O
putative	O
)	O
P450	B
enzyme	I
.	O

The	O
gene	O
CYP4X1	O
encodes	O
an	O
orphan	O
Cytochromes	O
P450	B
enzyme	I
expressed	O
mainly	O
in	O
the	O
brain	O
,	O
aorta	O
,	O
or	O
breast	O
.	O

Detailed	O
stopped	O
-	O
flow	O
kinetics	O
of	O
binding	O
of	O
camphor	O
to	O
cytochrome	O
P450cam	B
have	O
been	O
studied	O
for	O
site	O
-	O
directed	O
mutants	O
of	O
P450cam	B
.	O

In	O
regard	O
to	O
results	O
presented	O
for	O
ellagic	O
acid	O
,	O
and	O
since	O
it	O
is	O
known	O
to	O
exert	O
inhibition	O
on	O
CYP2C9	O
,	O
its	O
effect	O
may	O
be	O
due	O
to	O
a	O
decrease	O
in	O
hepatic	O
first	O
-	O
pass	O
metabolism	O
of	O
warfarin	O
due	O
to	O
its	O
ability	O
to	O
inhibit	O
such	O
Cytochrome	B
P450	I
Enzymes	I
isoform	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
guava	O
leaves	O
extract	O
and	O
quercetin	O
to	O
inhibit	O
some	O
of	O
hepatic	O
Cytochrome	B
P450	I
Enzymes	I
isoforms	O
associated	O
with	O
warfarin	O
metabolism	O
such	O
as	O
CYP2C9	O
,	O
2C8	O
and	O
3A4	O
may	O
be	O
responsible	O
for	O
increasing	O
warfarin	O
plasma	O
concentration	O
[	O
,	O
.	O

In	O
vitro	O
warfarin	O
-	O
herb	O
interactions	O
and	O
their	O
effects	O
on	O
hepatic	O
Cytochrome	B
P450	I
Enzymes	I
isoforms	O
showed	O
that	O
CYP2C9	O
,	O
2C8	O
and	O
3A4	O
activities	O
in	O
primary	O
isolated	O
and	O
cultured	O
rat	O
hepatocytes	O
were	O
not	O
affected	O
by	O
warfarin	O
.	O

Since	O
Cytochrome	B
P450	I
Enzymes	I
isoforms	O
other	O
than	O
2C9	O
,	O
2C8	O
and	O
3A4	O
are	O
involved	O
in	O
warfarin	O
metabolism	O
,	O
further	O
study	O
with	O
more	O
focus	O
on	O
pomegranate	O
peel	O
and	O
its	O
constituents	O
is	O
therefore	O
suggested	O
.	O

To	O
achieve	O
this	O
,	O
the	O
hit	O
compounds	O
evaluated	O
for	O
either	O
substrate	O
or	O
inhibitors	O
of	O
Cytochrome	B
P450	I
Enzymes	I
along	O
with	O
Cytochrome	B
P450	I
Enzymes	I
of	O
Human	O
Liver	O
Microsomes	O
.	O

These	O
metabolism	O
properties	O
were	O
explored	O
in	O
silico	O
and	O
summarized	O
by	O
predicting	O
the	O
metabolic	O
sites	O
as	O
well	O
as	O
metabolites	O
,	O
and	O
type	O
of	O
Cytochrome	B
P450	I
Enzymes	I
involved	O
enzymes	O
,	O
which	O
catalyzes	O
xenobiotics	O
/	O
drugs	O
in	O
phase	O
II	O
metabolism	O
and	O
transform	O
the	O
small	O
molecules	O
to	O
water	O
-	O
soluble	O
form	O
,	O
which	O
may	O
lead	O
to	O
the	O
easy	O
elimination	O
of	O
xenobiotics	O
.	O

It	O
indicates	O
that	O
cytochrome	B
c	I
can	O
be	O
used	O
for	O
pathology	O
assessment	O
for	O
living	O
cells	O
.	O

Thus	O
,	O
the	O
peak	O
at	O
1337	O
cm	O
^	O
1	O
can	O
be	O
useful	O
to	O
distinguish	O
between	O
cytochrome	B
c	I
and	O
b	O
,	O
as	O
the	O
vibration	O
at	O
1337	O
cm	O
^	O
1	O
represents	O
a	O
unique	O
peak	O
of	O
the	O
reduced	O
cyt	O
b	O
(	O
ferrous	O
(	O
Fe	O
^	O
2	O
+	O
)	O
cytochrome	O
)	O
.	O

Hence	O
,	O
the	O
ratio	O
of	O
intensities	O
750	O
/	O
1126	O
can	O
be	O
used	O
to	O
estimate	O
the	O
relative	O
amount	O
of	O
reduced	O
cytochromes	O
c	O
,	O
c_1	O
versus	O
reduced	O
cytochromes	O
b	O
.	O
The	O
vibrations	O
of	O
cytochrome	B
c	I
that	O
are	O
resonance	O
Raman	O
enhanced	O
in	O
the	O
brain	O
and	O
breast	O
tissues	O
are	O
demonstrated	O
(	O
with	O
green	O
arrows	O
)	O
in	O
,	O
and	O
.	O

Symmetric	O
vibrational	O
modes	O
of	O
the	O
porphyrin	O
ligand	O
in	O
cytochrome	B
c	I
are	O
resonance	O
Raman	O
enhanced	O
to	O
a	O
greater	O
degree	O
using	O
excitation	O
wavelengths	O
within	O
the	O
Soret	O
absorption	O
peaks	O
at	O
408	O
nm	O
(	O
ferric	O
,	O
Fe	O
^	O
3	O
+	O
)	O
,	O
416	O
nm	O
(	O
ferrous	O
,	O
Fe	O
^	O
2	O
+	O
)	O
states	O
,	O
whereas	O
asymmetric	O
modes	O
are	O
enhanced	O
to	O
a	O
greater	O
degree	O
using	O
excitation	O
wavelengths	O
within	O
the	O
Q	O
absorption	O
peak	O
at	O
500	O
-	O
550	O
nm	O
.	O

Detailed	O
vibrational	O
assignment	O
of	O
cytochrome	B
c	I
can	O
be	O
found	O
in	O
ref	O
Q	O
-	O
resonant	O
Raman	O
spectra	O
contain	O
unusually	O
strong	O
depolarized	O
bands	O
.	O

The	O
bands	O
of	O
cytochrome	B
c	I
at	O
750	O
,	O
1126	O
,	O
1248	O
,	O
1310	O
,	O
1363	O
cm	O
^	O
1	O
are	O
depolarized	O
and	O
represent	O
the	O
reduced	O
form	O
.	O

The	O
band	O
at	O
1584	O
cm	O
^	O
1	O
represents	O
the	O
reduced	O
form	O
of	O
cytochrome	B
c	I
and	O
it	O
is	O
not	O
observed	O
in	O
the	O
oxidized	O
form	O
.	O

Some	O
of	O
the	O
peaks	O
of	O
the	O
oxidized	O
form	O
of	O
cytochrome	B
c	I
(	O
around	O
750	O
,	O
1130	O
,	O
1172	O
,	O
1314	O
,	O
1374	O
,	O
1570	O
-	O
1573	O
and	O
1634	O
cm	O
^	O
1	O
)	O
have	O
the	O
same	O
positions	O
as	O
the	O
reduced	O
form	O
,	O
but	O
their	O
intensities	O
are	O
significantly	O
lower	O
except	O
the	O
band	O
1634	O
cm	O
^	O
1	O
corresponding	O
to	O
the	O
ferric	O
cytochrome	B
c	I
as	O
presented	O
in	O
.	O

Our	O
results	O
in	O
show	O
that	O
the	O
Raman	O
intensities	O
of	O
the	O
reduced	O
form	O
of	O
cytochrome	B
c	I
(	O
cyt	O
c	O
Fe	O
^	O
2	O
+	O
)	O
are	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
oxidized	O
form	O
(	O
cyt	O
c	O
Fe	O
^	O
3	O
+	O
)	O
and	O
they	O
support	O
earlier	O
results	O
presented	O
in	O
the	O
literature	O
.	O

We	O
used	O
1584	O
cm	O
^	O
1	O
vibrational	O
mode	O
(	O
_19	O
)	O
as	O
a	O
marker	O
band	O
of	O
ferrous	O
cyt	O
c	O
in	O
brain	O
and	O
breast	O
cancer	O
tissues	O
,	O
_19	O
of	O
ferrous	O
heme	O
c	O
(	O
1582	O
cm	O
^	O
1	O
)	O
,	O
_2	O
of	O
ferric	O
heme	O
c	O
(	O
1585	O
cm	O
^	O
1	O
)	O
,	O
_19	O
of	O
ferrous	O
heme	O
cyt	O
b	O
(	O
1586	O
cm	O
^	O
1	O
)	O
and	O
_2	O
of	O
ferrous	O
heme	O
b	O
(	O
1583	O
cm	O
^	O
1	O
)	O
we	O
can	O
eliminate	O
from	O
our	O
discussion	O
all	O
ferric	O
modes	O
due	O
to	O
the	O
fact	O
that	O
the	O
resonance	O
Raman	O
intensities	O
of	O
the	O
ferric	O
modes	O
are	O
very	O
weak	O
in	O
comparison	O
to	O
the	O
ferrous	O
bands	O
except	O
the	O
band	O
1634	O
cm	O
^	O
1	O
corresponding	O
to	O
the	O
ferric	O
cytochrome	B
c	I
.	O
Thus	O
,	O
the	O
bands	O
at	O
1584	O
cm	O
^	O
1	O
(	O
reduced	O
cyt	O
c	O
)	O
and	O
at	O
1634	O
cm	O
^	O
1	O
(	O
oxidized	O
cyt	O
c	O
)	O
of	O
cytochrome	B
c	I
can	O
be	O
used	O
as	O
a	O
very	O
important	O
parameter	O
controlling	O
the	O
level	O
of	O
reduction	O
in	O
cancer	O
tissues	O
.	O

The	O
Raman	O
spectra	O
in	O
,	O
and	O
do	O
not	O
provide	O
information	O
about	O
the	O
distribution	O
of	O
cytochrome	B
c	I
in	O
the	O
cancer	O
tissue	O
.	O

To	O
learn	O
about	O
the	O
distribution	O
of	O
cytochrome	B
c	I
we	O
used	O
Raman	O
polarized	O
imaging	O
.	O

The	O
anomalously	O
polarized	O
band	O
at	O
1584	O
cm	O
^	O
1	O
appearing	O
in	O
the	O
Q	O
-	O
resonant	O
Raman	O
spectra	O
is	O
characteristic	O
of	O
cytochrome	B
c	I
.	O
This	O
result	O
additionally	O
supports	O
our	O
previous	O
findings	O
from	O
and	O
that	O
the	O
Q	O
-	O
resonant	O
Raman	O
band	O
at	O
1584	O
cm	O
^	O
1	O
in	O
the	O
breast	O
and	O
brain	O
tissues	O
represents	O
cytochrome	B
c	I
.	O
shows	O
microscopy	O
image	O
,	O
Raman	O
image	O
,	O
and	O
the	O
average	O
Raman	O
spectra	O
of	O
lipids	O
(	O
blue	O
)	O
,	O
proteins	O
(	O
red	O
)	O
,	O
cytochrome	O
(	O
green	O
)	O
,	O
mitochondrion	O
(	O
magenta	O
)	O
at	O
532	O
nm	O
at	O
different	O
experimental	O
geometries	O
for	O
Raman	O
scattering	O
:	O
without	O
polarization	O
analyzer	O
,	O
at	O
parallel	O
and	O
perpendicular	O
polarizations	O
of	O
the	O
incident	O
and	O
Raman	O
scattered	O
beams	O
for	O
infiltrating	O
ductal	O
cancer	O
(	O
malignancy	O
grade	O
G2	O
)	O
.	O

Since	O
Raman	O
scattering	O
at	O
1584	O
cm	O
^	O
1	O
is	O
not	O
observed	O
in	O
the	O
oxidized	O
form	O
of	O
cytochrome	B
c	I
the	O
band	O
at	O
1584	O
cm	O
^	O
1	O
originates	O
from	O
the	O
reduced	O
form	O
of	O
cytochromes	O
c	O
.	O
Our	O
results	O
demonstrate	O
that	O
the	O
Raman	O
intensity	O
of	O
1584	O
cm	O
^	O
1	O
peak	O
is	O
the	O
most	O
sensitive	O
vibration	O
of	O
redox	O
status	O
in	O
the	O
cell	O
and	O
is	O
related	O
to	O
the	O
amount	O
of	O
the	O
reduced	O
cytochromes	O
c	O
.	O
Therefore	O
,	O
we	O
used	O
1584	O
cm	O
^	O
1	O
to	O
study	O
the	O
redox	O
state	O
of	O
mitochondrial	O
cytochrome	B
c	I
in	O
brain	O
and	O
breast	O
ex	O
vivo	O
human	O
tissues	O
.	O

To	O
check	O
whether	O
the	O
redox	O
state	O
of	O
cytochrome	B
c	I
is	O
related	O
to	O
cancer	O
aggressiveness	O
we	O
used	O
the	O
Raman	O
redox	O
state	O
biomarker	O
represented	O
by	O
the	O
Raman	O
intensity	O
of	O
1584	O
cm	O
^	O
1	O
peak	O
.	O

A	O
shows	O
the	O
intensity	O
of	O
the	O
750	O
,	O
1126	O
,	O
1337	O
and	O
1584	O
cm	O
^	O
1	O
Raman	O
peak	O
of	O
cytochrome	B
c	I
as	O
a	O
function	O
of	O
grade	O
.	O

B	O
shows	O
the	O
data	O
for	O
1584	O
cm	O
^	O
1	O
band	O
of	O
reduced	O
cytochrome	B
c	I
for	O
breast	O
normal	O
(	O
G0	O
)	O
and	O
cancer	O
(	O
invasive	O
ductal	O
cancer	O
)	O
human	O
tissue	O
(	O
G1	O
,	O
G2	O
,	O
G3	O
)	O
.	O

Based	O
on	O
the	O
average	O
values	O
(	O
number	O
of	O
patients	O
n	O
=	O
39	O
)	O
obtained	O
for	O
the	O
Raman	O
biomarker	O
of	O
cytochrome	B
c	I
I_1584	O
we	O
obtained	O
a	O
plot	O
as	O
a	O
function	O
of	O
cancer	O
grade	O
malignancy	O
.	O

In	O
the	O
view	O
of	O
the	O
results	O
presented	O
in	O
it	O
is	O
evident	O
that	O
the	O
Raman	O
biomarker	O
I_1584	O
measuring	O
contribution	O
of	O
cytochrome	B
c	I
in	O
the	O
human	O
breast	O
tissues	O
correlates	O
with	O
breast	O
cancer	O
aggressiveness	O
.	O

The	O
intensity	O
of	O
the	O
1584	O
cm	O
^	O
1	O
Raman	O
signal	O
corresponding	O
to	O
the	O
amount	O
of	O
reduced	O
cytochrome	B
c	I
increases	O
with	O
increasing	O
cancer	O
aggressiveness	O
.	O

It	O
indicates	O
that	O
cytochrome	B
c	I
plays	O
a	O
crucial	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
cancer	O
.	O

The	O
parabolic	O
dependence	O
of	O
the	O
Raman	O
biomarker	O
I_1584	O
of	O
the	O
reduced	O
cytochrome	B
c	I
in	O
vs	O
cancer	O
malignancy	O
shows	O
that	O
the	O
optimal	O
concentration	O
of	O
cytochrome	B
c	I
that	O
are	O
needed	O
to	O
maintain	O
cellular	O
homeostasis	O
corresponds	O
to	O
the	O
normalized	O
intensity	O
of	O
0	O
.	O
006	O
0	O
.	O
003	O
for	O
the	O
breast	O
tissues	O
.	O

The	O
concentrations	O
of	O
the	O
reduced	O
cytochrome	B
c	I
at	O
this	O
level	O
modulate	O
protective	O
,	O
signaling	O
-	O
response	O
pathways	O
,	O
resulting	O
in	O
positive	O
effects	O
on	O
life	O
-	O
history	O
traits	O
.	O

The	O
reduced	O
cytochrome	B
c	I
level	O
above	O
the	O
value	O
of	O
0	O
.	O
06	O
0	O
.	O
02	O
triggers	O
a	O
toxic	O
runaway	O
process	O
and	O
aggressive	O
breast	O
cancer	O
development	O
.	O

The	O
plot	O
provides	O
an	O
important	O
cell	O
-	O
physiologic	O
response	O
,	O
normally	O
the	O
reduced	O
cytochrome	B
c	I
operates	O
at	O
low	O
,	O
basal	O
level	O
in	O
normal	O
cells	O
,	O
but	O
it	O
is	O
strongly	O
induced	O
to	O
very	O
high	O
levels	O
in	O
pathological	O
cancer	O
states	O
.	O

It	O
is	O
interesting	O
to	O
check	O
if	O
the	O
other	O
characteristic	O
bands	O
of	O
cytochrome	B
c	I
and	O
cytochrome	B
b	I
correlate	O
with	O
breast	O
cancer	O
grade	O
malignancy	O
G0	O
-	O
G3	O
.	O

We	O
analyzed	O
the	O
Raman	O
intensity	O
ratio	O
of	O
the	O
peaks	O
at	O
750	O
cm	O
^	O
1	O
and	O
1126	O
cm	O
^	O
1	O
to	O
evaluated	O
the	O
relative	O
contribution	O
of	O
cytochrome	B
c	I
and	O
b	O
(	O
see	O
B	O
,	O
C	O
)	O
.	O

It	O
indicates	O
that	O
the	O
relative	O
contribution	O
of	O
cytochrome	B
c	I
is	O
higher	O
than	O
cytochrome	B
b	I
when	O
the	O
grade	O
of	O
malignancy	O
increases	O
.	O

C	O
,	O
F	O
show	O
that	O
the	O
intensity	O
of	O
the	O
1584	O
cm	O
^	O
1	O
Raman	O
signal	O
corresponding	O
to	O
the	O
concentration	O
of	O
reduced	O
cytochrome	B
c	I
increases	O
with	O
increasing	O
brain	O
tumor	O
aggressiveness	O
.	O

To	O
check	O
whether	O
cytochromes	O
c	O
is	O
upregulated	O
in	O
brain	O
tumors	O
we	O
studied	O
the	O
Raman	O
signals	O
at	O
1584	O
cm	O
^	O
1	O
corresponding	O
to	O
concertation	O
of	O
cytochrome	B
c	I
as	O
a	O
function	O
of	O
brain	O
tumor	O
malignancy	O
by	O
using	O
WHO	O
grade	O
.	O

shows	O
the	O
Raman	O
intensities	O
of	O
characteristic	O
vibrations	O
in	O
brain	O
tissue	O
corresponding	O
to	O
concentration	O
of	O
reduced	O
cytochrome	B
c	I
.	O
One	O
can	O
see	O
that	O
for	O
the	O
brain	O
tumors	O
the	O
Raman	O
intensity	O
of	O
all	O
characteristic	O
vibrations	O
of	O
cytochrome	B
c	I
increases	O
with	O
increasing	O
cancer	O
aggressiveness	O
up	O
to	O
G3	O
and	O
then	O
slightly	O
decreases	O
for	O
G4	O
.	O

The	O
results	O
presented	O
in	O
the	O
paper	O
suggest	O
that	O
the	O
redox	O
-	O
sensitive	O
peak	O
observed	O
at	O
1584	O
cm	O
^	O
1	O
with	O
excitation	O
at	O
532	O
nm	O
is	O
specifically	O
linked	O
to	O
cytochrome	B
c	I
.	O
and	O
can	O
be	O
considered	O
to	O
be	O
a	O
redox	O
state	O
marker	O
of	O
the	O
ferric	O
low	O
spin	O
heme	O
in	O
cyt	O
c	O
,	O
assigned	O
to	O
the	O
v_19	O
mode	O
,	O
vibrations	O
of	O
methine	O
bridges	O
(	O
CALPHAC	O
,	O
CALPHACH	O
bonds	O
)	O
and	O
the	O
CALPHACBETA	O
bond	O
.	O

We	O
found	O
that	O
concentration	O
of	O
cytochrome	B
c	I
is	O
upregulated	O
in	O
brain	O
and	O
breast	O
cancers	O
.	O

The	O
intensities	O
of	O
the	O
1584	O
cm	O
^	O
1	O
Raman	O
signal	O
corresponding	O
to	O
the	O
amount	O
of	O
the	O
reduced	O
cytochrome	B
c	I
increases	O
with	O
increasing	O
cancer	O
aggressiveness	O
.	O

We	O
found	O
the	O
dependence	O
of	O
the	O
Raman	O
biomarker	O
I_1584	O
of	O
the	O
reduced	O
cytochrome	B
c	I
vs	O
grade	O
of	O
cancer	O
malignancy	O
which	O
shows	O
that	O
the	O
optimal	O
concentration	O
of	O
cytochrome	B
c	I
that	O
are	O
needed	O
to	O
maintain	O
cellular	O
homeostasis	O
corresponds	O
to	O
the	O
normalized	O
Raman	O
intensity	O
of	O
0	O
.	O
006	O
0	O
.	O
003	O
for	O
the	O
breast	O
tissue	O
and	O
0	O
.	O
074	O
0	O
.	O
005	O
for	O
the	O
brain	O
tissue	O
.	O

The	O
reduced	O
cytochrome	B
c	I
level	O
above	O
these	O
values	O
triggers	O
a	O
toxic	O
runaway	O
process	O
and	O
aggressive	O
cancer	O
development	O
.	O

The	O
relation	O
between	O
the	O
Raman	O
signal	O
intensity	O
at	O
1584	O
cm	O
^	O
1	O
of	O
the	O
reduced	O
cytochrome	B
c	I
vs	O
cancer	O
grade	O
provides	O
an	O
important	O
cell	O
-	O
physiologic	O
response	O
demonstrating	O
that	O
the	O
reduced	O
cytochrome	B
c	I
operates	O
at	O
low	O
,	O
basal	O
level	O
in	O
normal	O
cells	O
,	O
but	O
it	O
is	O
strongly	O
induced	O
to	O
very	O
high	O
levels	O
in	O
pathological	O
cancer	O
states	O
.	O

We	O
analyzed	O
the	O
Raman	O
intensity	O
ratio	O
of	O
the	O
peaks	O
at	O
750	O
cm	O
^	O
1	O
and	O
1126	O
cm	O
^	O
1	O
to	O
evaluate	O
the	O
relative	O
contribution	O
of	O
cytochrome	B
c	I
and	O
b	O
in	O
human	O
breast	O
tissue	O
as	O
a	O
function	O
of	O
breast	O
cancer	O
grade	O
malignancy	O
G0	O
-	O
G3	O
at	O
excitation	O
532	O
nm	O
.	O

We	O
found	O
that	O
the	O
relative	O
contribution	O
of	O
cytochrome	B
c	I
is	O
higher	O
than	O
cytochrome	B
b	I
when	O
the	O
grade	O
of	O
malignancy	O
increases	O
.	O

Given	O
that	O
the	O
Raman	O
spectra	O
underling	O
the	O
relRI	O
trends	O
were	O
recorded	O
from	O
individual	O
cells	O
in	O
a	O
monolayer	O
of	O
cells	O
,	O
this	O
indicated	O
a	O
significantly	O
higher	O
active	O
cytochrome	B
-	I
c	I
content	O
per	O
cell	O
for	O
N	O
.	O
eutropha	O
and	O
Nitrosospira	O
grown	O
under	O
oxygen	O
-	O
deprived	O
conditions	O
than	O
was	O
seen	O
in	O
cells	O
grown	O
in	O
oxygen	O
abundance	O
.	O

The	O
ER	O
-	O
bound	O
enzyme	O
complex	O
belongs	O
to	O
the	O
cytochrome	B
P450	I
superfamily	I
.	O

The	O
metabolic	O
activation	O
of	O
PCBs	O
is	O
initiated	O
by	O
cytochrome	B
p450	I
(	O
CYP	O
)	O
family	O
members	O
and	O
includes	O
the	O
oxidation	O
of	O
PCBs	O
to	O
OH	O
-	O
PCBs	O
.	O

As	O
synthetic	O
OH	O
-	O
metabolites	O
of	O
PCB	O
28	O
-	O
induced	O
cytotoxicity	O
in	O
a	O
model	O
cell	O
culture	O
system	O
^	O
,	O
we	O
conclude	O
that	O
PCB	O
28	O
bioactivation	O
by	O
cytochrome	B
p450	I
(	O
Cyp	O
)	O
enzymes	O
leads	O
to	O
toxicity	O
in	O
Drosophila	O
.	O

However	O
,	O
several	O
factors	O
,	O
including	O
differences	O
in	O
intracellular	O
pH	O
,	O
membrane	O
lipid	O
composition	O
of	O
the	O
ER	O
(	O
relevant	O
for	O
ER	O
-	O
membrane	O
-	O
anchored	O
OSCs	O
and	O
P450s	O
)	O
,	O
and	O
availability	O
of	O
dedicated	O
co	O
-	O
factors	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
specialized	O
cytochrome	B
b5	I
enzymes	O
,	O
are	O
generally	O
regarded	O
to	O
cause	O
a	O
plant	O
enzyme	O
not	O
to	O
function	O
properly	O
in	O
a	O
yeast	O
cell	O
.	O

The	O
Photosynthetic	O
Electron	O
Transfer	O
Chain	O
employs	O
three	O
membrane	O
protein	O
complexes	O
:	O
PSI	O
,	O
PSII	O
,	O
their	O
respective	O
light	O
-	O
harvesting	O
complexes	O
(	O
LHCI	O
and	O
LHCII	O
)	O
,	O
and	O
the	O
cytochrome	O
b6	O
/	O
f	O
complex	O
(	O
Cyt	O
b6f	O
,	O
a	O
plastoquinol	O
-	O
plastocyanin	O
-	O
oxidoreductase	O
)	O
.	O

Formation	O
of	O
21	O
mol	O
O_2	O
^	O
(	O
mg	O
Chl	O
)	O
^	O
1	O
h	O
^	O
1	O
,	O
measured	O
as	O
an	O
SOD	O
-	O
dependent	O
cytochrome	O
c	O
reduction	O
,	O
was	O
observed	O
in	O
D1	O
/	O
D2	O
/	O
cytochrome	O
b559	O
complexes	O
illuminated	O
at	O
200	O
W	O
m	O
^	O
2	O
in	O
the	O
presence	O
of	O
an	O
artificial	O
electron	O
donor	O
.	O

Subcellular	O
localization	O
of	O
Carbon	O
Monoxide	O
can	O
also	O
regulate	O
ROS	O
production	O
,	O
for	O
instance	O
Taill	O
and	O
colleagues	O
have	O
demonstrated	O
that	O
CORM	O
-	O
2	O
treatment	O
inhibited	O
the	O
activity	O
of	O
NAD	O
(	O
P	O
)	O
H	O
oxidase	O
cytochrome	O
b_558	O
,	O
which	O
decreases	O
plasmatic	O
membrane	O
ROS	O
production	O
,	O
while	O
there	O
is	O
an	O
increase	O
on	O
mitochondrial	O
ROS	O
generation	O
by	O
targeting	O
cytochrome	O
c	O
oxidase	O
.	O

Under	O
Coos1	O
Is	O
Frame	O
-	O
Shifted	O
conditions	O
,	O
the	O
expression	O
levels	O
of	O
hyd	O
-	O
3b	O
genes	O
(	O
KKC1_RS10620	O
-	O
KKC1_RS10635	O
)	O
encoding	O
group	O
3b	O
[	O
NiFe	O
]	O
hydrogenase	O
catalytic	O
subunits	O
and	O
their	O
maturation	O
protease	O
were	O
upregulated	O
,	O
whereas	O
those	O
of	O
hyd	O
-	O
1a	O
genes	O
(	O
KKC1_RS00385	O
-	O
KKC1_RS00400	O
)	O
encoding	O
group	O
1a	O
[	O
NiFe	O
]	O
hydrogenase	O
catalytic	O
subunits	O
,	O
a	O
cytochrome	B
b	I
subunit	O
,	O
and	O
their	O
maturation	O
protease	O
were	O
downregulated	O
.	O

Conversely	O
,	O
the	O
group	O
1a	O
[	O
NiFe	O
]	O
hydrogenase	O
is	O
a	O
periplasmic	O
,	O
unidirectional	O
H_2	O
-	O
uptake	O
hydrogenase	O
,	O
and	O
the	O
cytochrome	B
b	I
subunit	O
is	O
considered	O
a	O
putative	O
electron	O
carrier	O
,	O
as	O
are	O
other	O
group	O
1	O
hydrogenases	O
(	O
Greening	O
et	O
al	O
.	O

One	O
of	O
these	O
peaks	O
characterizes	O
more	O
than	O
1	O
,	O
000	O
different	O
sequences	O
of	O
mitochondrial	O
cytochrome	B
b	I
molecules	O
at	O
p	O
=	O
379	O
.	O

However	O
,	O
in	O
the	O
case	O
p	O
=	O
379	O
,	O
out	O
of	O
1	O
,	O
889	O
proteins	O
,	O
1	O
,	O
048	O
(	O
two	O
-	O
thirds	O
)	O
are	O
mitochondrial	O
cytochrome	B
b	I
.	O
This	O
value	O
is	O
approximately	O
equal	O
to	O
that	O
part	O
of	O
the	O
peak	O
that	O
rises	O
above	O
the	O
total	O
mass	O
of	O
protein	O
lengths	O
in	O
.	O

For	O
a	O
large	O
number	O
of	O
differing	O
amino	O
acid	O
residue	O
sequences	O
,	O
but	O
with	O
the	O
same	O
p	O
-	O
value	O
,	O
cytochrome	B
b	I
is	O
precisely	O
typical	O
as	O
being	O
representative	O
of	O
animals	O
.	O

Some	O
of	O
the	O
major	O
topics	O
that	O
the	O
speakers	O
discussed	O
were	O
whether	O
P450	O
was	O
synthesized	O
in	O
the	O
rough	O
or	O
smooth	O
endoplasmic	O
reticulum	O
,	O
whether	O
there	O
were	O
one	O
or	O
two	O
P450s	O
(	O
some	O
questioned	O
whether	O
changes	O
in	O
phospholipids	O
might	O
be	O
responsible	O
for	O
the	O
altered	O
activities	O
)	O
,	O
the	O
role	O
of	O
cytochrome	B
b_5	I
(	O
Estabrook	O
,	O
Mannering	O
)	O
,	O
the	O
purification	O
of	O
P450	O
from	O
rabbit	O
liver	O
(	O
Coon	O
,	O
Sato	O
)	O
,	O
the	O
chemical	O
mechanism	O
(	O
s	O
)	O
of	O
catalysis	O
(	O
Ullrich	O
,	O
McMahon	O
,	O
Udenfriend	O
,	O
Daly	O
,	O
Witkop	O
,	O
Jerina	O
)	O
,	O
and	O
the	O
biological	O
basis	O
of	O
P450	O
induction	O
.	O

Curiously	O
,	O
plant	O
-	O
like	O
hallmark	O
electron	O
transfer	O
enzymes	O
and	O
transporters	O
are	O
found	O
throughout	O
the	O
genome	O
,	O
such	O
as	O
a	O
cytochrome	O
b6c1	O
complex	O
and	O
a	O
CO2	O
-	O
concentrating	O
transporter	O
.	O

In	O
the	O
previous	O
genome	O
an	O
operon	O
annotated	O
as	O
a	O
cytochrome	O
b_6f	O
was	O
annotated	O
.	O

However	O
,	O
while	O
genes	O
indeed	O
include	O
a	O
cytochrome	O
b_6	O
,	O
there	O
is	O
no	O
homology	O
to	O
a	O
cytochrome	O
f	O
,	O
but	O
there	O
is	O
to	O
a	O
cytochrome	O
c_1	O
.	O

This	O
leads	O
us	O
to	O
believe	O
that	O
this	O
organism	O
has	O
a	O
cytochrome	O
b_6c_1	O
,	O
which	O
is	O
a	O
novel	O
-	O
hybrid	O
type	O
complex	O
III	O
also	O
found	O
in	O
G	O
.	O
stearothermophilus	O
(	O
Sone	O
et	O
al	O
.	O
.	O
Curiously	O
,	O
the	O
iron	O
-	O
sulfur	O
cluster	O
of	O
C	O
.	O
thermarum	O
TA2	O
.	O

Supporting	O
this	O
proposition	O
,	O
while	O
a	O
b_6c_1	O
has	O
not	O
been	O
examined	O
,	O
a	O
synthetically	O
constructed	O
b_6c_1	O
was	O
constructed	O
and	O
was	O
able	O
to	O
functionally	O
replace	O
a	O
cytochrome	O
b_6f	O
in	O
Rhodobacter	O
capsulatus	O
in	O
the	O
process	O
of	O
cellular	O
photosynthesis	O
(	O
Saribas	O
et	O
al	O
.	O
.	O
At	O
the	O
electron	O
-	O
accepting	O
end	O
of	O
the	O
respiratory	O
chain	O
,	O
C	O
.	O
thermarum	O
TA2	O
.	O

These	O
similarities	O
include	O
a	O
cytochrome	O
b_6c_1	O
complex	O
that	O
is	O
a	O
possible	O
homolog	O
of	O
the	O
plant	O
cytochrome	O
b_6f	O
,	O
the	O
similarity	O
in	O
F_1F_O	O
-	O
ATP	O
synthase	O
c	O
-	O
subunit	O
rotor	O
ring	O
size	O
,	O
and	O
the	O
means	O
to	O
capture	O
inorganic	O
carbon	O
.	O

The	O
family	O
of	O
cytochromes	O
are	O
localized	O
in	O
the	O
third	O
complex	O
in	O
the	O
electron	O
transport	O
chain	O
,	O
also	O
known	O
as	O
complex	O
III	O
or	O
Coenzyme	O
Q	O
-	O
Cyt	O
c	O
reductase	O
,	O
sometimes	O
called	O
the	O
cytochrome	O
bc_1	O
complex	O
(	O
cytochrome	B
b	I
,	O
cytochrome	O
c_1	O
)	O
,	O
as	O
well	O
as	O
in	O
cytochrome	O
c	O
loosely	O
associated	O
with	O
the	O
inner	O
membrane	O
of	O
the	O
mitochondrion	O
.	O

Using	O
different	O
excitations	O
,	O
we	O
are	O
able	O
to	O
monitor	O
contribution	O
of	O
cytochrome	O
family	O
in	O
the	O
electron	O
transfer	O
chain	O
in	O
the	O
mitochondrial	O
respiration	O
originating	O
from	O
cytochrome	B
b	I
,	O
c_1	O
in	O
complex	O
III	O
,	O
cytochrome	O
c	O
,	O
and	O
a	O
,	O
a_3	O
cytochromes	O
in	O
complex	O
IV	O
.	O

The	O
amount	O
of	O
cytochrome	B
b	I
is	O
practically	O
the	O
same	O
for	O
all	O
grades	O
of	O
brain	O
tumor	O
.	O

(	O
presence	O
of	O
CYP	O
and	O
cytochrome	B
b5	I
)	O
.	O

In	O
addition	O
,	O
plants	O
express	O
redox	O
co	O
-	O
factors	O
dedicated	O
to	O
secondary	O
metabolism	O
,	O
such	O
as	O
specialized	O
cytochrome	B
b5	I
proteins	O
,	O
and	O
many	O
CYPs	O
depend	O
on	O
such	O
co	O
-	O
factors	O
for	O
optimal	O
activity	O
.	O

EROD	B
activity	O
was	O
determined	O
using	O
the	O
methods	O
of	O
Peters	O
et	O
al	O
.	O
,	O
with	O
mild	O
modifications	O
.	O

EROD	B
enzyme	O
activity	O
assay	O
was	O
conducted	O
applying	O
the	O
complex	O
mixtures	O
of	O
Alternaria	O
toxins	O
to	O
test	O
their	O
potential	O
to	O
activate	O
the	O
Aryl	O
Hydrocarbon	O
Receptor	O
signalling	O
pathway	O
.	O

Progestin	O
receptor	O
membrane	O
component	O
1	O
is	O
a	O
single	O
transmembrane	O
heme	O
-	O
binding	O
protein	O
containing	O
a	O
cytochrome	B
b_5	I
motif	O
,	O
which	O
has	O
been	O
proposed	O
as	O
a	O
progesterone	O
binding	O
protein	O
in	O
vertebrates	O
(	O
,	O
.	O

For	O
example	O
,	O
Progestin	O
Receptor	O
Membrane	O
Component	O
1	O
is	O
a	O
heme	O
-	O
binding	O
protein	O
with	O
a	O
cytochrome	B
b_5	I
motif	O
,	O
which	O
binds	O
and	O
activates	O
P450	O
proteins	O
and	O
is	O
involved	O
in	O
steroidogenesis	O
and	O
drug	O
metabolism	O
.	O

Pgrmc1	O
has	O
a	O
role	O
in	O
the	O
regulation	O
of	O
cholesterol	O
and	O
steroid	O
synthesis	O
because	O
of	O
its	O
cytochrome	B
b_5	I
motif	O
and	O
its	O
ability	O
to	O
bind	O
and	O
activate	O
P450	O
proteins	O
(	O
,	O
.	O

The	O
recombinant	O
baculosomes	O
with	O
hyperexpressed	O
CYP3A4	O
and	O
coexpressed	O
NADPH	O
cytochrome	O
P450	O
reductase	O
and	O
cytochrome	B
b_5	I
,	O
was	O
used	O
as	O
source	O
of	O
enzyme	O
.	O

Progesterone	O
receptor	O
membrane	O
component	O
1	O
is	O
a	O
multifunctional	O
protein	O
with	O
a	O
C	O
-	O
terminal	O
cytochrome	B
b_5	I
domain	O
^	O
.	O

Progesterone	O
Receptor	O
Membrane	O
Component1	O
regulates	O
cell	O
proliferation	O
and	O
apoptosis	O
in	O
granulosa	O
and	O
luteal	O
cells	O
via	O
interaction	O
between	O
its	O
cytoplasmic	O
cytochrome	B
b_5	I
binding	O
domain	O
(	O
amino	O
acids	O
70	O
-	O
130	O
)	O
and	O
plasminogen	O
activator	O
inhibitor	O
RNA	O
-	O
binding	O
protein	O
-	O
1	O
(	O
PAIR	O
-	O
BP1	O
)	O
^	O
,	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
17	O
,	O
20	O
-	O
lyase	O
activity	O
of	O
CYP17A1	O
is	O
dependent	O
on	O
augmentation	O
by	O
cytochrome	B
b_5	I
(	O
CYB5A	O
)	O
in	O
addition	O
to	O
electron	O
transfer	O
from	O
P450	O
Oxidoreductase	O
.	O

In	O
the	O
mammalian	O
liver	O
,	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
-	O
anchored	O
P450s	O
function	O
together	O
with	O
their	O
redox	O
partners	O
cytochrome	O
P450	O
reductase	O
and	O
cytochrome	B
b_5	I
in	O
the	O
oxidative	O
metabolism	O
and	O
elimination	O
of	O
numerous	O
endobiotics	O
(	O
arachidonic	O
acid	O
,	O
retinoic	O
acid	O
,	O
steroids	O
,	O
vitamin	O
D	O
)	O
as	O
well	O
as	O
xenobiotics	O
(	O
pharmacological	O
and	O
recreational	O
drugs	O
,	O
carcinogens	O
,	O
toxins	O
and	O
other	O
foreign	O
substances	O
of	O
dietary	O
or	O
environmental	O
origin	O
)	O
,	O
.	O

Hepatocyte	O
spheroids	O
formed	O
in	O
this	O
device	O
were	O
subjected	O
to	O
different	O
flow	O
rates	O
,	O
of	O
which	O
a	O
flow	O
rate	O
of	O
50	O
L	O
/	O
min	O
provided	O
the	O
optimal	O
microenvironment	O
for	O
spheroid	O
formation	O
,	O
maintained	O
significantly	O
higher	O
rates	O
of	O
albumin	O
and	O
urea	O
synthesis	O
,	O
yielded	O
higher	O
CYP3A1	O
(	O
cytochrome	O
P450	O
3A1	O
)	O
and	O
CYP2C11	O
(	O
cytochrome	O
P450	O
2C11	O
)	O
enzyme	O
activities	O
for	O
metabolism	O
,	O
and	O
demonstrated	O
higher	O
expression	O
levels	O
of	O
liver	O
-	O
specific	O
genes	O
.	O

Markers	O
of	O
pharmacokinetics	O
/	O
toxicity	O
:	O
(	O
1	O
)	O
Sofarenib	O
metabolism	O
:	O
The	O
metabolism	O
of	O
sorafenib	O
is	O
well	O
-	O
established	O
and	O
occurs	O
mainly	O
in	O
the	O
liver	O
through	O
two	O
pathways	O
:	O
Phase	O
I	O
oxidation	O
mediated	O
by	O
cytochrome	B
P450	I
3A4	I
,	O
and	O
phase	O
II	O
conjugation	O
mediated	O
by	O
UDP	O
glucuronosyltransferase	O
1A9	O
.	O

Moreover	O
,	O
up	O
-	O
regulation	O
of	O
genes	O
coding	O
for	O
cytochrome	B
P	I
-	I
450	I
and	O
monooxygenase	O
by	O
the	O
red	O
and	O
blue	O
light	O
,	O
respectively	O
,	O
which	O
was	O
observed	O
in	O
our	O
analysis	O
,	O
seem	O
to	O
support	O
the	O
role	O
of	O
putative	O
white	O
collar	O
proteins	O
or	O
phytochromes	O
in	O
AMPK	O
and	O
MAPK	O
based	O
signal	O
transduction	O
.	O

The	O
low	O
-	O
spin	O
soluble	O
cyt	O
c	O
of	O
mitochondria	O
in	O
which	O
the	O
heme	O
-	O
attachment	O
site	O
is	O
located	O
towards	O
the	O
N	O
-	O
terminus	O
,	O
and	O
the	O
sixth	O
ligand	O
located	O
towards	O
the	O
C	O
-	O
terminus	O
belongs	O
to	O
class	O
I	O
.	O
Cytochrome	B
c	I
transfers	O
electrons	O
from	O
complex	O
III	O
to	O
complex	O
IV	O
,	O
also	O
known	O
as	O
cytochrome	O
oxidase	O
,	O
which	O
is	O
the	O
final	O
enzyme	O
of	O
the	O
electron	O
transport	O
system	O
.	O

Cytochrome	B
c	I
,	O
which	O
is	O
reduced	O
to	O
cyt	O
c	O
Fe	O
^	O
2	O
+	O
(	O
ferrous	O
)	O
by	O
the	O
electron	O
from	O
the	O
complex	O
III	O
,	O
passes	O
an	O
electron	O
to	O
the	O
copper	O
binuclear	O
center	O
,	O
being	O
oxidized	O
back	O
to	O
cytochrome	O
c	O
(	O
cyt	O
c	O
Fe	O
^	O
3	O
+	O
(	O
ferric	O
)	O
)	O
.	O

The	O
overall	O
human	O
brain	O
samples	O
statistic	O
was	O
:	O
n	O
(	O
G0	O
)	O
=	O
1	O
,	O
n	O
(	O
G1	O
)	O
=	O
17	O
,	O
n	O
(	O
G2	O
)	O
=	O
9	O
,	O
n	O
(	O
G3	O
)	O
=	O
4	O
,	O
n	O
(	O
G4	O
)	O
=	O
13	O
,	O
where	O
G0	O
describes	O
healthy	O
tissue	O
,	O
G1	O
,	O
G2	O
,	O
G3	O
,	O
G4	O
the	O
cancer	O
tissues	O
with	O
increasing	O
malignancy	O
grade	O
Cytochrome	B
c	I
from	O
the	O
equine	O
heart	O
(	O
C7752	O
,	O
Sigma	O
-	O
Aldrich	O
,	O
Pozna	O
,	O
Poland	O
)	O
was	O
used	O
without	O
additional	O
purification	O
.	O

In	O
summary	O
,	O
we	O
conclude	O
that	O
nicotine	O
metabolism	O
by	O
CYP2B6	B
is	O
stereoselective	O
,	O
and	O
common	O
polymorphisms	O
in	O
CYP2B6	B
significantly	O
influence	O
the	O
oxidation	O
of	O
both	O
(	O
S	O
)	O
and	O
(	O
R	O
)	O
nicotine	O
to	O
nicotine	O
iminium	O
and	O
nornicotine	O
.	O

However	O
,	O
the	O
small	O
contribution	O
of	O
CYP2B6	B
to	O
nicotine	O
metabolism	O
in	O
the	O
liver	O
,	O
and	O
its	O
undetectable	O
activity	O
in	O
human	O
brain	O
tissue	O
,	O
make	O
it	O
highly	O
unlikely	O
that	O
this	O
genetic	O
variation	O
influences	O
complex	O
smoking	O
behaviors	O
.	O

Moreover	O
,	O
even	O
if	O
sorafenib	O
is	O
not	O
a	O
substrate	O
for	O
the	O
cytochrome	O
isoforms	O
CYP2B6	B
,	O
CYP2C8	O
,	O
and	O
CYP2C9	O
and	O
the	O
UDP	O
glucuronosyltransferase	O
UGT1A1	O
,	O
the	O
biological	O
agent	O
in	O
vivo	O
inhibits	O
activity	O
of	O
these	O
enzymes	O
with	O
potential	O
pharmacological	O
consequences	O
and	O
drug	O
-	O
interaction	O
events	O
.	O

Regorafenib	O
and	O
its	O
major	O
metabolites	O
are	O
also	O
reported	O
to	O
inhibit	O
a	O
number	O
of	O
cytochromes	O
(	O
CYP2C8	O
,	O
CYP2C9	O
,	O
CYP2B6	B
,	O
Cytochrome	O
P450	O
3a4	O
,	O
CYP2D6	O
)	O
,	O
UGT1A	O
enzymes	O
(	O
UGT1A9	O
,	O
UGT1A1	O
)	O
,	O
and	O
transporters	O
(	O
BCRP	O
)	O
and	O
induce	O
others	O
(	O
CYP1A2	O
,	O
CYP2B6	B
,	O
CYP2C19	O
,	O
CYP3A4	O
)	O
with	O
potential	O
alteration	O
in	O
the	O
exposure	O
of	O
co	O
-	O
administered	O
drugs	O
.	O

One	O
knockdown	O
(	O
CYP303a1	O
,	O
human	O
orthologue	O
CYP2B6	B
)	O
never	O
showed	O
the	O
uptake	O
of	O
PCB	O
28	O
and	O
was	O
therefore	O
excluded	O
from	O
further	O
analysis	O
.	O

Among	O
the	O
166	O
patients	O
who	O
were	O
tested	O
for	O
the	O
CYP2B6	B
gene	O
,	O
the	O
most	O
common	O
phenotype	O
was	O
EM	O
(	O
Extensive	O
Metabolizer	O
)	O
(	O
50	O
.	O
00	O
%	O
,	O
n	O
.	O

The	O
genes	O
that	O
are	O
overexpressed	O
in	O
Theca	O
cells	O
(	O
cluster	O
4	O
)	O
are	O
particularly	O
involved	O
in	O
cholesterol	O
import	O
(	O
SCARB1	O
,	O
STARD5	O
)	O
,	O
bile	O
acid	O
metabolism	O
(	O
CH25H	O
)	O
,	O
HDL	O
-	O
mediated	O
lipid	O
transport	O
(	O
APOA1	O
,	O
PLTP	O
,	O
SCARB1	O
)	O
,	O
lipid	O
degradation	O
(	O
LPL	O
,	O
PLIN5	O
)	O
,	O
and	O
steroidogenesis	O
(	O
CYP27A	O
,	O
CYP7B1	O
,	O
TM7SF2	O
)	O
.	O

Further	O
analysis	O
showed	O
a	O
significant	O
negative	O
correlation	O
between	O
LC3II	O
/	O
I	O
ratio	O
and	O
cell	O
viability	O
(	O
P	O
<	O
.	O
01	O
)	O
,	O
and	O
apoptosis	O
rate	O
,	O
cytochrome	B
C	I
and	O
cleaved	O
caspase3	O
correlated	O
positively	O
with	O
LC3II	O
/	O
I	O
ratio	O
.	O

As	O
shown	O
in	O
Figure	O
BE	O
,	O
cell	O
viability	O
was	O
significantly	O
increased	O
,	O
apoptosis	O
rate	O
,	O
expressions	O
of	O
cytochrome	B
C	I
and	O
cleaved	O
caspase3	O
were	O
remarkably	O
decreased	O
by	O
3MA	O
pretreatment	O
compared	O
with	O
the	O
corresponding	O
bubble	O
alone	O
groups	O
of	O
10	O
,	O
20	O
and	O
30	O
minutes	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

3MA	O
induced	O
a	O
significant	O
decrease	O
in	O
cell	O
viability	O
as	O
well	O
increases	O
in	O
apoptosis	O
rate	O
,	O
cytochrome	B
C	I
and	O
cleaved	O
caspase3	O
in	O
1	O
or	O
5	O
minutes	O
groups	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

A	O
descriptive	O
study	O
assessed	O
Cytochrome	B
P450	I
3a4	I
and	O
Udp	O
Glucuronosyltransferase	O
1a9	O
genetic	O
variability	O
by	O
sequencing	O
the	O
germline	O
DNA	O
of	O
three	O
patients	O
with	O
metastatic	O
colorectal	O
cancer	O
experiencing	O
severe	O
toxic	O
hepatitis	O
after	O
sorafenib	O
treatment	O
and	O
reported	O
that	O
two	O
patients	O
were	O
heterozygous	O
for	O
the	O
UGT1A9	O
*	O
22	O
(	O
rs3832043	O
)	O
polymorphism	O
.	O

This	O
drug	O
undergoes	O
hepatic	O
metabolism	O
by	O
Cytochrome	B
P450	I
3a4	I
and	O
,	O
to	O
a	O
minor	O
extent	O
,	O
by	O
CYP2C9	O
.	O

Lenvatinib	O
is	O
metabolized	O
in	O
liver	O
microsomes	O
mostly	O
through	O
Cytochrome	B
P450	I
3a4	I
(	O
>	O
80	O
%	O
)	O
and	O
,	O
to	O
a	O
minor	O
extent	O
,	O
by	O
aldehyde	O
oxidase	O
and	O
acts	O
as	O
a	O
substrate	O
for	O
Atp	O
-	O
Binding	O
Cassette	O
transporters	O
,	O
encoded	O
by	O
the	O
ABCB1	O
and	O
ABCG2	O
genes	O
,	O
such	O
as	O
BCRP	O
and	O
P	O
-	O
glycoprotein	O
.	O

The	O
results	O
demonstrate	O
that	O
cytochrome	B
b	I
5	I
plays	O
a	O
dual	O
role	O
in	O
the	O
CYP3A4	O
-	O
catalyzed	O
oxidation	O
of	O
ellipticine	O
:	O
(	O
1	O
)	O
cytochrome	B
b	I
5	I
mediates	O
CYP3A4	O
catalytic	O
activities	O
by	O
donating	O
the	O
first	O
and	O
second	O
electron	O
to	O
this	O
enzyme	O
in	O
its	O
catalytic	O
cycle	O
,	O
indicating	O
that	O
NADH	O
:	O
cytochrome	B
b	I
5	I
reductase	O
can	O
substitute	O
NADPH	O
-	O
dependent	O
POR	O
in	O
this	O
enzymatic	O
reaction	O
and	O
(	O
2	O
)	O
cytochrome	B
b	I
5	I
can	O
act	O
as	O
an	O
allosteric	O
modifier	O
of	O
the	O
CYP3A4	O
oxygenase	O
.	O

However	O
,	O
because	O
they	O
are	O
microsomes	O
(	O
particles	O
of	O
broken	O
endoplasmic	O
reticulum	O
)	O
,	O
other	O
enzymes	O
(	O
proteins	O
)	O
of	O
the	O
endoplasmic	O
reticulum	O
membrane	O
(	O
ie	O
NADH	O
:	O
cytochrome	B
b	I
_5	I
reductase	O
and	O
cytochrome	B
b	I
_5	I
)	O
are	O
also	O
expressed	O
at	O
basal	O
levels	O
in	O
these	O
Supersomes	O
(	O
Gentest	O
Corp	O
.	O
,	O
Woburn	O
,	O
MI	O
,	O
USA	O
)	O
.	O

We	O
also	O
utilized	O
CYP3A4	O
-	O
Supersomes	O
which	O
also	O
contained	O
over	O
-	O
expressed	O
cytochrome	B
b	I
_5	I
,	O
in	O
a	O
molar	O
ratio	O
of	O
CYP3A4	O
to	O
cytochrome	B
b	I
_5	I
of	O
1	O
-	O
5	O
(	O
Gentest	O
Corp	O
.	O
,	O
Woburn	O
,	O
MI	O
,	O
USA	O
)	O
.	O

Incubation	O
mixtures	O
used	O
to	O
study	O
the	O
ellipticine	O
metabolism	O
by	O
human	O
hepatic	O
microsomes	O
or	O
Supersomes	O
contained	O
in	O
a	O
final	O
volume	O
of	O
0	O
.	O
5	O
cm	O
^	O
3	O
100	O
mmol	O
dm	O
^	O
3	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
1	O
mmol	O
dm	O
^	O
3	O
NADPH	O
or	O
NADH	O
,	O
0	O
.	O
025	O
mmol	O
dm	O
^	O
3	O
ellipticine	O
(	O
dissolved	O
in	O
0	O
.	O
005	O
cm	O
^	O
3	O
dimethyl	O
sulfoxide	O
,	O
DMSO	O
)	O
and	O
0	O
.	O
5	O
mg	O
protein	O
of	O
human	O
hepatic	O
microsomes	O
or	O
100	O
nmol	O
dm	O
^	O
3	O
human	O
recombinant	O
CYP3A4	O
in	O
Supersomes	O
either	O
with	O
or	O
without	O
cytochrome	B
b	I
_5	I
.	O

The	O
incubation	O
mixtures	O
for	O
measuring	O
the	O
testosterone	O
metabolism	O
contained	O
in	O
a	O
final	O
volume	O
of	O
0	O
.	O
5	O
cm	O
^	O
3	O
:	O
100	O
mmol	O
dm	O
^	O
3	O
potassium	O
phosphate	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
50	O
mol	O
dm	O
^	O
3	O
testosterone	O
(	O
0	O
.	O
0025	O
cm	O
^	O
3	O
of	O
stock	O
methanol	O
solution	O
per	O
incubation	O
)	O
,	O
1	O
mmol	O
dm	O
^	O
3	O
NADPH	O
or	O
NADH	O
,	O
and	O
100	O
nmol	O
dm	O
^	O
3	O
human	O
recombinant	O
CYP3A4	O
in	O
Supersomes	O
either	O
with	O
or	O
without	O
cytochrome	B
b	I
_5	I
.	O

Incubation	O
mixtures	O
used	O
to	O
assess	O
DNA	O
adduct	O
formation	O
by	O
ellipticine	O
contained	O
0	O
.	O
5	O
mg	O
protein	O
of	O
human	O
hepatic	O
microsomes	O
or	O
100	O
nmol	O
dm	O
^	O
3	O
human	O
recombinant	O
CYP3A4	O
in	O
Supersomes	O
either	O
with	O
or	O
without	O
cytochrome	B
b	I
_5	I
,	O
0	O
.	O
1	O
mmol	O
dm	O
^	O
3	O
ellipticine	O
(	O
dissolved	O
in	O
0	O
.	O
0075	O
cm	O
^	O
3	O
methanol	O
)	O
,	O
and	O
0	O
.	O
5	O
mg	O
of	O
calf	O
thymus	O
DNA	O
in	O
a	O
final	O
volume	O
of	O
0	O
.	O
75	O
cm	O
^	O
3	O
as	O
described	O
previously	O
[	O
,	O
.	O

CYP2B6	O
variants	O
,	O
reference	O
allele	O
P450	O
oxidoreductase	O
(	O
POR	O
)	O
,	O
and	O
reference	O
allele	O
cytochrome	B
b	I
_5	I
vectors	O
were	O
previously	O
generated	O
,	O
and	O
recombinant	O
proteins	O
previously	O
expressed	O
in	O
insect	O
cells	O
,	O
as	O
described	O
.	O
,	O
Haplotype	O
selection	O
was	O
based	O
on	O
the	O
known	O
clinical	O
significance	O
and	O
frequency	O
of	O
the	O
polymorphism	O
,	O
and	O
a	O
desire	O
to	O
inform	O
the	O
mechanistic	O
basis	O
for	O
the	O
influence	O
of	O
these	O
polymorphisms	O
on	O
metabolism	O
.	O

In	O
the	O
case	O
of	O
the	O
Cyp1a2	B
and	O
Cyp2c29	O
,	O
the	O
mRNA	O
expression	O
was	O
significantly	O
decreased	O
in	O
SPF	O
and	O
GF	O
female	O
mice	O
compared	O
to	O
the	O
control	O
.	O

Interestingly	O
,	O
the	O
sex	O
differences	O
were	O
erased	O
in	O
GF	O
mice	O
,	O
and	O
the	O
expression	O
of	O
Cyp3a11	O
was	O
about	O
the	O
same	O
in	O
both	O
sexes	O
.	O

In	O
other	O
words	O
,	O
there	O
is	O
significant	O
interaction	O
between	O
the	O
gender	O
and	O
presence	O
of	O
the	O
gut	O
microbiome	O
,	O
which	O
together	O
influence	O
the	O
Cyp3a11	O
mRNA	O
expression	O
.	O

Sort	O
=	O
Bait	O
interacts	O
with	O
cytochrome	O
P450	O
CYP2E1	O
and	O
CYP11B2	B
,	O
while	O
the	O
affinity	O
of	O
TBXAS1CYP2E1	O
complex	O
formation	O
is	O
fivefold	O
higher	O
in	O
the	O
presence	O
of	O
low	O
-	O
molecular	O
-	O
weight	O
non	O
-	O
peptide	O
endogenous	O
bioregulator	O
isatin	O
(	O
2	O
,	O
3	O
-	O
dioxindole	O
)	O
.	O

CYP11B2	B
,	O
which	O
is	O
also	O
known	O
as	O
aldosterone	O
synthase	O
,	O
additionally	O
exhibits	O
18	O
-	O
hydroxylase	O
and	O
18	O
-	O
methyl	O
oxidase	O
activity	O
,	O
which	O
are	O
required	O
to	O
convert	O
corticosterone	O
to	O
aldosterone	O
via	O
the	O
18	O
-	O
hydroxycorticosterone	O
intermediate	O
.	O

In	O
CYP90B1	O
,	O
the	O
active	O
site	O
is	O
characterized	O
by	O
the	O
conformations	O
side	O
-	O
chain	O
in	O
and	O
steroid	O
-	O
core	O
out	O
,	O
similar	O
to	O
CYP11A1	B
,	O
and	O
for	O
CYP90B1	O
the	O
3	O
-	O
hydroxy	O
group	O
hydrogen	O
is	O
bonded	O
with	O
H385	O
and	O
the	O
carbonyl	O
oxygen	O
of	O
V216	O
via	O
a	O
water	O
molecule	O
.	O

However	O
,	O
due	O
to	O
the	O
perpendicular	O
position	O
of	O
the	O
CYP90B1	O
steroid	O
core	O
,	O
the	O
C	O
-	O
22	O
is	O
located	O
closer	O
to	O
the	O
heme	O
iron	O
(	O
4	O
.	O
1	O
)	O
and	O
gets	O
hydrolyzed	O
,	O
whereas	O
20	O
-	O
C	O
is	O
too	O
far	O
from	O
the	O
heme	O
group	O
(	O
4	O
.	O
9	O
)	O
to	O
get	O
hydrolyzed	O
,	O
unlike	O
in	O
CYP11A1	B
where	O
both	O
positions	O
are	O
hydroxylated	O
.	O

Within	O
the	O
adrenal	O
,	O
A4	O
can	O
serve	O
as	O
a	O
substrate	O
for	O
CYP11B1	B
,	O
yielding	O
the	O
11	O
-	O
oxygenated	O
androgen	O
precursor	O
,	O
11OHA4	O
,	O
with	O
conversion	O
of	O
testosterone	O
to	O
11BETA	O
-	O
hydroxytestosterone	O
(	O
11OHT	O
)	O
,	O
also	O
occurring	O
.	O

The	O
EV	O
CYPs	O
(	O
CYP	B
1A1	I
and	O
2A6	O
)	O
exert	O
an	O
additive	O
effect	O
on	O
the	O
basal	O
CYPs	O
of	O
the	O
recipient	O
cells	O
.	O

The	O
genetic	O
variation	O
of	O
cytochrome	B
B	I
and	O
MHC	O
-	O
DRB	O
differed	O
in	O
Chinese	O
woodchucks	O
with	O
different	O
susceptibility	O
to	O
WHV	O
infection	O
.	O

These	O
data	O
will	O
be	O
benefit	O
for	O
understanding	O
the	O
pathogenesis	O
of	O
hepadnavirus	O
infection	O
,	O
and	O
cytochrome	B
B	I
and	O
MHC	O
-	O
DRB	O
alleles	O
will	O
be	O
helpful	O
for	O
selection	O
suitable	O
animals	O
for	O
WHV	O
infection	O
.	O

5	O
per	O
species	O
)	O
for	O
the	O
cytochrome	O
oxidase	O
subunit	O
1	O
(	O
CO1	O
)	O
and	O
cytochrome	B
B	I
(	O
CytB	O
)	O
gene	O
regions	O
for	O
the	O
shark	O
and	O
teleost	O
species	O
commonly	O
encountered	O
in	O
the	O
West	O
Coast	O
and	O
Gascoyne	O
Coast	O
bioregions	O
of	O
Western	O
Australia	O
were	O
downloaded	O
from	O
GenBank	O
/	O
BOLD	O
databases	O
where	O
available	O
.	O

Orthochlorinated	O
PCBs	O
such	O
as	O
PCB	O
128	O
,	O
PCB	O
153	O
,	O
PCB	O
155	O
and	O
PCB	O
180	O
induce	O
the	O
expression	O
of	O
CYP2B1	B
.	O

While	O
berberine	O
increased	O
CYP1A1	O
mRNA	O
to	O
a	O
level	O
approaching	O
that	O
of	O
TCDD	O
-	O
exposed	O
HepG2	O
cells	O
,	O
our	O
findings	O
suggested	O
that	O
an	O
increase	O
in	O
miR	O
-	O
21	O
-	O
3p	O
might	O
be	O
the	O
reason	O
for	O
the	O
mild	O
increase	O
in	O
CYP1A1	B
protein	I
level	O
by	O
berberine	O
as	O
compared	O
to	O
that	O
induced	O
by	O
TCDD	O
.	O

While	O
the	O
CYP1A1	O
mRNA	O
was	O
increased	O
,	O
berberine	O
-	O
induced	O
miR	O
-	O
21	O
-	O
3p	O
suppressed	O
the	O
increase	O
in	O
CYP1A1	B
protein	I
and	O
function	O
.	O

Likewise	O
Guth	O
did	O
not	O
detect	O
PROD	B
activity	O
in	O
StrataTest	O
^	O
(	O
LOD	O
4	O
pmol	O
/	O
min	O
/	O
mg	O
protein	O
)	O
.	O

Attempts	O
to	O
induce	O
PROD	B
activities	O
in	O
the	O
human	O
reconstructed	O
skin	O
model	O
EpiDerm	O
^	O
using	O
quite	O
a	O
number	O
of	O
CYP2B6	O
inducers	O
(	O
phenobarbital	O
,	O
rifampicin	O
,	O
6	O
-	O
(	O
4	O
-	O
chlorophenyl	O
)	O
imidazo	O
[	O
2	O
,	O
1	O
-	O
b	O
]	O
[	O
1	O
,	O
3	O
]	O
thiazole	O
-	O
5	O
-	O
carbaldehyde	O
-	O
O	O
-	O
(	O
3	O
,	O
4	O
-	O
dichlorobenzyl	O
)	O
oxime	O
(	O
CITCO	O
)	O
as	O
well	O
as	O
cyclophosphamide	O
)	O
also	O
failed	O
(	O
Gtz	O
et	O
al	O
.	O
.	O
In	O
contrast	O
to	O
these	O
negative	O
findings	O
Baron	O
et	O
al	O
.	O

report	O
detection	O
of	O
PROD	B
activity	O
in	O
proliferating	O
human	O
keratinocytes	O
in	O
culture	O
and	O
its	O
induction	O
by	O
phenobarbital	O
.	O

reported	O
that	O
native	O
human	O
skin	O
had	O
a	O
low	O
level	O
of	O
CYP3A4	O
protein	O
,	O
moderately	O
induced	O
after	O
24	O
h	O
by	O
2	O
mM	O
phenobarbital	O
,	O
which	O
,	O
however	O
,	O
was	O
not	O
accompanied	O
by	O
an	O
increase	O
in	O
CYP3A4	O
-	O
dependent	O
BROD	B
activity	O
by	O
phenobarbital	O
(	O
0	O
.	O
5	O
-	O
2	O
mM	O
for	O
24	O
,	O
48	O
and	O
72	O
h	O
)	O
nor	O
by	O
rifampicin	O
(	O
50	O
and	O
100	O
M	O
for	O
24	O
h	O
)	O
nor	O
by	O
dexamethasone	O
(	O
10	O
and	O
50	O
M	O
for	O
24	O
,	O
48	O
and	O
72	O
h	O
)	O
.	O

It	O
is	O
unclear	O
why	O
our	O
patient	O
did	O
not	O
exhibit	O
any	O
side	O
or	O
adverse	O
effects	O
;	O
however	O
,	O
it	O
could	O
be	O
that	O
the	O
Carbamazepine	O
he	O
received	O
played	O
a	O
role	O
,	O
although	O
studies	O
have	O
shown	O
that	O
there	O
is	O
little	O
or	O
no	O
in	O
vivo	O
effects	O
of	O
CYP	B
2D6	I
on	O
Paliperidone	O
.	O

CYP26B1	B
metabolizes	O
retinoic	O
acid	O
,	O
a	O
compound	O
with	O
potential	O
anticancer	O
abilities	O
.	O

In	O
this	O
regard	O
,	O
a	O
recent	O
Genome	O
-	O
Wide	O
Association	O
Study	O
revealed	O
an	O
association	O
of	O
CYP26B1	B
with	O
esophageal	O
squamous	O
cell	O
carcinoma	O
risk	O
.	O

In	O
isolated	O
RCs	O
of	O
PSII	O
,	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
was	O
found	O
to	O
exhibit	O
SOD	O
activity	O
.	O

As	O
proposed	O
by	O
Pospil	O
,	O
the	O
catalytic	O
formation	O
of	O
H_2O_2	O
by	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
proceeds	O
as	O
a	O
two	O
-	O
step	O
reduction	O
-	O
oxidation	O
reaction	O
involving	O
two	O
molecules	O
of	O
O_2	O
^	O
.	O

The	O
first	O
step	O
is	O
reduction	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
(	O
Fe	O
^	O
3	O
+	O
)	O
to	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
(	O
Fe	O
^	O
2	O
+	O
)	O
,	O
Reaction	O
(	O
106	O
)	O
.	O

The	O
second	O
step	O
is	O
the	O
oxidation	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
(	O
Fe	O
^	O
2	O
+	O
)	O
by	O
HO_2	O
^	O
,	O
the	O
protonated	O
form	O
of	O
O_2	O
^	O
,	O
with	O
formation	O
of	O
D1	O
/	O
D2	O
/	O
Cytochrome	O
B559	O
(	O
Fe	O
^	O
3	O
+	O
)	O
and	O
H_2O_2	O
,	O
Reaction	O
(	O
107	O
)	O
.	O

In	O
addition	O
,	O
they	O
isolated	O
mitochondrial	O
and	O
cytosol	O
fractions	O
and	O
observed	O
a	O
time	O
-	O
dependent	O
release	O
of	O
Cytochrome	B
C	I
to	O
cytosol	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
release	O
of	O
Cytochrome	B
C	I
from	O
the	O
mitochondria	O
was	O
simultaneous	O
with	O
Aif1p	O
(	O
apoptosis	O
-	O
inducing	O
factor	O
)	O
release	O
;	O
Aif1p	O
is	O
involved	O
in	O
chromatin	O
condensation	O
and	O
DNA	O
degradation	O
;	O
these	O
are	O
related	O
to	O
a	O
function	O
of	O
mitochondrial	O
permeabilization	O
induced	O
by	O
Human	O
Lf	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
kinetics	O
of	O
human	O
CYP17A1	O
favors	O
the	O
conversion	O
of	O
17OH	O
-	O
pregnenolone	O
to	O
dehydroepiandrosterone	O
over	O
that	O
of	O
17OH	O
-	O
progesterone	O
to	O
androstenedione	O
.	O

The	O
apparent	O
K_m	O
and	O
v_max	O
of	O
CYP17A1	O
for	O
17OH	O
-	O
progesterone	O
are	O
10	O
-	O
fold	O
higher	O
(	O
K_m	O
)	O
and	O
10	O
-	O
fold	O
lower	O
(	O
v_max	O
)	O
than	O
those	O
for	O
17OH	O
-	O
pregnenolone	O
.	O

Thus	O
,	O
the	O
catalytic	O
efficiency	O
(	O
k_cat	O
/	O
K_m	O
)	O
for	O
the	O
17	B
,	I
20	I
-	I
lyase	I
reaction	O
by	O
one	O
mole	O
of	O
CYP71A1	O
is	O
about	O
100	O
-	O
fold	O
higher	O
for	O
17OH	O
-	O
pregnenolone	O
than	O
for	O
17OH	O
-	O
progesterone	O
.	O

The	O
absence	O
of	O
SOAT1	O
can	O
increase	O
the	O
availability	O
for	O
the	O
retina	O
of	O
fatty	O
acids	O
,	O
which	O
are	O
used	O
as	O
the	O
enzyme	O
substrates	O
,	O
whereas	O
the	O
absence	O
of	O
Cytochromes	O
P450	O
27a1	O
and	O
CYP46A1	B
abolishes	O
the	O
production	O
of	O
27	O
-	O
hydroxycholesterol	O
and	O
24	O
-	O
hydroxycholesterol	O
,	O
which	O
are	O
activating	O
ligands	O
for	O
LXRs	O
.	O

The	O
present	O
work	O
provides	O
insights	O
into	O
potential	O
mechanisms	O
that	O
could	O
underlie	O
the	O
deteriorations	O
in	O
retinal	O
function	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
mice	O
.	O

Further	O
studies	O
are	O
required	O
to	O
target	O
more	O
precisely	O
the	O
major	O
contributors	O
to	O
changes	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
.	O

In	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
,	O
retinal	O
function	O
was	O
dependent	O
on	O
sex	O
and	O
was	O
normal	O
in	O
female	O
animals	O
,	O
in	O
agreement	O
with	O
our	O
previous	O
findings	O
that	O
Apolipoprotein	O
E	O
absence	O
elicits	O
strong	O
compensatory	O
mechanisms	O
that	O
minimize	O
retinal	O
impact	O
of	O
this	O
protein	O
absence	O
.	O

Future	O
work	O
will	O
map	O
these	O
responses	O
by	O
retinal	O
proteomics	O
in	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
for	O
comparison	O
to	O
Apoe	O
^	O
/	O
results	O
.	O

We	O
propose	O
the	O
following	O
model	O
to	O
unify	O
the	O
available	O
data	O
and	O
to	O
identify	O
the	O
questions	O
that	O
remain	O
unanswered	O
to	O
completely	O
explain	O
changes	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
.	O

Accordingly	O
,	O
glucose	O
utilization	O
and	O
fatty	O
acid	O
BETA	O
-	O
oxidation	O
could	O
be	O
increased	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
as	O
a	O
compensatory	O
response	O
to	O
decreased	O
LXR	O
activation	O
and	O
/	O
or	O
increased	O
fatty	O
acid	O
availability	O
.	O

Apparently	O
,	O
other	O
processes	O
could	O
also	O
become	O
affected	O
in	O
the	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
retina	O
as	O
suggested	O
by	O
retinal	O
proteomics	O
.	O

We	O
comprehensively	O
characterized	O
the	O
retina	O
of	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Soat1	O
^	O
/	O
and	O
Cyp27a1	O
^	O
/	O
Cyp46a1	B
^	O
/	O
Apoe	O
^	O
/	O
mice	O
and	O
identified	O
some	O
of	O
the	O
homeostatic	O
responses	O
to	O
the	O
blockage	O
of	O
the	O
major	O
pathways	O
of	O
retinal	O
cholesterol	O
output	O
and	O
storage	O
.	O

Cyp27b1	B
-	O
KO	O
rats	O
and	O
Vdr	O
(	O
R270L	O
)	O
rats	O
were	O
fed	O
25	O
(	O
OH	O
)	O
D_3	O
for	O
comparison	O
of	O
its	O
effects	O
on	O
rickets	O
symptoms	O
.	O

During	O
25D	O
-	O
F	O
-	O
2	O
feeding	O
,	O
the	O
average	O
daily	O
food	O
intake	O
was	O
18	O
.	O
6	O
3	O
.	O
7	O
g	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
and	O
18	O
.	O
1	O
0	O
.	O
7	O
g	O
in	O
Vdr	O
(	O
R270L	O
)	O
rats	O
,	O
whereas	O
the	O
body	O
weight	O
of	O
Cyp27b1	B
-	O
KO	O
rats	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
Vdr	O
(	O
R270L	O
)	O
rats	O
.	O

Consequently	O
,	O
the	O
food	O
intake	O
per	O
kg	O
body	O
weight	O
was	O
calculated	O
to	O
be	O
113	O
.	O
2	O
16	O
.	O
9	O
g	O
/	O
kg	O
bw	O
/	O
day	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
and	O
56	O
.	O
0	O
6	O
.	O
4	O
g	O
/	O
kg	O
bw	O
/	O
day	O
in	O
Vdr	O
(	O
R270L	O
)	O
rats	O
.	O

Thus	O
,	O
the	O
dose	O
of	O
25	O
(	O
OH	O
)	O
D_3	O
was	O
calculated	O
to	O
be	O
168	O
.	O
9	O
25	O
.	O
1	O
g	O
/	O
kg	O
bw	O
/	O
day	O
in	O
Cyp27b1	B
-	O
KO	O
rats	O
and	O
80	O
.	O
9	O
7	O
.	O
7	O
g	O
/	O
kg	O
bw	O
/	O
day	O
in	O
Vdr	O
(	O
R270L	O
)	O
rats	O
(	O
the	O
values	O
are	O
shown	O
as	O
the	O
means	O
SEMs	O
(	O
n	O
=	O
2	O
-	O
3	O
animals	O
/	O
group	O
)	O
)	O
.	O

Liver	O
mitochondrial	O
and	O
microsomal	O
fractions	O
were	O
prepared	O
from	O
Cyp27b1	B
-	O
KO	O
rats	O
using	O
the	O
same	O
methods	O
as	O
described	O
in	O
our	O
previous	O
study	O
^	O
.	O

Two	O
-	O
way	O
ANOVA	O
was	O
performed	O
for	O
the	O
analysis	O
of	O
the	O
bone	O
mineral	O
density	O
and	O
levels	O
of	O
plasma	O
Ca	O
,	O
Parathyroid	O
Hormone	O
,	O
1	O
,	O
25	O
(	O
OH	O
)	O
_2D_3	O
,	O
25	O
(	O
OH	O
)	O
D_3	O
and	O
its	O
metabolites	O
in	O
Cyp27b1	B
-	O
KO	O
and	O
mutant	O
Vdr	O
(	O
R270L	O
)	O
rats	O
fed	O
the	O
F	O
-	O
2	O
or	O
25D	O
-	O
F	O
-	O
2	O
diet	O
.	O

